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It is not the most intellectual or the strongest species that survives, 
but the species that survives is the one that is able to adapt to or 
adjust best to the changing environment in which it finds itself. 
Attributed to Charles Darwin 
  
   
 Abstract 
 
Selectivity for cancer cells is one of the most important characteristics of anticancer agents. The transition 
from cytotoxic chemotherapy to molecularly targeted cancer drug discovery and development resulted in an 
increasing number of successful therapies that impacted the lives of a large number of cancer patients. 
The extreme toxicity and the development of resistance have made it essential to keep searching for new 
potential targeted anticancer agents, endowed with higher efficacy and minor toxicity. 
In order to achieve this goal, I followed different approaches: 
- starting from antiproliferative compounds, I sought their molecular target; 
- developing STAT3 inhibitors, I obtained dual-target compounds with enhanced cytotoxicity; 
- employing computationally driven drug design, I investigated new chemical scaffolds, able to disrupt 
STAT3 dimerization and characterized by suitable drug-like properties. 
 
1,2,5-Oxadiazoles have received considerable attention in recent years from Prof. Barlocco’s research group 
because of the interesting results as potential antitumor agents. Among all, MD77 displayed a very 
interesting antiproliferative profile. Therefore, I focused my research efforts in the identification of its 
molecular target employing a combined synthetic-computational approach. I synthetized a wide pool of 
MD77 derivatives which were evaluated for their antiproliferative activity by the MTT-assay on human colon 
cancer cells by Dr. N. Ferri (University of Padua, Italy) and underwent a structure-activity relationship analysis 
using Activity Miner module of Cresset Forge, in collaboration with Prof. S. Guccione’s research group 
(University of Catania, Italy). The obtained disparity matrix will be used as query in search of a potential 
target. 
 
Platinum based anticancer drugs are still among the most effective drugs used for the treatment of solid 
cancers. Their strong side effects and the increasing resistance are limitations to their use. Even if DNA was 
established to be the primary target of platinum drugs, an extensive investigation into their biochemistry 
highlighted the evidence that also non-DNA targets, such as STAT3, are involved in determining cytotoxic 
effects. The second part of my PhD project, carried out in collaboration with Dr. I. Rimoldi’s research group 
(University of Milan) and Dr. N. Ferri (University of Padua), aimed at the identification of Pt(II) complexes 
endowed with antiproliferative activity due to a dual mechanism of action: interference with DNA replication 
and inhibition of STAT3 signaling pathway. Among the synthesized derivatives, Pt-15b and Pt-16a were 
selected for in vivo studies thanks to the collaboration with Prof. C. Marzano and Prof. V. Gandin (University 
of Padua), showing that the chemotherapy with these compounds reduced the tumor mass similarly to 
cisplatin and, despite the higher dose, they seemed to be better tolerated than the reference compound. 
 
A dual targeting approach was also pursed, in collaboration with Prof. A. Sparatore’s research group, by 
investigating a new series of sulfurated compounds as STAT3 and NF-kB inhibitors. Dithiolethiones (DTTs) 
and methanethiosulfonates (MTTSs) were synthetized in light of their recently reported chemopreventive 
and anticancer activities. 
 
Fragment-based drug design (FBDD) has emerged as promising methodology to generate lead molecules 
against therapeutic targets in the past decade. Compared with high-throughput screening hits, the advantage 
is that the identified small molecules are expected to be efficiently optimized into a drug candidate which 
maintains low molecular weight and possesses both binding affinity and favorable pharmacokinetic profile. 
The aim of this branch of my PhD project was the identification of new chemical scaffolds able to disrupt 
 STAT3 protein-protein interactions and characterized by an increased activity and appropriate drug-like 
properties, employing a FBDD approach. The computational protocol was firstly validated and then applied 
on a larger base set of fragments leading to nine drug candidates. The synthesized compounds and the 
commercial ones were evaluation by an in vitro binding assay to determine their affinity for the target. 
 
This project was partially supported by PRIN Research Project, grant no. 20105YY2H_007. 
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1.1 Cancer 
Cancer affects all of humankind. The incidence of cancer has increased from 12.7 million in 2008 to 14.1 
million in 2012. This trend is expected to continue, bringing the number of cancer cases close to 25 million 
over the next two decades. [1] 
The most common sites of cancer diagnosed in 2012 include: 
 lung (16.7% of the total), prostate (15.0%), colorectum (10.0%), stomach (8.5%), and liver (7.5%), 
among men; 
 breast (25.2% of the total), colorectum (9.2%), lung (8.7%), cervix (7.9%), and stomach (4.8%), among 
women. 
However, there is a marked variability across local, national, and regional boundaries. Worldwide, differences 
in cancer incidence can be related to different causes and, by inference, different opportunities for 
prevention. Indeed, each tumor type may be characterized with reference to epidemiology, etiology, 
pathology, genetics, and prevention. Nevertheless, it is clear that cancer is not a single disease but a 
multiplicity of different diseases, therefore, understanding cancer biology is critical to develop rationally 
designed therapy and offer preventive options. 
The survival of organisms depends on the accurate transmission of genetic information from one cell to its 
daughters. Such faithful transmission requires not only extreme accuracy in replication of DNA and precision 
in chromosome distribution, but also the ability to survive spontaneous and induced DNA damage while 
minimizing the number of heritable mutations. 
Hence, the identification of the differences between tumor cells and normal ones is crucial: cumulative 
genetic and epigenetic changes may mediate, amongst other effects, altered metabolism or modified 
intracellular signaling in response to growth-altering stimuli. Cancer cells provide their own growth signals, 
ignoring inhibitory ones, avoiding cell death, replicating without limit, sustaining angiogenesis, and invading 
tissues through basement membranes and capillary walls. 
Thus, the roles of cancer stem cells (a subpopulation of tumor cells with aberrant unlimited proliferative 
potential and the capacity to confer tumor heterogeneity and to migrate) and the tumor microenvironment 
have to be considered in the search of novel approaches to cancer therapy. The tumor microenvironment 
encompasses the biochemical and cellular composition of the tissue. Bidirectional signaling between cancer 
and stromal cells has effects on cancer cell division, immune cell function, and resistance to therapeutic 
intervention, resulting in poor clinical outcome. For these reasons, a combined therapy that targets cancer 
cells and modifies the tumor microenvironment (i.e. anti-angiogenic therapy) could have synergic benefits. 
 
Curative or palliative treatments [2] require a wide strategy and, at the moment, the fundamental therapeutic 
approaches include: 
 Surgery, often the first approach used against the disease, it is effective if the tumor mass is 
sufficiently small to allow its safe removal. It is usually combined with radiotherapic and 
chemotherapic treatments in order to increase chances of healing and survival. 
 Radiotherapy (ionizing radiations, X-ray or γ-ray) which targets the tumor DNA leading to the death 
of cancer cells as a consequence of their inadequate capacity to repair their own genomic damages. 
It can be used alone or in association with chemotherapy to treat self-contained cancers and to 
control primary metastatic cancers. 
 Immunotherapy, using the patient immune system to eradicate neoplasms. Actually, this therapy 
requires the administration of α-interferon and interleukin-2 in order to increase T and B lymphocyte 
levels. 
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 Chemotherapy, fundamental against both primary cancer and metastasis. It is characterized by 
administration of cytotoxic drugs, which enter into the bloodstream, thus reaching any part of the 
body. 
Surgery and radiation therapy are preferred for restricted cancers while immunotherapy and chemotherapy 
are recommended for metastatic cancers. 
1.1.1 Chemotherapy and targeted therapy 
Antitumor agents [2] are most effective at killing cells that are rapidly dividing due to the higher vulnerability 
to their cytotoxic action. Indeed, slow-growing cancers, such as non-small cell lung cancer (NSCLC) 
characterized by a high percentage of cells in G0 phase, are comparatively less sensitive to standard 
chemotherapy. Some chemotherapeutic agents are cell cycle non-specific (e.g. alkylating agents), some 
others attack cells at very specific phases in the cell cycle (for instance antimetabolites mainly act on cells in 
S phase while mitotic-spindle inhibitors kill cells in M phase). It is very important to fight cancer as soon as 
possible in order to increase the chances of therapeutic success. 
The selectivity for cancer cells is one of the most important characteristics of anticancer agents. This feature 
is only an ideal because all anticancer drugs have side effects on healthy tissues. These effects refer 
specifically to rapidly proliferating tissues: bone marrow (leukopenia, thrombocytopenia, anemia, 
immunosuppression and infection), gastrointestinal mucosa (stomatitis, enteritis, muco-membranous colitis, 
diarrhea), cutaneous annexes (alopecia) and gonads (amenorrhea and azoospermia). 
Beyond side effects, another problem associated with chemotherapy is the rising of resistance which can 
compromise therapy. This phenomenon has many causes: it can arise naturally, regardless of the contact 
between drug and cell, or it can be acquired if a continuous treatment with the same drugs produce 
modifications in the cell. 
The transition from cytotoxic chemotherapy to molecularly targeted cancer drug discovery and development 
resulted in an increasing number of successful therapies that impacted the lives of a large number of cancer 
patients. [3] Also targeted therapy drugs, like any drug used to treat cancer, can technically be considered 
“chemotherapy.” But while standard chemotherapies act on all rapidly dividing cells, both normal and 
cancerous, targeted cancer therapy drugs block the growth and spread of cancer by interfering with specific 
molecules that are involved in these processes. 
Considering their different mechanism, targeted therapies are often cytostatic (blocking tumor cell 
proliferation), whereas standard chemotherapy agents are cytotoxic (killing tumor cells). Moreover, they are 
often able to selectively attack cancer cells since they are more dependent on the targets than normal cells, 
doing less damage to these latter having different (and often less severe) side effects than standard 
chemotherapy drugs. Resistance can also occur as a consequence of modifications of the target itself and/or 
the development of a new pathway capable of bypassing it. 
For this reason, even if the first approach consists in mono-chemotherapy, the combination of targeted 
therapies or a targeted therapy with one or more traditional chemotherapy drugs could be more effective [4] 
fighting tumor cells through various mechanisms and overcoming resistance problems. Moreover, in order 
to limit side effects (such as immunosuppression), these drugs are administrated according to treatment 
cycles. In this way the organism can recover from side effects and new cancer cells can enter in replication 
phase. 
Most targeted therapies use either small molecules or monoclonal antibodies, developed for targets that are 
located inside the cell or on its surface, respectively. 
Since signaling pathways regulate a plethora of biological processes mediating cell survival, proliferation, 
response to growth factors, and related biological processes, transcription factors are important meeting 
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points for controlling these homeostasis processes through modulation of gene expression. Therefore, 
considering their dysregulation in many cancer cell lines, targeting transcription factors, such as STAT3 (see 
Section 1.2), as well as the DNA itself (see Section 1.3), may increase the efficiency of anticancer therapy. 
Moreover, although cancer chemotherapy plays a very important role in the reduction of mortality, the 
extreme toxicity of anticancer drugs and the development of resistance to their action have made it essential 
to continue researching with the aim to identify new compounds endowed with higher efficacy and minor 
toxicity. 
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1.2 STAT3 
STATs (Signal Transducer and Activator of Transcription) are latent cytosolic transcription factors that directly 
relate signals from the plasma membrane to the nucleus and, depending on their main function, the seven 
isoforms [5] can be categorized into two groups: 
 STAT2, STAT4 and STAT6 are activated by a reduced number of cytokines, which are involved in 
development of T-cells and interferon-γ (IFN- γ) pathway; 
 STAT1, STAT3 and STAT5 are concerned respectively with IFN signaling, development of mammary 
glands and response to growth hormone and embryogenesis. They are also involved in cell cycle 
control and apoptosis. 
According to their physiological role, in pathological conditions STAT3 and STAT5 are the isoforms more 
related to human cancer. [6] In particular STAT3 was found to participate in cell signaling events, leading to 
oncogenic transformation, and to be constitutively activated in more than half of breast and lung cancers, 
hepatocellular carcinomas, multiple myelomas, and in more than 95% of head and neck cancers. [7,8] 
Constitutive STAT3 dimer induces nuclear translocation, DNA-binding, transactivation of target genes, 
oncogenic transformation, and tumorigenesis. Furthermore, numerous reports have shown that blocking 
constitutively activated STAT3 signaling leads to tumor cell apoptosis, with minimal effect on normal cells. [9] 
This selective inhibition might reflect an irreversible dependence of tumor cells on high levels of activated 
STAT3 for growth and survival, whereas normal cells could withstand lower levels of STAT3 activity or use 
alternative pathways. [8] 
STAT proteins are characterized by seven structurally and functionally conserved domains (see Section 5.2) 
and among them, the Src homology 2 (SH2) is the one primarily involved in its activation, triggered by 
cytokines and growth factors, as well as by oncogenic proteins, such as Src and Ras. Upon phosphorylation 
of the tyrosine residue at position 705, STAT3 dimerizes through specific reciprocal SH2-phosphotyrosine 
interaction (Figure 1). [8] 
Figure 1. STAT3 connects inflammation and cancer. [10] 
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The dimer translocates into the nucleus, binds to specific DNA-binding elements and activate the 
transcription of target genes involved in cell proliferation, differentiation, apoptosis and inflammation. [6] 
In detail, STAT3 promotes the activation of cell inflammatory pathway, including the pro-inflammatory 
transcription factor NF-кB pathway, playing an important role in inflammation acute-phase. Neoplasm and 
inflammation are connected by extrinsic/environmental (chemical carcinogens, infection, ultraviolet 
radiation, stress and cigarette smoke) and intrinsic/genetic pathways. Since it promotes the malignant 
properties correlated with chronic inflammation, STAT3 is crucial for both of these mechanisms. Moreover, 
STAT3 seems to facilitate tumor evasion of the immune system, positively regulating the transcription of 
different cytokines that suppress the immune response. [10] 
Another heavily impaired process in cancer is apoptosis. Genes coding for apoptosis inhibitors (such as Blc-2 
family) are STAT3 targets and, for this reason, are overexpressed in cancerous cell. Besides suppressing 
apoptosis, STAT3 also enhances proliferation by controlling the expression of proteins that lead the cell cycle 
throughout each phase (such as cyclin D1 protein). [7] 
Also angiogenesis is essential for tumor growth at the primary site and for its progression to the metastatic 
site in order to satisfy the high demand of oxygen and energy required for growth and metabolism. This 
process is regulated by the balance of pro-angiogenic (e.g., basic fibroblast growth factor and VEGF-A) and 
anti-angiogenic (e.g., endostatin and angiostatin) factors in the tumor microenvironment. STAT3 modulates 
angiogenesis up-regulating various pro-angiogenic factors, [6] and participates in metastatic progression 
through different molecular mechanisms, such as inducing the expression of matrix metalloproteinases. [11] 
1.2.1 STAT3 signaling pathway 
Growth factors, cytokines and other polypeptide ligands, unable to cross the cytoplasmic membrane, have 
to interact with membrane receptors and the message has to be internalized and transferred to the nucleus 
where it determines the expression of the ligand-dependent genetic program. STAT3 recruitment, activation, 
nuclear translocation and deactivation has a main role in the general above mentioned signaling pathway. 
In regard to STAT3 activation, there are several pathways among which the most significant is the JAK/STAT 
canonical pathway, where STAT3 is activated by phosphorylation and dimer formation. Otherwise, the non-
canonical one is characterized by dimer formation without tyrosine phosphorylation. 
In detail, STAT3 is located in the cytoplasm or on the cytosolic side of the cellular membrane in a latent 
hypophosphorylated form. Many membrane receptors have intrinsic tyrosine-kinase activity (such as growth 
factors receptors including EGFR and HER2) but some others, lacking this property (such as IL-6 or interferon 
receptors), have to recruit cytoplasmic tyrosine kinases (TKs), for instance JAK (Janus Kinase) proteins, to 
operate as mediators for STAT activation. Therefore, in the JAK/STAT3 canonical pathway, after ligand-
receptor association and activation, its phosphorylated portion acts as a docking site for the SH2 domain of 
the STAT3 monomer. STAT3 itself is phosphorylated at the C-terminus tyrosine residue (Tyr 705 in STAT3) 
leading to dimer formation, through a reciprocal pTyr - SH2 domain interaction. This complex translocates 
into the nucleus, binds specific DNA-response elements and modulates gene transcription. [12] 
Recent studies demonstrate that not only phosphorylated STAT3 but also unphosphorylated STAT3 can form 
the dimer, translocate into the nucleus, and bind to the STAT3 binding sites. Therefore, even if the 
mechanism of unphosphorylated STAT3 binding to the promoter remains unclear, its significant role in 
oncogenesis has been validated. [13] 
The importation exploits the active transport through the nuclear pore complexes (NPC), since the 
dimensions (about 180 kDa) of the dimeric structure are excessive for passive diffusion. Importins are 
karyopherin involved in STAT nuclear translocation. They are constituted of two subunits, respectively 
importin-α and importin-β. After the binding with STAT dimer, importin α interacts with importin-β and 
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mediates the movement of the complex into the nucleus. [14] The isoforms usually implicated in the canonical 
STAT3 activation pathway are importin-α5 and -α7, while the unphosphorylated STAT3 dimer move to the 
nucleus thanks to the participation of importin-α3. This mechanism suggests that in addition to 
phosphorylated STAT3, also the non-canonical pathway (unphosphorylated STAT3) permits the transcription 
of STAT3 target genes, playing an important role in oncogenesis. [13] If in the JAK/STAT activation pathway the 
tyrosine activation domain plays a crucial role for dimerization, in the non-canonical pathway this role seems 
to be performed by the N-terminal domain probably interacting with another domain (maybe the SH2 
domain) instead of forming homotopic interactions. Indeed, while the N-terminal domain is essential for 
unphosphorylated STAT3 dimerization, deletion of the same domain allows the complexation of canonical 
pTyr-STAT3. [15] 
Like the nuclear import, nuclear export requires the presence of carriers called exportins, which mediate the 
translocation of STAT3 dimer, that has already interacted with DNA target sequences, from the nucleus to 
the cytoplasm. [15] 
Recent studies have shown that STAT3 activation can be negatively modulated by different mechanisms, 
including direct dephosphorylation of JAKs and STATs, proteolytic disruption through ubiquitin-proteasome 
pathway and participation of specific inhibiting protein families, such as PIAS (proteins that inhibit activated 
STAT proteins family) and SOCS (suppressors of cytokine signaling family). [12] 
1.2.2 STAT3 inhibitors 
The association between constitutive STAT3 activation and malignant transformation was originally 
discovered more than 20 years ago. [16] Since then, substantial efforts have been made towards the 
identification of novel STAT3 inhibitors. Despite the potential involvement of uSTAT3 in oncogenesis and 
signaling in cancer cells, to date, the research has focused on the inhibition of the phosphorylated form. [17] 
Two general approaches have been explored in the inhibition of STAT3 signaling [12,18]: indirect, involving the 
inhibition of factors that lead to STAT3 activation, and direct, based on the interaction of small molecules 
with the protein. However, since all known STAT3 inhibitors are still at the experimental stage and not in a 
suitable form for clinical utility, the challenge is the discovery of new drug candidates, with high potency and 
in vivo activity. In order to achieve this goal, a direct inhibitory approach is preferred, as the nonspecific 
nature of the indirect strategy could cause important adverse effects. Regarding the direct approach, 
considerable attention has been directed at disrupting the STAT3 dimerization, a fundamental step in the 
activation process. The slow progress in obtaining suitable STAT3 inhibitors for clinical development could be 
attributed to the challenge of targeting protein-protein interactions (PPIs), given the large surface area of the 
target and the chemistry of these interactions. [19] 
Based on their structural characteristics, the direct inhibitors can be divided into five groups: peptides, 
peptidomimetics, natural compounds, synthetic compounds and oligonucleotides. [12] 
The purpose of part this PhD project is the identification of novel synthetic compounds able to directly inhibit 
STAT3 activity through binding to its SH2 domain. In the literature, there are several promising small 
molecules candidates identified through computational studies and screening of chemical libraries, which 
are able to inhibit STAT3 activity [12]. They include: 
 3,4- disubstituted-1,2,5 oxadiazoles (see Section 2.1); 
 platinum-based compounds (see Section 1.3.3); 
 compounds containing pTyr-mimetic fragments, such as 4-phosphonodifluoromethyl-cinnamate 
[20,21], arylsulfonamide [22], 4-amino and 4- hydroxyl salicyclic acid [23], catechol structure [24] or purine 
scaffold [25]. 
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1.3 Platinum based anticancer drugs 
Although metal-based compounds were exploited for years for the treatment of several diseases, the 
discovery of cisplatin [26] (cis-[PtCl2(NH3)2]) in the 1960s meaningfully enhanced the attention to the field of 
chemotherapy based on metalorganic entities [27]. Over the last fifty years, a huge amount of analogues was 
prepared with the aim to enlarge the spectrum of activity, overcome the resistance issue and reduce the 
toxicity of both the first (cisplatin) and the second (carboplatin [28]) generation of platinum compounds (Figure 
2). 
Among all, oxaliplatin [29] achieved anticancer activity in cell lines intrinsically resistant to cisplatin and 
carboplatin as well as in those that had developed acquired resistance, while satraplatin was the first orally 
administered platinum drug with a promising profile in the treatment of prostate cancer. Up to now, the 
Food and Drug Administration (FDA)-approved platinum based anticancer drugs cisplatin, carboplatin and 
oxaliplatin are still among the most effective drugs used for the treatment of solid cancers, but the strong 
side effects and the increasing resistance are limitations to their use, thus highlighting the need for new 
platinum-based chemotherapeutics. [30] 
Since DNA was established to be the primary target of platinum drugs, an extensive investigation was carried 
out in order to characterize the mechanism of cellular accumulation and the types of adducts formed with 
the DNA. 
1.3.1 How platinum-based chemotherapeutics work  
The metals’ property to become positively charged ions in aqueous solution makes them able to interact with 
negatively charged biological molecules. In aqueous solution, cisplatin (as well as platinum complexes in 
general) undergoes a series of aquation and hydrolysis reactions due to the displacement of the chloro 
ligands by water molecules (Figure 3). [31] 
Upon administration to the bloodstream through an intravenous injection, cisplatin is relatively stable (68% 
of the complex remains in its original form / 24% as chloridohydroxido species) due to the high concentration 
of chloride ions. All these species are suitable for passive diffusion across the cell membrane and the lower 
concentration of chloride ions inside the cell facilitates aquation reactions to form the cationic aqua species 
unable to diffuse back out of the cell before interacting with intracellular targets. [27] 
  
Figure 2. Main platinum drugs in clinics. 
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Even if passive diffusion is the major mechanism of transport for entering into the cells, active transport in 
cisplatin uptake was also observed. These active or facilitated pathways also have a role in resistance issue 
which, for instance, appeared to be increased in cells transfected with copper-transporting P-type ATPase 
(ATP7B, an efflux transporter) or lacking copper transporter 1 (Ctr-1, an influx transporter). [32,33] Besides, 
different organic cation transporters (OCTs) were related to specific tumor activities of various platinum 
complexes: OCT1 and OCT2 increased accumulation and cytotoxicity of oxaliplatin but not those of cisplatin 
and carboplatin. These results also strongly suggest that the expression of OCTs could be a marker for 
selecting specific platinum-based therapies in individual patients. [34] 
Once inside the cell, the hydrolysis reactions which replaced one or both of the chloro ligands by water 
molecules lead to the formation of different activated species endowed with a higher reactivity towards 
nucleophiles considering that water is a much better leaving group than chloride. The formation of the 
monoaqua species cis-[Pt(NH3)2Cl(H2O)]+ is the rate-limiting step in DNA coordination. This activated species 
binds guanine-N7 (or adenine-N7) releasing the water molecule and leading to monofunctional adducts, 
which is considered to be unable to display cytotoxic effects. Indeed, the release of a second chloride is 
necessary to produce intrastrand and interstrand cross-links, responsible for platinum drug ability to block 
DNA replication and/or transcription. [31] 
Compared to cisplatin, oxaliplatin displayed a lower reactivity with DNA probably due to a slower dissociation 
rate of the oxalate ligand under physiological conditions. Moreover, oxaliplatin uptake was proved to be 
independent from Ctr-1 transporter at higher concentrations. Therefore, differences in spectrum of activity 
could be a consequence of its different uptake mechanism but could also be related to the formation of Pt-
adducts able to flee from being identify by DNA recognition and repair systems. [29] 
  
Figure 3. Cytotoxic pathway for cisplatin: after entering the cell, cisplatin is aquated, 
then binds to cellular DNA. If the DNA lesion is not repaired by the cell (path a), cell 
death (apoptosis) can occur. [31] 
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A deeper analysis of platinum complex biochemistry highlighted the evidence that non-DNA targets (such as 
STAT3) are involved in determining cytotoxic effects, too; therefore: 
 inside the nucleus, platinum drug reacts preferentially with DNA, due to the high nucleotide 
concentration; [35] 
 in the cytosol, it targets thiol-containing proteins leading to cytotoxic effects or being deactivated, 
due to the interaction with thiol-rich metallothioneins (MT) or conjugation to glutathione (GSH). [36] 
However, some studies hypothesized that the binding to GSH may also represent a valid mechanism for the 
drug storage inside the cell, thus modulating the kinetics of DNA platination. [37] 
The equilibrium between these aspects is different for each platinum drug. For instance, only 5-10% of 
cisplatin covalently bound to cells is detectable in DNA fraction while 75-85% of the drug resulted bound to 
proteins. [38] 
 
The insurgence of resistance is a common drawback in platinum-based chemotherapy and the molecular 
mechanisms can be divided into two main groups: [38] 
 mechanisms that prevent the drug from reaching its cellular targets, due to a diminished 
influx/increased efflux process or drug inactivation; 
 mechanisms responsible for inhibiting the possible cell-death pathways (necrosis or apoptosis), once 
platinum-DNA adducts are formed thanks to enhanced DNA repair processes (such as nucleotide 
excision repair (NER) involved in the removal of platinum 1,2-lesions from DNA). 
1.3.2 Structure–activity relationships 
Early studies on cisplatin allowed to determine the structural features that a platinum compound requires 
for displaying antitumor properties (Figure 4a): [31] 
 the compound should have two amines coordinated with a cis-geometry, as the trans ones were 
proved inactive or at least less active; 
 although it does not appear sufficient for exhibiting activity, the complex has to possess two groups 
that can be more easily lost, the so-called “leaving groups”, once again arranged in cis configuration; 
 the leaving groups, which the toxic profile of the compound relies on, should be moderately bound 
to the metal center as the ones with too labile groups result excessively toxic whereas those carrying 
functions too tightly bound are inactive; 
 the neutrality of the compound is necessary; 
 the fewer are the alkyl groups on the amine ligands, the greater is the activity. At least one hydrogen 
atom should be carried by each amine ligand for a significant activity to be observed. 
The majority of the research efforts focused on platinum(II) compounds resulted in a plethora of new 
platinum complexes which proved to possess anticancer properties without adhering to the SAR rules 
Figure 4. a. The general structure of platinum(II) complexes where X = leaving groups (e.g. 
two chloro groups or a bidentate malonate), ligand R = H or an alkyl substituent. b. The 
general structure of a platinum(IV) complex and its reduction to more reactive platinum(II) 
analogue, where: A = cis amine, Y = leaving groups in equatorial plane, and X = axial ligands. 
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mentioned above. [39] One of the approaches to overcome the toxicity consists in the use of prodrugs that are 
selectively activated in tumors and the use of carrier groups capable of selectively targeting tumors. 
Platinum(IV) compounds [40], such as satraplatin, showed high activity, low toxicity and an increased stability 
so that they might be orally administered. Considering the inert oxidation state, they behave as prodrugs 
that have to be reduced to their active platinum(II) analogues with the loss of the axial ligands [41] (Figure 4b). 
These latter play a pivotal role in modulating pharmacokinetic parameters such as the rate of reduction, the 
lipophilicity and the molecular targeting. [27] In addition, the axial ligands themselves could confer additional 
cytotoxicity upon their release. 
1.3.3 Platinum compounds and STAT3 
The connection between these chemotherapic agents, which typically form bifunctional DNA cross-links, and 
STAT3 activity is supported by literature (Figure 5). Indeed, kinetically liable platinum(IV) complexes, 
reported by Turkson and co-workers to induce tumor regression in a mouse model of colon cancer, were 
established to inhibit STAT3 activity in living cells through an irreversible interaction with the STAT3-DNA-
binding domains. [42,43] Besides, the involvement of STAT3-activated cellular responses in cisplatin resistant 
tumors was highlighted by the ability of Stattic, an effective STAT3 inhibitor targeting the SH2 domain, to 
restore the sensitivity to platinum-based drugs both in vitro and in vivo. [44,45] 
Compound IS3295 was found to display selective inhibition of constitutive STAT3 over STAT1 (STAT3, IC50 = 
1.4 μM vs STAT1, IC50 = 4.1 μM), inducing cell cycle arrest and apoptosis, by directly binding STAT3, both as 
monomer and dimer. Its inhibitory activity occurred through non-competitive kinetics and by irreversibly 
binding STAT3 through a cysteine residue of the protein. Preliminary evaluations of the potential activity of 
IS3295 complex on human and mouse cancer cells demonstrated its ability to induce cell cycle arrest and 
apoptosis, making the development of platinum compounds as STAT3 inhibitors very promising. [42] 
Moreover, cells readily become resistant to anticancer drugs that target a single protein, utilizing alternative 
metabolic pathways. [46] 
  
Figure 5. Structures of platinum complexes developed as STAT3 inhibitors. 
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1.4 Topoisomerases 
DNA topoisomerases are nuclear enzymes which play an essential role in the management of the topological 
state of DNA in cells. DNA is rolled up on itself to form a double helix, which has to be temporarily 
(transcription or recombination) or permanently (replication) separated in order to access the information 
stored herein. 
There are two classes of topoisomerases, type I and type II, and they have a key role in regulating the degree 
of DNA supercoils, causing a break into the DNA, followed by the formation of a phosphodiester bond 
between a tyrosine residue of the enzyme and one at the ends of the broken strand. [47] 
Figure 6. Catalytic cycle of type I (a) [48] and type II (b) [49] topoisomerases. 
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Type I DNA topoisomerases are monomeric proteins which mediate the relaxation of DNA supercoils 
generated during transcription and replication by introducing a transient nick in one strand of duplex DNA. 
[50] They consist of 765 residues and include four domains: N-terminal domain (1-214), core domain (215-
635), linker domain (636-712) and C-terminal domain (713-765). For its catalytic cycle, DNA topoisomerase I 
requires neither ATP hydrolysis nor the presence of bivalent cations; the cycle can be divided in four phases 
as shown in Figure 6a. In the first step, the enzyme ties the DNA and produces a break in a single strand of 
DNA forming a covalent complex. Then, it links interrupted strands by using the energy stored in the substrate 
(supercoiled form) and finally releases DNA. Topoisomerases I are further classified in two subfamilies: type 
IA which binds to a 5’ phosphate (called type I-5’), and type IB which links to a 3’ phosphate (called type I-3’). 
[47] 
Type II DNA topoisomerases are homodimer proteins and cleave both DNA strands. These enzymes are 
composed of 1531 residues divided in three domains: ATPase domain (1-659), DNA binding/cleavage domain 
(660-1163) and C-terminal tail (1164-1531). The two subtypes of topoisomerases II (IIA and IIB) are 
characterized by a similar mechanism but differ in overall tertiary structure. [47] In presence of Mg2+, the 
tyrosine from each topoisomerase II monomer (Tyr804 in human Topo IIA or Tyr821 in human Topo IIB) binds 
DNA. [51] The catalytic cycle requires the hydrolysis of two molecules of ATP and the presence of bivalent 
cations and, in particular, it can be divided in six phases as shown in Figure 6b. At the first step, topoisomerase 
binds a duplex DNA segment and then, thanks to two ATP molecules, it associates with a second DNA 
filament. ATP molecules catalyze the cleavage and opening of the first DNA strand and the movement of the 
second, passing through the opening. Finally, the broken strands are bonded and the product can be 
released. 
1.4.1 DNA Topoisomerases inhibitors 
Topoisomerase inhibitors (Figure 7) can be divided according to: 
 the mechanism of inhibition in 
o compounds able to form a covalent complex between the enzyme and the DNA (such as 
camptothecin and etoposide); 
o inhibitors impairing the functions of topoisomerases through noncovalent interactions by 
hydrogen bonding, electrostatic, Van der Waals and hydrophobic forces (suppressors such 
as β- lapachon); 
 the selectivity versus type I (e.g. camptothecin) or type II enzymes (e.g. etoposide), although several 
are not selective (e.g. saintopin). 
Topoisomerase poisons are so called due to their interference with the relegation phase of cycle reaction, 
resulting in DNA damage, cell cycle arrest and apoptosis. Despite the high structural heterogeneity (e.g. 
camptothecin, indolocarbazoles and indenoisoquinolines), these molecules form the ternary complex 
interacting with the same residues of topoisomerase I, Arg352 and Glu356 thanks to the high mobility of their 
side chains. [52] 
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Figure 7. DNA topoisomerase inhibitors. 
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1.5 Hit finding 
The drug discovery and development process can generally be identified with preclinical and clinical studies, 
respectively. This long, expensive and high-risk business starts with target identification and validation. 
Afterwards, in vitro and in vivo experimental models and/or computational approaches are capitalized to 
identify a potential hit, which has to undergo secondary assays and optimization processes to give a lead 
compound and then a potential drug candidate. Chemical tests for efficacy, joined with early safety and 
toxicity studies, are performed in preclinical phase, and are usually followed by investigations on formulation, 
stability and scale up synthesis. Besides, this molecular target screening approach, a High-Throughput 
Screening (HTS) can sometimes be performed even without knowing the target, which will be identified later 
(phenotypic screening approach); a third strategy could also be the drug repurposing screen in which a known 
drug, already marked and approved for a particular indication, is used as lead for the treatment of a different 
disease. 
Generally, the HTS could involve: 
 synthetic chemical libraries, composed of molecules characterized by a high structural diversity (for 
instance obtained by the diversity-oriented synthesis approach); 
 targeted focused libraries, which consist of compounds known to be active against a particular target 
(with natural or synthetic origin, small molecules or peptides or peptidomimetics, etc.); 
 fragment based libraries, built up by fragments selected from active compounds. 
1.5.1 Scaffold hopping 
The aim of scaffold hopping is to discover structurally innovative entities starting from known active 
molecules, by modifying the central core structure but maintaining some essential features of the template. 
Therefore, scaffold hopping has been widely applied by medicinal chemists to discover equipotent 
compounds with novel backbones that have improved properties. For instance, the replacement of a 
lipophilic scaffold with a more polar one will increase the solubility of the compound, while the substitution 
of a metabolically labile scaffold with a more stable/less toxic one will improve the pharmacokinetic 
properties. Moreover, the replacement of a very flexible scaffold (such as a peptide backbone) with a rigid 
central one can significantly improve the binding affinity, leading to a novel structure that is patentable. [53] 
In literature, there are different criteria for defining how different derivatives must be from their parent 
compounds in order to be classified as scaffold hopping. For instance, Boehm et al. classified two scaffolds 
as different if they were synthesized using different synthetic routines, no matter how small the change might 
be. On the other hand, Sun et al. rationalized the concept of scaffold hopping by focusing on the degree of 
change associated with the original parent molecule. [54] 
1.5.2 Fragment-based drug design 
Fragment-based drug design (FBDD) has emerged as promising methodology to generate lead compounds 
active against therapeutic targets in the past decade. Compared with high-throughput screening hits, the 
advantage is that the identified small molecules are expected to be optimized efficiently into a drug candidate 
which maintains low molecular weight and possesses both a great binding affinity and a favorable 
pharmacokinetic profile. 
This screening could be run using different experimental approaches (physical or computational methods), 
according to the sample range and the specific information. For instance, among physical techniques, the 
throughput of a biochemical approach is higher than Surface Plasmon Resonance (SPR) (>10.000 vs 1000s) 
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or X ray crystallography and isothermal titration calorimetry one (10s and <10, respectively). While 
fluorescence method can be used with a wide range of throughput (10-1000s). 
On the other hand, in silico site-directed FBDD [55] is a computational approach (Figure 8) whose fragment 
libraries are built from known inhibitors and are divided into binding site-specific sublibraries, according to 
docking poses. 
Linkers are chosen from known inhibitors or applying the concept of bioisosterism, merged potential 
candidates may be quickly screened via computational docking methods to further narrow the number of 
molecules that will be selected for synthesis and testing. Table 1 shows a comparison between conventional 
and in silico site-directed FBDD methods. 
 
 Conventional FBDD In silico site-directed FBDD 
Fragments library Screened by X-ray, NMR and 
other methods 
Built from known inhibitors and 
divided into binding site specific sub-
libraries according to docking poses 
Linkers Selected from linker libraries 
or by chemical intuition 
Original linkers or bioisosteres 
derived from original linkers 
Merge methods Fragments are randomly 
merged together 
Fragments selected from sublibraries 
are merged together 
Pre-selected candidates According to structural 
variety, purchase/synthesis 
availability or chemical 
intuition 
According to computational docking 
results 
Table 1. Comparison of conventional FBDD and in silico site-directed FBDD. 
 
FBDD has proven to be a successful approach to identify potent inhibitors for specific targets, among which 
also STAT3. [55,56] 
 
Figure 8. Site-directed FBDD strategy. The first step is to screen fragment libraries fitted to 
the site that might be essential for ligand-binding. The chemically merged privileged 
fragments may maintain their original orientation in the protein binding pocket, and thus 
jointly contribute to the final binding energy. 
 Chapter 2 – MD77 derivatives 
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
MD77 derivatives 
  
Chapter 2 – MD77 derivatives 
 
18 
2.1 Research project 
1,2,5-Oxadiazoles have received considerable attention in recent years from Prof. Barlocco’s research group 
in light of the interesting biological results supporting a potential antitumor activity. In particular, these 
compounds have been investigated for inhibitory effects towards STAT3 signaling pathway. [57-60] 
Starting from the oxadiazole ureido derivative AVS-0288, in collaboration with one of its discoverer, Prof. B-
M. Kwon (Korea University of Science and Technology), the above mentioned research group investigated 
different compounds, structurally related to the parent molecule and able to increase STAT3 inhibition. On 
this respect, the antiproliferative potential of the 1,2,5-oxadiazole ring was explored by synthesizing several 
new compounds differently substituted at positions 3 and 4 of the heterocycle. Of note, the derivative 
bearing the amide function (MD77) emerged for its interesting biological results (Table 2). In order to deepen 
its anti-proliferative activity profile, this compound was submitted to a panel of 58 human tumor cell lines, 
derived from 9 cancer cell types (NCI, Bethesda, USA). 
 
 
Anti-proliferative activity (IC50 µM) 
H460 1.8 
HCT-116 1.3 
MCF-7 20.5 
A549 1.3 
HSF N.E. 
 
Table 2. MD77 structure and biological activity: H460 = non-small-cell lung 
carcinoma; HCT-116 = colorectal cancer; MCF-7 = breast cancer; A549 = lung 
adenocarcinoma; HSF = human skin fibroblasts. 
Besides, an in vitro competitive binding test, the AlphaScreen-based assay confirmed MD77 ability to disrupt 
the interaction between STAT3 and a phospho-Tyr (pTyr) peptide (5-carboxyfluorescein (FITC)-GpYLPQTV), 
by interfering with the STAT3-SH2 domain (IC50 = 17.7 µM). 
In light of these data, I designed and synthesized a small group of MD77 derivatives aimed at structure-
activity relationship (SAR) studies. Although some of them are endowed with antiproliferative activity, no 
one displayed affinity for STAT3-SH2 domain. Since the introduced modifications did not justify the total loss 
of STAT3 affinity, MD77 was retested and, differently from the data published in ref. [59], it resulted to be 
inactive. 
Hence, considering MD77 antiproliferative profile and the cytotoxicity emerged for its derivatives, I focused 
my research efforts in the identification of the actual molecular target of this series. In order to achieve this 
goal, I employed a combination of synthetic and computational approaches. 
In collaboration with Prof. S. Guccione’s research group (University of Catania, Italy), structure-activity 
relationship studies were carried out through the innovative Activity Miner module as implemented in the 
software Cresset Forge [61,62]. As the Activity Miner module has to be applied on a broad range of structurally 
and electronically heterogeneous derivatives, the starting pool of derivatives was enlarged. 
A wide pool of synthesized derivatives, summed up in Figure 9, underwent the MTT-assay on human colon 
cancer cells and a structure-activity relationship analysis. This computational phase, in which the 3D shape 
and the electrostatic environment similarity were correlated with the change in activity, was performed by 
using Cresset Forge as software. 
Once all the antiproliferative activity will be available, this analysis will be repeated to obtain an improved 
disparity matrix that could be used as query for recognizing a potential target [63].  
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Besides, considering their structural characteristics (see Section 2.3.4 and Ref.  [59]), MD77 and some of its 
derivatives were assayed as topoisomerase inhibitors or DNA intercalators, thanks to the collaboration with 
Prof. L. Dalla Via (University of Padua). Screening assays are ongoing. 
 
This project was supported by PRIN Research Project, grant no. 20105YY2H_007. 
  
Figure 9. MD77 derivatives 
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2.2 Synthetic chemistry 
  
Scheme 1. Reagents and conditions: i) NH2OH . HCl, NaHCO3, MeOH, 2h, reflux; ii) NCS, DMF, 12h, rt; iii) KCN, 
Et2O/H2O, 5h, rt; iv) NH2OH . HCl, NaHCO3, MeOH, 12h, reflux; v) 2N NaOH, 12h, reflux; vi) a. NaOH, 12h, 0°C; b. 
NaNO2, 20% HClO4, 14h, rt; c. NH2OH . HCl, NaOH, 2h, 95°C; d. urea, 3h, reflux; vii) R1-PhCOCl, DMAP, dry ClCH2CH2Cl2, 
45 min, 120°C, mw, N2; viii) a. 60% NaH, dry DMF, 30 min, 0°C, N2, b. R1-PhCOCl, 12h, 60°C; ix) BBr3, dry CH2Cl2, 12h, 
rt, N2; x) (BnO)2PHO, CCl4, DIPEA, DMAP, dry CH3CN, 3h, -10°C, N2; xi) H2, Pd/C, MeOH, 3h, rt, 1 atm; xii) SnCl2, AcOEt, 
7h, reflux; xiii) NaOH, EtOH, 3h, reflux; xiv) (EtO)2CO, dry MgCl, dry EtOH, 12h, 40°C, Ar; xv) H2, Pd/C, AcOEt/MeOH 
(9:1), 24h, rt; xvi) ClCH2COOCH2CH3, dry DMF, 24h, rt, N2; xvii) 1M NaOH, THF/EtOH (1:1), 30 min, reflux. 
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Compounds of Series 1 were prepared following the general procedures reported in Scheme 1. In detail, a 
one-pot reaction on ethyl benzoylacetate (according to a literature method [64]) afforded 4-phenyl-1,2,5-
oxadiazol-3-amine, intermediate 105a, while the key intermediates 105b-d,g-j,l and 105r were synthesized 
from the appropriate benzaldehyde following the multi-step procedure previously reported in literature. [59] 
4-phenyl-1,2,5-oxadiazol-3-yl-benzamides (Series 1) were obtained by coupling reactions of these 4-phenyl-
1,2,5-oxadiazol-3-amines with the suitable benzoyl chlorides. The hydrolysis of 1dk,lg and 1dt led to 
compounds 1dm,mg and 1du, respectively. The latter underwent a Fisher esterification (1dv) and the nitro 
group of 1dr and 1rg was reduced (1ds and 1sg). Moreover, compounds 1dm and 1mg were phosphorylated 
with dibenzylphosphite [65] and intermediates 1dn and 1ng were subsequently debenzylated by a catalytic 
hydrogenation over Pd/C leading to derivatives 1do and 1og. 1pg was prepared by substitution reaction of 
phenol 1mg with methyl chloroacetate [66] and hydrolyzed to 1qg in basic conditions. 
Finally, coupling reactions performed with 105d and aliphatic acyl chlorides gave compounds 2-5, while 
compound 6 was obtained by reductive amination of benzaldehyde with 105d (Scheme 2). 
The other N-heteroaryl-benzamides herein presented (7da,dg, 8da,dg, 9da,dg, 10da,dg, 119da,dg and 
12da,dg) were prepared starting from the corresponding heteroarylamines (2-amino-5-(4-chlorophenyl)-
1,3,4-oxadiazole, 109, 114, 116, 118 and 121) which were coupled with the suitable benzoyl chloride in 
presence of the proper basis (pyridine, trimethylamine or 60% sodium hydride). 
In details, compounds 7da,dg were prepared from the commercially available 2-amino-5-(4-chlorophenyl)-
1,3,4-oxadiazole by acylation in pyridine, as shown in Scheme 3. 
For the synthesis of the N-(4-(4-chlorophenyl)-isoxazol-3-yl)benzamides (8da,dg), the key intermediate 109 
was obtained by a Sandmeyer reaction (106) in aqueous solution [67] performed on the commercially available 
ethyl 5-amino-4-(4-chlorophenyl)isoxazol-3-carboxylate. The treatment with hydrazine monohydrate (107) 
and subsequently with sodium nitrite in acetone and hydrochloric acid as catalyst gave the carbonyl azide 
Scheme 3. Reagents and conditions: i) a. dry Py, 10 min, 0°C, N2; b. R-PhCOCl, 3-16h, rt. 
Scheme 2. Reagents and conditions: i) a. 60% NaH, dry DMF, 30 min, 0°C, N2; b. 
RCOCl, 12h, 60°C; ii) a. PhCHO, AcOH, 3h, rt; b. NaBH4, 1h, 0°C. 
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(108) with a Curtius rearrangement. The addition of water led to the desired 3-amino-4-(4-
chlorophenyl)isoxazole (109) [68] which was acylated with the proper benzoyl chloride in presence of 
trimethylamine, providing the final benzamide (Scheme 4). 
As described in Scheme 5, the key intermediate 4-amino-3-(4-chlorophenyl) isoxazole (114) was prepared 
starting from the commercially available 4-chlorobenzaldehyde which was firstly treated with hydroxylamine 
hydrochloride and then with N-chlorosuccinimmide. [59] The chloroxime 102d reacted with 110, previously 
synthesized following a well-described literature procedure [69], and the resulting ethyl 3-(4-chlorophenyl)-4-
isoxazolcarboxylate (111) was firstly hydrolyzed in acidic condition and then the acyl azide was formed by the 
Scheme 4. Reagents and conditions: i) NaNO2, AcOH/H2O (1:1), THF, 1h, rt; ii) NH2NH2 . H2O, EtOH, 
90 min, rt; iii) NaNO2, CO(CH3)2/10% HCl (1:1), 40 min, rt; iv) AcOH, H2O, 1h, reflux; v) a. NEt3, dry 
CH2Cl2, 30 min, 0°C, N2; b. R-PhCOCl, 90 min, 40°C. 
Scheme 5. Reagents and conditions: i) a. NH2OH . HCl, NaHCO3, MeOH/H2O (2:1), 2h, rt; b. NCS, DMF, 16h, rt; 
ii) pyrrolidine, toluene, 16h, rt; iii) NEt3, dry Et2O, 18h, rt, N2; iv) 6N HCl, AcOH, 6h, reflux; v) DPPA, NEt3, dry t-
BuOH, 16h, reflux, N2; vi) a. TFA, dry CH2Cl2, 16h, rt, N2; b. 1N NaOH; vii) a. 60% NaH, dry DMF, 30 min, 0°C, N2, 
b. R-PhCOCl, 12h, 60°C. 
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direct reaction of the carboxylic acid with diphenyl phosphoryl azide (DPPA). According to Curtius 
rearrangement, acyl azide group decomposed to isocyanate which underwent nucleophilic attack to yield the 
corresponding carbamate (113). N-Boc protecting group was successively removed with trifluoroacetic acid 
and the amine 114 was finally condensed with the suitable acyl chloride in presence of 60% sodium hydride 
leading to 9da,dg. 
The synthesis of 10da,dg started from the commercially available 5-chloro-1-methyl-4-nitroimidazole which 
underwent a Suzuki coupling reaction (115) [70] followed by a catalytic hydrogenation with Pd/C to afford 
amine 116 [71]. This latter was condensed using triethylamine as basis leading to the final products, as shown 
in Scheme 6. 
The synthetic pathway for the obtainment of furan derivatives (Scheme 7) started from 4-
chlorophenylacetonitrile which was treated with metallic Na, ethyl formate and ethanol for 16 hours leading 
to the sodium salt intermediate 117. The latter was cyclized by a one-pot reaction [72] to intermediate 118 
which was condensed with the proper acyl chloride, in presence of triethylamine by a microwave assisted 
reaction to obtain compounds 119da,dg. The ester group was firstly hydrolyzed (120da,dg) and then the final 
compounds 11da,dg were obtained by decarboxylation [73]. 
Scheme 6. Reagents and conditions: i) 4-ClPhB(OH)2, K2CO3, TBAB, Pd(PPh3)2Cl2, H2O, 16 h, 75-85°C, N2; ii) H2 (30 
atm), Pd(OH)2, CH2Cl2/MeOH (9:1), 16 h, rt; iii) a. NEt3, dry CH2Cl2, 30 min, 0°C, N2; b. R-PhCOCl, 90 min, 0°C. 
Scheme 7. Reagents and conditions: i) HCOOCH2CH3, Na, dry EtOH, 16h, reflux, N2; ii) a. Cl(COOCH2CH3)2, dry DMF, 
5h, rt, N2; b. 1,5-diazabicyclo[4.3.0]non-5-ene, dry EtOH, 16h, reflux, N2; iii) R-PhCOCl, NEt3, dry CH2Cl2, 40 min, 
80°C, mw, N2; iv) 1N NaOH, THF/EtOH (1:1), 1h, reflux; v) Ag2CO3, AcOH, dry DMSO, 16h, 120°C, N2. 
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The synthesis of N-(4-cloro-[1,1-biphenyl]-2-yl) benzamides (12da,dg) started from 2-iodoaniline which was 
arylated with a Suzuki reaction (121) [74] and condensed in presence of triethylamine as basis with the suitable 
acyl chloride, as shown in Scheme 8.  
Scheme 8. Reagents and conditions: i) 4-ClPhB(OH)2, saturated Na2CO3, Pd(PPh3)4, dry 
toluene/EtOH (20:1), 16h, 70°C, N2; ii) a. 60% NaH, dry DMF, 30 min, 0°C, N2, b. R-
PhCOCl, 12h, 60°C. 
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2.3 Results and discussion 
Starting from AVS-0288 [57], a STAT3 inhibitor characterized by an oxadiazole ureido scaffold, Prof. Barlocco’s 
research group identified MD77 [59] as promising candidate for lead optimization. Its antiproliferative activity 
was evaluated on a panel of 58 human tumor cell lines (NCI, Bethesda, USA) while its ability to disrupt STAT3 
dimerization was proven by the AlphaScreen-based assay. 
Therefore, in order to deeply understand the structural characteristics responsible for its STAT3 affinity, I 
designed and synthesized a small set of derivatives, performing iterative modifications on the scaffold. 
This first group of analogues underwent biological evaluation, resulting to be cytotoxic but without affinity 
for the STAT3-SH2 domain. Since the structural diversity of these derivatives with respect to the parent 
compound did not justify this complete loss of activity in the AlphaScreen-based assay, MD77 was retested 
showing no activity on STAT3 dimerization, differently from the data previously published [59]. 
However, considering the interesting cytotoxic profile of this class of compounds, I looked for their real 
molecular target, employing a combined synthetic-computational approach. Firstly, I enlarged the pool of 
MD77 derivatives obtaining a wide range of structural and electronical heterogeneity, and, in collaboration 
with Prof. S. Guccione’s research group (University of Catania, Italy), a structure-activity relationship analysis 
was performed using the Activity Miner module of Cresset Forge [61,62]. This approach should help in defining 
whether the electronic characteristics or the position of the substituent prevail in these derivatives, affecting 
on their antiproliferative activity. 
Regarding the performing iterative modifications, I firstly decided to maintain the 1,2,5-oxadiazole scaffold 
and the amide linkage (compounds 1-5) and changed electronic characteristics and/or the positions of the 
substituents. Therefore, I designed and synthesized compounds characterized by: 
 different functional groups at position 4 of the heterocycle; 
 various substituents on the phenyl ring of the benzamide; 
 the replacement of the benzamide with aliphatic moieties. 
Then, the attention was focused on the amidic function, which was reduced to the corresponding amine (6), 
and the 1,2,5-oxadiazole scaffold, which was replaced with 1,3,4-oxadiazole isomer (7da,dg) and other 
heterocycles (such as isoxazole (8da,dg and 9da,dg), imidazole (10da,dg) and furan (11da,dg) rings) or the 
phenyl ring (12da,dg). 
Part of the synthesized compounds was evaluated for its antiproliferative activity by MTT-assay on human 
colon cancer cells (HCT-116) by Dr. N. Ferri (University of Padua, Italy). Besides, in order to find where small 
structural differences cause a large change in activity, each pair of molecules was compared in silico by the 
Active Miner module. The field difference map generated by Cresset Forge displays the surfaces as relative 
values between pairs of molecules or as sum of all molecules, considering electrostatic or hydrophobic or 
steric fields. Once all the antiproliferative results will be available, this analysis will be repeated on the whole 
library and the generated disparity matrix will be used as query in search of a potential target [63]. 
 
Moreover, considering the structural characteristics of this class of compounds, MD77 and some of its 
derivatives are under evaluation (with other structurally different compounds synthesized by Prof. Barlocco’s 
research group) for their potential activity as topoisomerase inhibitors or DNA intercalators. Indeed, even if 
it was traditionally thought that only molecules with fused-ring structures could be good DNA intercalators, 
it was shown that the presence of basic, cationic, or electrophilic functional groups was often necessary, 
while the fused-ring structures were not always required. [75,76] 
These assays are performed by Prof. L. Dalla Via (University of Padua) who also selected a pool of compounds 
to be tested on human cervical (HeLa), ovarian (A2780) and mesothelioma (MSTO-211H) cancer cell lines. 
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2.3.1 Antiproliferative activity 
This series of compounds was evaluated for its antiproliferative activity by MTT-assay on human colon cancer 
cells (HCT-116) by Dr. N. Ferri (University of Padua, Italy). The available results were reported as half maximal 
inhibitory concentration (IC50) in Tables 3,4. 
 
 Cmp R R1 IC50  µM 
 
MD77 p-Cl p-CF3 1.3 
1aa H H n.a. 
1ag H p-CF3 n.a. 
1ad H p-Cl n.t. 
1ba o-Cl H 76.3 
1bg o-Cl p-CF3 56.7 
1ca m-Cl H 73.4 
1cg m-Cl p-CF3 15.4 
1da p-Cl H n.a. 
1de p-Cl o-CF3 n.a. 
1df p-Cl m-CF3 7.4 
1dd p-Cl p-Cl n.a. 
1dh p-Cl p-Br n.t. 
1di p-Cl p-CH3 n.t. 
1dk p-Cl p-OCH3 n.a. 
1dm p-Cl p-OH n.a. 
1dn p-Cl p-OPO(OBn)2 n.t. 
1do p-Cl p-OPO3H2 n.a. 
1dr p-Cl p-NO2 46.7 
1ds p-Cl p-NH2 n.a. 
1dt p-Cl p-CN 19.4 
1du p-Cl p-COOH n.a. 
1dv p-Cl p-COOCH2CH3 n.t. 
1hg p-Br p-CF3 n.t. 
1gg p-CF3 p-CF3 24.1 
1ig p-CH3 p-CF3 n.t. 
1gd p-CF3 p-Cl 0.95 
1ja p-Ph H n.t. 
1jg p-Ph p-CF3 n.t. 
1lg p-OBn p-CF3 n.t. 
1mg p-OH p-CF3 n.a. 
1ng p-OPO(OBn)2 p-CF3 n.t. 
1og p-OPO3H2 p-CF3 n.t. 
1pg p-OCH2COOCH2CH3 p-CF3 n.t. 
1qg p-OCH2COOH p-CF3 n.t. 
1rg p-NO2 p-CF3 58.2 
1sg p-NH2 p-CF3 n.a. 
Table 3. Antiproliferative activity of Series 1 on HCT-116: not active (n.a.) means IC50 is higher than 100 µM, 
while not tested (n.t.) means that it is currently under evaluation.  
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 Cmp X R1 IC50  µM 
 
2 C=O Cy n.t. 
3 C=O (CH2)5CH3 n.t. 
4 C=O (CH2)2CH3 n.a. 
5 C=O CH3 n.t. 
6 CH2 Ph n.t. 
 
7da 1,2,4-oxadiazole H 14.7 
7dg 1,2,4-oxadiazole CF3 45.0 
8da 1,2-isoxazole H n.a. 
8dg 1,2-isoxazole CF3 n.a. 
9da 1,5-isoxazole H n.a. 
9dg 1,5-isoxazole CF3 n.a. 
10da N-Me-Imidazole H n.a. 
10dg N-Me-Imidazole CF3 52.3 
11da Furan H n.t. 
11dg Furan CF3 n.a. 
12da Phenyl H n.a. 
12dg Phenyl CF3 n.a. 
Table 4. Antiproliferative activity of Series 2-12 on HCT-116: not active (n.a.) means IC50 is higher than 100 
µM, while not tested (n.t.) means that it is currently under evaluation. 
Preliminary results showed that isomers bearing the chlorine atom in ortho (1bg, IC50 = 56.7 μM) and meta 
(1cg, IC50 = 15.4 μM) positions, respectively, were endowed with lower antiproliferative activity than the 
parent compound. In particular, 1bg showed moderate growth inhibition properties, while 1cg exhibited a 
more interesting activity, although the para substitution remained the preferred. 
Regarding the effects of moving the CF3 group to different positions on the phenyl ring, the isomers 1de (n.a) 
and 1df (IC5 = 7.4 μM) indicated the ortho position as detrimental, because 1de completely lost the activity, 
whereas the meta isomer retained almost the same biological properties of the lead. 
When the CF3 group in para position of the benzoyl ring was substituted by NO2 (1dr, IC50 = 46.7 μM) or CN 
(1dt, IC50 = 19.4 μM) group, a partial cytotoxic activity was retained. Analogously, 1rg, bearing NO2 substituent 
instead of the p-Cl atom on the 4-phenyl ring, showed modest growth inhibition properties (IC50 = 58.2 μM). 
If the phenyl rings were both substituted with the Cl atoms (1dd) or with the CF3 groups (1gg) a different 
behavior was observed: the first one was completely inactive, while the latter showed a moderate activity 
(IC50 = 24.1 μM). 
Among the bioisosteric analogues of MD77, only 7dg and 10dg presented cytotoxic activity (IC50 = 45.0 and 
52.3 μM, respectively). Otherwise, 1da analogue, 7da, characterized by the 1,3,4-oxadiazole ring displayed a 
significant cytotoxicity (IC50 = 14.7 μM). 
Compound 1gd, bearing the same substituents of MD77 but in inverted position, was slightly more potent 
with respect to the reference MD77 (IC50 = 0.95 versus 1.3 μM, respectively). 
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2.3.2 AlphaScreen-based assay 
Considering AVS-0288 inhibitory activity on STAT3 pathway, compounds 1-12 were evaluated by Prof. A. Asai 
(University of Shizuoka, Japan) for their potential inhibition of the interaction between STAT3-SH2 domain 
and pTyr-containing peptides at 30 μM concentration. The obtained data indicated that all the synthesized 
derivatives did not disrupt STAT3 dimerization. 
2.3.3 Cresset Forge 
In the attempt to understand the key factors that affect the activity on HCT-116 of these derivatives, a 
structure-activity relationship analysis was performed using Cresset Forge [61,62] as software. 
This technique allows the assessment of the structure-activity landscape for a series of aligned compounds 
based on the chemical similarity principle, which asserts that molecules having similar features often have 
comparable bioactivities. [77] Therefore, Activity Miner module pinpointed those pairs of derivatives where 
small structural differences cause changes in activity. 
The disparity between a pair of molecules was calculated as the difference in their activity divided by the 
distance between them, where the distance was obtained from their 2D or 3D similarity. 
Molecule pairs that had a low disparity and high similarity defined bioisosteres or flat regions in the SAR. 
These regions could be useful to modify the physicochemical properties of the molecules without losing 
activity and this overview could help to create a ‘protein’s eye view’ of the scaffold. 
The compounds alignment was performed starting from MD77 crystallographic coordinates (for sake of 
clarity, the three rings were named A, B and C as shown in Figure 10a), as we found that its molecular 
arrangement in the solid state almost corresponds to the most stable conformation calculated in vacuo. [59] 
To verify the reliability of this approximation, the crystal structures of two monosubstituted analogues, 
bearing the phenyl ring carrying either the Cl atom on system A (1ad) or the CF3 group on ring C (1ag), were 
determined. 
As compounds share a fair degree of structural similarity across the series, they were aligned considering on 
their maximum common substructure with reference MD77. The functional groups, which were not part of 
the maximum common substructure, were aligned basing on a combination of three-dimensional shape and 
molecular interaction fields. 
Therefore, Activity Miner module on this aligned dataset (Figure 10b) allowed the activity cliff analysis (Figure 
10c-f) and generated the disparity matrix (Figure 11) across the ligands. This technique will be repeated once 
all the antiproliferative activity will be available. 
 
Cresset Forge software provided various field difference maps as sum of the electrostatic or hydrophobic or 
steric fields for the whole pool of molecules. In detail: 
 Average Electrostatics or Hydrophobics of Actives (Figure 10c,d), calculated considering only the 
active molecules and pointed out the essential structural features for the activity; 
 Active Cliff Summary of Electrostatics or Hydrophobics (Figure 10e,f) displayed the effects of the 
introduced modifications (in the different regions) on the activity considering both cytotoxic and 
inactive compounds. 
This graphical representation could provide indications about the electrostatic, hydrophobic and shape 
features underlying the cytotoxic activity. These preliminary results, discussed considering MD77 as 
reference, suggested that an increasing of negative electrostatic field on the core B of the structure could 
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have positive effects on the activity (in cyan in Figure 10c), while an enhanced π electrostatic potential on 
the system C is not suitable (in red in Figure 10c). Besides, electron withdrawing substituents which generate 
a more positive (or less negative) electrostatic field (in red in Figure 10e) in meta position on ring A are 
beneficial for activity, whereas opposite characteristics are required for para position. 
As for the hydrophobic and steric aspects, Figure 10d highlighted the regions (in yellow) where active 
molecules could make hydrophobic interactions, while Figure 10f showed that steric hindrance in para 
position was well tolerated on ring A (green area), but not on system B (magenta area). Otherwise, steric 
bulk in ortho or meta position at phenyl A (magenta area) was detrimental for activity. 
As previously introduced, the Activity Miner module also generated a preliminary disparity matrix (Figure 
11a), in which the similarity value for each pair of compounds was computed as the average of their three-
dimensional field and shape similarity. [78,79] The height of each wedge corresponds to the ‘distance’ between 
them: a smaller wedge reflects very similar compounds. The color of the wedge points out the direction the 
activity is going: red means the activity is decreasing; green means the activity is increasing between the pair. 
The shading evidences the disparity, which relates to how steep the activity cliff is.  
Figure 10. a. MD77 structure, used as reference compound in the discussion. b. Representative low 
energy conformations of the aligned compounds. c. Average electrostatic field of activity. d. Average 
hydrophobics of activity. e. Active cliff summary of electrostatic field. f. Active cliff summary of 
hydrophobics. 
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Figure 11. a. Disparity matrix, calculated by 
running the Activity Miner module of Cresset 
Forge. b-g. Field difference maps, displaying the 
regions having stronger fields than the 
corresponding regions in the compared molecule 
(MD77). 
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The result is a focused view of the SAR around a particular compound which can help to understand subtle 
molecule-to-molecule structure-activity changes and identify potential outliers. 
This outcome can also be visually represented by the field difference maps (Figure 11b-g), displaying the 
regions having stronger fields than the corresponding regions in the compared molecule. 
For instance, the most active derivative 1gd has almost the same potential profile of MD77 (Figure 11b), in 
line with their equivalent biological activity. 
Small differences of positive and negative electrostatic potential are reported for isomer 1cg which maintain 
cytotoxicity. Also a negative electrostatic potential localized on system C substituent (NO2 in 1dr, Figure 11c, 
and CN in 1dt) seems to be well tolerated. Otherwise, compounds 1bg (Figure 11d) and 1rg (Figure 11e) 
showed an inversion of the potential distribution at level of the substituted position of ring A, possibly 
resulting in their lower in activity.  
As for the bioisosteric analogues of MD77, where the oxadiazole was replaced by 1,3,4-oxadiazole (7dg) or 
with N-methylimidazole (10dg), important field differences were observed (Figure 5f,g), which could justify 
the lower activity. Indeed, in 10dg there is an inversion of electrostatic potential and 7dg lacks the π-cloud 
over the 1,3,4-oxadiazole ring compared to the corresponding groups of the parent MD77. 
2.3.3.1 Computational methodologies 
A qualitative 3D model based on a molecular field technology was tine up using the Activity Miner module as 
implemented in Cresset Forge v10.4.2 software. Through the shape and electrostatic character of molecules, 
qualitative and quantitative 3D models of activity were calculated using Cresset’s patented ligand comparison 
method to align, score and compare molecules from a biological viewpoint. This technology helps you to 
understand how compounds interact with protein targets. Working from just a few 2D structures of known 
active ligands, Forge generates a series of conformations that the ligands might adopt under physiological 
conditions. It analyses them to find sets with a high molecular field similarity and hence with similar shape 
and binding properties to find the bioactive conformation. The eXtended Electron Distribution (XED) force 
field was used to generate molecular fields [80]; all other settings were left as default. MD77 crystallographic 
structure [59] was used as template to align its derivatives and calculate field differences. Compounds were 
drawn by using ChemDraw [81] program and VEGA ZZ suite [82,83]. 
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2.3.4 Crystallographic studies 
The X-ray structure determination of two representative terms 1ag and 1da was carried out to understand 
in the solid state the influence of the phenyl substituents on the conformation, in order to find out the role 
of each molecular features for the activity (Figure 12). 
The comparison between the crystal structures of 1ag, 1da and MD77 shows an almost perfect 
superimposition. This molecular arrangement corresponds to the most stable conformation calculated in 
vacuo, as evidenced in the previous results [59]. For both derivatives, the analysis of the crystal packing shows 
that adjacent molecules are connected by NH…O, CH…N, and C=O…F (1ag), CH…Cl (1da) type contacts, also 
stabilized by stacking interactions. These findings pointed out that the two derivatives arrange the amidic 
linker and the two benzene moieties in the same way of the reference molecule MD77, despite the presence 
in this latter of substituents in both phenyl rings, which lead to an increased number of intermolecular 
interactions. 
This result supports the hypothesis that the 3D electrostatic environment could have a greater influence on 
the activity over other types of geometry. 
  
Figure 12. a. ORTEP [84] views of 1ag (above) and 1da (below), showing the 
arbitrary atom-labeling scheme. Atomic displacement parameters for non-H 
atoms are at 40% probability level. b. The overlay of the crystallographic 
structure of MD77 in red onto 1ag and 1da in green and blue, respectively. 
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2.4 Conclusions 
In my PhD project, I aimed at the identification of molecularly targeted chemotherapic agents and, in this 
section, I described the method I employed in order to search for the molecular target of antiproliferative 
compounds, structurally related with AVS-0288. 
Among its 1,2,5-oxadiazole derivatives, MD77 displayed a very interesting antiproliferative profile but, 
differently from the parent compound, it was not characterized by STAT3 affinity. Therefore, I focused my 
research efforts in the identification of its molecular target employing a combined synthetic-computational 
approach. A wide pool of synthesized derivatives underwent the MTT-assay on human colon cancer cells and 
a SAR analysis using Cresset Forge as software, whereas the remaining compounds are under evaluation. 
This methodology will allow the assessment of a structure-activity landscape for a series of aligned 
compounds based on the principle of the ‘activity cliff’ and this overview could help to build up a ‘protein’s 
eye view’ of the scaffold which will be used as query in search of a potential target. 
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3.1 Research project 
In light of literature data reported in Section 1.3, this branch of my PhD project, carried out in collaboration 
with Dr. I. Rimoldi’s research group (University of Milan) and Dr. N. Ferri (University of Padua), was focused 
on the design, synthesis and biological evaluation of Pt(II) complexes endowed with antiproliferative activity 
due to a dual mechanism of action: interference with DNA replication and inhibition of STAT3 signaling 
pathway. 
 
This project was supported by PRIN Research Project, grant no. 20105YY2H_007. 
3.1.1 3-aminomethyl-1,2,5-oxadiazole derivatives as ligands in Pt(II) complexes 
Starting from the 1,2,5-oxadiazole derivative AVS-0288 [57], known as potent STAT3 inhibitor, and taking 
advantage of the experience of Dr. Rimoldi’s research group in platinum compounds [85,86], I synthesized 3-
aminomethyl-1,2,5-oxadiazole derivatives as ligands in Pt(II) complexes (Figure 13). The scaffold (13 and Pt-
13) was firstly functionalized by a para-chlorophenyl system at position 4 of the heterocycle (14 and Pt-14) 
and then by a substituted benzoyl group at its aminomethyl moiety (15a-c and Pt-15b,c). 
Due to compound 15a instability as free amine, its biological activity was not evaluated and its Pt(II) complex 
was not synthesized. All the other ligands (13, 14, 15b,c) and the corresponding Pt(II) complexes were 
evaluated for their antiproliferative activity on colorectal cancer cells (HCT-116) and their ability to disrupt 
STAT3 dimerization. According to these data, 15b and Pt-15b were selected for further investigation aimed 
at deeply understanding their molecular mechanism. 
3.1.2 3-hydroxylaminomethyl-1,2,5-oxadiazole derivatives as ligands in Pt(II) complexes 
Considering the characteristics of STAT3-SH2 (see Section 5.2) domain and how different substituents at the 
para position of the benzoyl function could modulate the keto-enol equilibrium ratio (and the stability) of 
ligands 15a-c, I hypothesized that these ligands could interact with the target as enols. In order to verify this 
thesis, I substituted the primary amine with a hydroxylamine (16a), blocking the equilibrium in the keto form. 
 
Compound 16a was coordinated to the corresponding Pt(II) complex and in light of Pt-16a very interesting 
profile, the benzoyl (Pt-16b) and para-methoxybenzoyl (Pt-16c) derivatives were synthesized (Figure 14) and 
they are currently under biological evaluation. 
  
Figure 13. 3-aminomethyl-1,2,5-oxadiazole derivatives. 
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Meanwhile, the preliminary data led us to select Pt-15b and Pt-16a for in vivo studies. 
  
Figure 14. 3-hydroxylaminomethyl-1,2,5-oxadiazole derivatives 
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3.2 Synthetic chemistry 
The strategies for the synthesis of compounds 14-16, Pt-13-16 are shown in Scheme 9-11. 
Compound 14 was synthesized starting from the commercially available 4-chlorocinnamic acid (Scheme 9). 
According to the literature procedure [87], it was esterified (122) and, subsequently, reduced with DIBAL-H to 
give intermediate 123. The sodium nitrate-mediated cyclization of the 4-chlorocinnamyl alcohol afforded the 
corresponding 4-phenyl-3-furoxanmethanol derivative (124) and its N-oxide moiety was removed upon 
treatment with trimethylphosphite [88] to give intermediate 125. Azide 126 was prepared by a one-pot 
reaction [89], in presence of NaN3 and Ph3P in CCl4/DMF, and converted to the amine (14) by catalytic 
hydrogenation. The final product was isolated as hydrochloride salt. 
The synthesis of compounds 15a-c (Scheme 10) started from the commercially available para-
chloropropiophenone which was treated with tert-butyl nitrite and chlorotrimethylsilane to obtain the 
correspondent α-ketooxime 127. This latter was converted to the bis-oxime 128, in presence of 
hydroxylamine hydrochloride and sodium hydroxide [90], and then cyclized with potassium hydroxide and 
cesium carbonate at high temperature to give the intermediate 129. Treatment with n-butyllithium and the 
suitable methyl benzoate gave ketones 130a-c, which underwent α-oximation with tert-butyl nitrite and 
chlorotrimethylsilane. The reduction of compounds 131a-c with zinc in trifluoroacetic acid or by using lithium 
triethylborohydride in tetrahydrofuran led to compounds 15a-c or 16a-c, respectively (Scheme 10). 
 
The corresponding platinum(II) complexes (Scheme 11) were prepared according to the classical 
methodology [91]: 13 (commercially available), 14 . HCl, 15b,c . HCl and 16a-c were treated with K2PtCl4 in 
water in presence of 4 M HCl affording the target compounds Pt-13, Pt-14, Pt-15b,c, Pt-16a-c, respectively. 
Ligand 15a was not coordinated to the platinum core due to its instability as free amine, as shown in Section 
3.3.1.3. 
  
Scheme 9. Reagents and conditions: i) TMSCl, dry EtOH, 12h, rt, N2; ii) DIBAL-H, dry toluene, 3h, -78°C to rt, N2; 
iii) NaNO2, AcOH, 48h, rt; iv) P(OCH3)3, 24h, reflux, N2; v) NaN3, Ph3P, dry CCl4/DMF (1:4), 5h, 90°C, N2; vi) a. 
Pd/C, H2, MeOH, 20 atm, 4h; b. 2M HCl in Et2O. 
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Scheme 10. Reagents and conditions: i) t-BuONO, TMSCl, dry 
THF/CH2Cl2, 12h, -20°C to rt, N2; ii) NH2OH HCl, NaOH, H2O, 3h, 
reflux; iii) KOH, Cs2CO3, ethylen glycol, 90 min, 160°C, N2; iv) 
2.5M n-BuLi in hexane, R-PhCOOCH3, dry THF, -55°C for 1h, 
then rt for 12h, N2; v) t-BuONO, TMSCl, dry THF, 12h, -20°C to 
rt, N2; vi) a. Zn, TFA, 40 min, rt; b. 2M HCl in Et2O; vii) LiBHEt3, 
dry THF, 3h, -78°C, N2. 
Scheme 11. Reagents and conditions: i) K2PtCl4, 4M HCl, H2O, 2h, reflux. 
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3.3 Results and discussion 
This part of my PhD project aimed at the design, synthesis and biological evaluation of Pt(II) complexes 
characterized by a dual mechanism of action, interfering with DNA replication and inhibiting STAT3 signaling 
pathway. 
3.3.1 3-aminomethyl-4-methyl-1,2,5-oxadiazoles 
The structure of a known STAT3 inhibitor (AVS-0288 [57]) had to be modified in order to obtain a scaffold able 
to chelate platinum and the aminomethyl moiety was devised as the pivotal feature to be introduced at the 
3-position of the 1,2,5-oxadiazole ring. Therefore, according to the structure of the parent compound, I 
gradually substituted the 3-aminomethyl-4-methyl-1,2,5-oxadiazole (13) with a para-chlorophenyl system at 
4-position of the heterocycle (14) and a substituted benzoyl group on the aminomethyl chain (15a-c), as 
shown in Figure 15. 
The scaffold of 15a-c is characterized by a chiral center in α position to a keto group. Analytical data pointed 
out how the introduction of different substituents at the para position of the benzoyl function influenced the 
keto-enol equilibrium ratio. This aspect was evaluated by RP-HPLC at different pH conditions, by chiral 
column chromatography and using 1H NMR. This characteristic could modulate not only the chemo-physical 
properties but also the ligand stability. Indeed, compound 15a displayed stability as hydrochloride salt, while 
it quickly degraded as free amine. In light of this results, its biological activity was not evaluated and its Pt(II) 
complex was not synthesized. All the other ligands (13, 14, 15b,c) were used in coordination with Pt(II) center 
(Figure 16). 
Metal complexes were characterized in terms of structure and stability by analyzing the coordination 
environment of the Pt(II) core (195Pt NMR spectra and X-ray crystal structure), their aqueous stability (UV-vis 
spectra in physiological conditions during a period of 48 h) and their lipophilicity using RP-HPLC technique. 
  
Figure 15 
Figure 16 
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Ligands (13, 14, 15b,c) and their corresponding complexes were tested by MTT assay for cytotoxic activity on 
colorectal cancer cells (HCT-116) and by the AlphaScreen-based assay to determine the effect on STAT3 
dimerization. 
The MTT assay highlighted that whilst ligands generally showed a negligible (13, 14 . HCl and 15c . HCl) or 
weak (15b . HCl) cytotoxic activity (IC50 95.2 µM), their coordination to the Pt center resulted in an increased 
cytotoxicity. In particular, Pt-15b displayed an IC50 value of 18.4 µM, being about 5 times more effective than 
the uncoordinated 15b . HCl ligand. 
Regarding the AlphaScreen-based assay, if compounds 13 and 14 . HCl were inactive, compounds 15b . HCl 
and 15c . HCl not only disrupted STAT3 dimerization (IC50 value of 8.2 ± 0.1 µM and 19.4 ± 0.7, respectively) 
but were selective over STAT1 (IC50 value >30 µM), a different STAT isoform characterized by a high degree 
of sequence homology with STAT3 but an opposite physiological role. [92] Moreover, the coordination to 
platinum led to higher inhibitory activity but lower selectivity, partially maintained by Pt-15b and Pt-15c. 
On the basis of these preliminary data, I focused the attention on compound Pt-15b for further investigations 
in order to deeply understand its molecular mechanism. 
The ability of Pt-15b to interact with DNA was confirmed by binding studies, using 9-ethylguanine as model. 
Pt-15b intracellular and nuclear accumulation was determined by ICPMS, pointing out that even if the 
efficiency of Pt-15b in reaching the DNA was significantly lower than cisplatin, its diffusion across the cell 
membrane was threefold higher. Besides, a significant induction of p53 was observed. 
Although the AlphaScreen-based assay clearly demonstrated the capacity of Pt-15b to inhibit STAT3 
dimerization, a possible effect on phosphorylation was excluded but an induction of the protein expression 
was observed. Finally, considering the resistance issue and despite the interaction of Pt-15b with GSH 
(binding studies were performed by using 1H NMR), its antiproliferative activity was evaluated on cell lines 
poorly sensitive to cisplatin, highlighting a significant inhibition of cell viability for DLD-1 (colorectal cancer 
cell line). 
3.3.1.1 Analysis of the coordination environment of Pt(II) core 
The identity and purity of all synthesized compounds and their Pt(II) complexes were determined by 1H NMR, 
195Pt NMR, ESI-MS or elemental analysis (see Chapter 6 - Experimental part: Chemistry). The observed 
chemical shifts (around -2070 ppm) for 195Pt NMR spectra were in the range expected for a Pt(II) core with a 
N2Cl2 coordination environment [93], as confirmed by single-crystal X-ray diffraction of Pt-13 (performed by 
Dr. F. Meneghetti, University of Milan, Italy). The ORTEP [84] diagram of Pt-13 is shown in Figure 17 with 
selected bond distances and angles. 
Figure 17. ORTEP view of the asymmetric unit of Pt-13. 
For the sake of clarity, only one of the two independent 
molecules shows the arbitrary atom labeling scheme, 
which is also followed by the other molecule. Ellipsoids 
are drawn at 40% probability and H atoms are shown as 
spheres of arbitrary radius. Selected averaged bond 
distances (Å): Pt-N1, 1.956(1)[1.967(1)]; Pt-N3, 2.046(1) 
[2.057(1)]; Pt-Cl1, 2.274(1)[2.276(1)]; Pt-Cl2, 
2.294(1)[2.300(1)]; N1-C2, 1.291(1)[1.290(1)]; N3-C3, 
1.497(1)[1.484(1)]. Angles (°): N1-Pt-N3, 80.8(1) 
[80.6(1)]; N3-Pt-Cl1, 90.7(1)[89.9(1)]; Cl1-Pt-Cl2, 
91.6(1)[92.6(1)]; Cl2-Pt-N1, 96.8(1)[97.1(1)]; C2-N1-Pt, 
119.9(1)[119.3(1)]; C3-N3-Pt, 112.2(1) [113.1(1)]; C2-
C3-N3, 110.5(1)[113.1(1)]. Values in the square brackets 
refer to the second molecule present in the asymmetric 
unit. 
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This compound crystallized with two independent molecules in the asymmetric unit, which were almost 
planar and parallel-oriented. The Pt coordination was slightly distorted square planar and the chlorine atoms 
were cis to each other. The angles around the Pt atoms were close to the expected 90° and 180°. The mean 
deviation of the PtNNClCl coordination plane was ca. 0.030(6) Å (N1) and the methyl groups lied almost in 
the same plane of the oxadiazole ring. The determined lengths and angles were in agreement with the 
literature for similar Pt(II) complexes. [94] The crystal packing consists of molecular layers, parallel to the ab 
plane, where consecutive molecules interact through Pt…Pt contacts at 3.612 and 3.3364 Å, forming chains 
along the c axis [95] also consolidated by N-H…Cl type interactions. 
3.3.1.2 Aqueous stability and lipophilicity 
The aqueous stability for Pt(II) complexes was performed using 0.9% w/v NaCl solution in DMF by monitoring 
UV-vis spectra at their respective λmax during a period of 48 hours. Each compound was first dissolved in DMF 
and then diluted with physiological solution to 100 μM final concentration (1% v/v DMF). 
Pt-13, Pt-14 and Pt-15b demonstrated good stability in physiological solution with negligible variation of their 
UV peak profile after 48 hours, as shown in Figure 18. Aqueous stability of Pt-15c is still under evaluation. 
The values of log Pow were determined using RP-HPLC technique. [96-98] The lipophilicity increased along the 
series (-0.123 and 2.28 for 13 and 14 . HCl, respectively), reaching the maximum value of 1.09 and 3.01 with 
15b . HCl (in the keto and enolic form, respectively, as explained in Section 3.3.1.3). The same trend 
characterized the corresponding Pt(II) complexes (-0.773, 2.00 and 2.99 for Pt-13, Pt-14 and Pt-15b, 
respectively) still satisfying the Lipinski’s lipophilicity criterion for ‘druglikeness’. 
Furthermore, 15c displayed a value of log Pow higher than 5 while Pt-15c is under evaluation. 
3.3.1.3 pH dependent enolization of ligands 15a-c 
The scaffold of compounds 15a-c is characterized by a chiral center in α position to a keto group. The amine 
derivatives 15a-c showed a keto-enolic equilibrium responsible for the racemization at the chiral center. [99,100] 
The tautomerism of the free amines 15b,c was evaluated at different pH conditions by RP-HPLC (Figure 19a): 
the peaks showed the different ratio between the ketone and the enol species. This experiment was also 
performed on 15a, which unfortunately quickly degraded as free amine after treatment in basic condition. 
Compound 15a . HCl enolization was observed by using 1H NMR. Figure 19b shows its time-dependent 
enolization ratio: the alkyl hydrogen bonded to a carbon atom in α position relative to the carbonyl group is 
characterized by a singlet at 6.80 ppm; however, after 36 hours this peak disappeared because of the 
formation of an equilibrium between the two tautomeric forms and, as a consequence, a downfield chemical 
shift of the aromatic system could be detected.  
Figure 18. UV spectra profiles of Pt-15b (a), Pt-14 (b) and Pt-13 (c) for their stability evaluation under physiological 
conditions.  
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3.3.1.4 In vitro biological evaluation 
MTT assay on HCT-116. The cytotoxic effect of the new ligands and their corresponding Pt(II) complexes was 
initially assessed in cultured colorectal cancer cells HCT-116 (Table 5). The cell viability was estimated by MTT 
assay after 48 hour incubation with increasing concentrations (10 ÷ 150 µM) of the compounds. 
 
AphaScreen-based assay. This test, performed by Prof. A. Asai (University of Shizuoka, Japan), is an in vitro 
competitive binding test used to identify compounds able to inhibit the binding of SH2-containing proteins 
to their correspondent phosphopeptides (5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and FITC-
GpYDKPHVL for STAT1). Compounds characterized by an interesting affinity were also investigated for their 
selectivity versus STAT1, a different STAT isoform characterized by a high degree of sequence homology to 
STAT3 (78%) but an opposite physiological role. [92] Data are summed up in Table 5. 
  
Figure 19. a. Compounds 15b and 15c pH-dependent enolization ratio (keto/enol). RP-HPLC was performed on a Partisil 
ODS at 25°C, using water/acetonitrile (50:50) and a flow rate of 1 mL/min. The UV traces were measured at 230 nm. b. 
1H NMR of compound 15a . HCl in CD3OD. 
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MTT on HCT-116 a AlphaScreen b (IC50, µM) 
IC50 (µM) STAT3 STAT1 
13 n.a. >30  
Pt-13 122.9 0.4 ± 0.04 1.2 ± 0.1 
14 ∙ HCl n.a. >30  
Pt-14 150 0.3 ± 0.01 1,9 ± 0.1 
15b ∙ HCl 95.2 8.2 ± 0.1 >30 
Pt-15b 18.4 1.4 ± 0.1 5.9 ± 0.4 
15c ∙ HCl n.a. 19.4 ± 0.7 >30 
Pt-15c n.a. 0.5 ± 0.1 4.1 ± 4.5 
Table 5. Biological properties of 3-aminomethyl-4-methyl-1,2,5-oxadiazole derivatives. a IC50 values 
measured by MTT assay on HCT-116 cell lines (n.a. means not active at 150 µM) b The ability to 
disrupt the binding of STAT to the cognate pTyr–peptide (5-carboxyfluorescein (FITC)-GpYLPQTV 
for STAT3 and FITC-GpYDKPHVL for STAT1) is expressed as IC50. 
3.3.1.5 DNA binding study 
In order to verify the ability of Pt-15b to interact with deoxyguanosine-rich regions of DNA, binding studies 
were performed with the model nucleobase 9-ethylguanine (9-EtG) by using 1H NMR (Figure 20). [101,102] The 
N7of guanine is the putative binding position for the metal center, thus a downfield chemical shift of the H8 
next to N7 in 1H NMR should be observed after binding. The experiment was realized using 0.9 % w/v NaCl-
D2O solution in DMF-d7 in order to mimic physiological conditions. In the free 9-EtG, the H8 is characterized 
by a singlet at 7.68 ppm; however, after 12 hours it was possible to evidence the presence of a new singlet 
at 8.32 ppm, thus confirming the binding between Pt-15b and 9-EtG. 
Figure 20. Binding study of 9-ethylguanine with Pt-15b in 20 % physiological D2O solution- 
DMF-d7: stack plot of 1H NMR for aromatic region. 
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3.3.1.6 Intracellular and nuclear accumulation of Pt-15b and induction of p53 
In order to explore the molecular mechanism of action of Pt-15b, the presence of 195Pt was measured from 
total homogenates and nuclear DNA preparations of HCT-116 cell line incubated with the complex (25 and 
50 µM) or cisplatin (10 and 25 µM). A concentration-dependent accumulation of Pt was observed in the DNA 
extract (Figure 21a). However, the efficiency of Pt-15b in reaching the DNA was significantly lower than 
cisplatin: at 25 µM the amount of Pt measured was 0.48±0.30 ng Pt/µg DNA and 9.0±0.1 ng Pt/µg DNA for 
Pt-15b and cisplatin, respectively. By contrast, Pt-15b diffused across the cell membrane with higher 
efficiency than cisplatin, reaching a threefold higher intracellular concentration after incubation with 25 µM 
(126.6 ng Pt/µg protein and 42.3 ng Pt/µg protein for Pt-15b and cisplatin, respectively) (Figure 21b). [29] 
 
Although Pt-15b was incorporated less efficiently than cisplatin into the nuclear DNA, the incubation of HCT-
116 cell line with increasing concentrations of Pt complex for 24 hours determined the induction of p53, as 
determined by Western blot analysis (Figure 22). 
These results suggested that Pt-15b could elicit its cytotoxic effect by interacting with nuclear DNA thus 
inducing the expression of p53, similarly to cisplatin. 
  
Figure 21. DNA and intracellular concentration of 195Pt in HCT-116 cell line incubated 
with Pt-15b and cisplatin. Cells were seeded (250,000/35 mm petri dish) and incubated 
with McCoy’s supplemented with 10% FCS; 24 hours later the medium was replaced with 
one containing 10% FCS and indicated concentrations of compound or cisplatin. After 3 
hours, the nuclear DNA and total cell homogenates were prepared. 195Pt concentrations 
were determined by ICPMS and normalized with total DNA and protein contents. 
Figure 22. Effect of Pt-15b on p53 expression in 
HCT-116 cell line. Cells were seeded (250,000/35 
mm petri dish) and incubated with McCoy’s 
supplemented with 10% FCS; 24 hours later the 
medium was replaced with one containing 10% FCS 
and the reported concentrations of Pt-15b and 
cisplatin. The incubation was continued for a 
further 24 hours at 37°C and Western blot analysis 
was performed from total cell lysates. α-tubulin 
antibody was utilized as loading control. 
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3.3.1.7 Effect of Pt-15b on STAT3 expression and phosphorylation 
The data obtained with the AlphaScreen-based assay clearly demonstrated the capacity of 15b and Pt-15b 
to inhibit the binding between the SH2 and the phosphotyrosine of the other monomer and, therefore, the 
dimerization. In order to deeply explore the pharmacological activity, a series of experiments aimed at 
investigating the expression and the phosphorylation state of STAT3 were performed. 
HCT-116 cells were incubated with 25 µM concentration of 15b and Pt-15b for 24 hours and both total 
protein extracts and RNA were prepared. As shown in Figure 23a, both compounds did not significantly affect 
the STAT3 tyrosine phosphorylation state, with a 7.2% and 10.4% inhibition after incubation with 15b and Pt-
15b, respectively. 
Under the same experimental conditions, a significant induction of STAT3 mRNA was observed by 
quantitative real time PCR (Figure 23b). In particular, 15b determined a 2.4±0.43 fold induction of STAT3, 
while Pt-15b was more potent by upregulating the STAT3 mRNA levels by 3.3±0.5 fold. These data indicate 
that Pt-15b did not inhibit the phosphorylation of STAT3 but more likely could affect its transcriptional 
activation, reflecting a significant induction of STAT3 mRNA expression. Unfortunately, it was not possible to 
directly measure the STAT3 transcriptional activity by a luciferase assay due to the interference of the Pt(II) 
complex with the assay. 
3.3.1.8 Glutathione binding study 
Glutathione (GSH), a thiol-containing tripeptide, is considered to be responsible for most of the drug 
resistance mechanism, especially towards Pt drugs. [38, 103, 104] The GSH-binding study with Pt-15b was 
conducted using 0.9 % w/v NaCl-D2O solution in DMSO-d6. The 1H NMR spectrum showed the appearance of 
two multiplets at 3.04-3.09 and 3.10-3.14 ppm that may be assigned to the methylene protons next to the 
SH group, which are set at 2.60-2.70 and 2.74-2.82 ppm in the unbound form. These signals underlined the 
interaction between Pt-15b and GSH, thus limiting the bioavailability of the metal compound (Figure 24). 
  
Figure 23. Effect of 15b and Pt-15b on STAT3 expression and 
phosphorylation in HCT-116 cell line. Cells were seeded and incubated 
with McCoy’s supplemented with 10% FCS; 24 hours later the medium 
was replaced with one containing 10% FCS and the reported 
concentrations of 15b and Pt-15b. The incubation was continued for a 
further 24 hours at 37°C and Western blot analysis (a) and real time PCR 
(b) were performed from total cell lysates and total RNA, respectively. The 
ratio of phosphoSTAT3/STAT3 signals are shown in the histogram plot (a). 
 Chapter 3 – Platinum (II) Complexes 
 
47 
3.3.1.9 Cytotoxic effect of Pt-15b and 15b on cell lines poorly sensitive to cisplatin 
The cytotoxicity of Pt-15b was then assessed on two additional cancer cell lines poorly sensitive to 
cisplatin[85], like the breast cancer cell line MCF-7 and the colorectal cancer cell line DLD-1, in comparison 
with HCT-116. As shown in Figure 25, Pt-15b did not affect the cell viability of MCF-7 at the concentration 
range of 1÷25 µM, while a significant inhibition was observed for DLD-1 at 25 µM concentration. As expected, 
cisplatin showed a limited cytotoxic efficacy on all three cell lines with no concentration-dependent action. 
The MCF-7 resulted particularly resistant to both Pt-15b and cisplatin. 
 
Figure 24. Binding study of GSH with Pt-15b in physiological D2O solution- DMSO-d6: 
stack plot of 1H NMR for aliphatic region. 
Figure 25. Cytotoxic effects of Pt-15b complex and cisplatin on DLD-1, HCT-116 and MCF-7 cell lines. Cells were seeded 
at the density of 40,000/well in a 48 well tray. The day after the medium was replaced with one containing 10% FCS 
and the reported concentrations of Pt-15b and cisplatin. After 48 hours the cell viability was estimated by MTT assay. 
Each bar represents the mean ± SD of three determinations. Pt-15b and cisplatin versus control * P<0.05; ** P<0.01; 
*** P<0.001. 
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3.3.2 3-hydroxylaminomethyl-4-methyl-1,2,5-oxadiazoles 
As described in Section 5.2, SH2 domain is crucial for STAT3 dimerization. Among its different hot spots, 
subpocket A, which hosts the key pTyr705 of the other monomer, is characterized by polar and basic residues 
Lys591, Ser611, Ser613 and Arg609 which are engaged as hydrogen bond donors (HBD) or hydrogen bond 
acceptors (HBA) with the inhibitors. 
Therefore, considering these characteristics of STAT3-SH2 domain and the keto-enol equilibrium ratio of the 
differently substituted ligands, I hypothesized that 15b and 15c could interact with this hot spot as enols. In 
the attempt to verify this theory, I substituted the primary amine of 15a with a hydroxylamine (16a, Figure 
26), blocking the equilibrium in the keto form and resulting in no affinity for the SH2 domain (IC50 value >30 
µM versus STAT3 and STAT1). 
However, considering 16a promising antiproliferative activity (IC50 7.2 µM), it was coordinated with a 
platinum core (Pt-16a) resulting in a cytotoxic compound (IC50 value of 5.0 µM), able to selectively disrupt 
STAT3 dimerization (IC50 value of 3.4 ± 0.3 µM versus STAT3 and 23.5 ± 1.6 µM versus STAT1). In light of these 
results and in order to deeply characterize these last derivatives (16a and Pt-16a) and justify their particular 
behavior, further investigations are ongoing. Meanwhile, the benzoyl (Pt-16b) and para-methoxybenzoyl (Pt-
16c) derivatives were synthesized and are currently under biological evaluation. 
3.3.2.1 Enolization of ligand 16a 
The substitution of the primary amine (15b) with a hydroxylamine (16a) resulted in the stabilization of the 
keto form, as confirmed by chiral column chromatography (Figure 27) 
  
Figure 26 
Figure 27. a. Compound 15b chromatogram performed at physiological pH by normal phase HPLC on a Chiralcel OD-H 
column at 25°C, using hexane/ethanol (90:10) and a flow rate of 1 mL/min. The UV traces were measured at 230 nm. b. 
Compound 16a chromatogram performed at physiological pH by normal phase HPLC on a Lux cellulose 4 column at 
25°C, using hexane/isopropanol (90:10) and a flow rate of 1 mL/min. The UV traces were measured at 230 nm. 
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3.3.3 In vivo tumor growth inhibition 
According to all these preliminary data, the in vivo antitumor activity of Pt-15b and Pt-16a was evaluated 
thanks to the collaboration with Prof. C. Marzano and Prof. V. Gandin (University of Padua). 
Tumor growth inhibition was determined in a model of solid tumor, the syngeneic murine Lewis lung 
carcinoma (LLC) implanted i.m. in C57BL/6 mice. From day 7 after tumor inoculation, when tumors became 
visible, tumor-bearing mice received daily i.p. doses of Pt-15b (30 mg kg−1), Pt-16a (30 mg kg−1), or cisplatin 
(1.5 mg kg−1). Cisplatin treatment schedule was selected according to standard protocols designed to 
optimize its efficacy and minimize the occurrence of adverse events. [105] 
As shown in Table 6, Pt-16a tested at 30 mg kg−1 induced a significant tumor growth inhibition that was, 
however, lower than that promoted by cisplatin, while the chemotherapy with Pt-15b, tested at 30 mg kg−1, 
reduced the tumor mass by roughly 85%, a slightly lower value compared with the one obtained by the 
reference metallo-drug. 
 
 
Daily dose i.p. 
(mg kg-1) 
Average tumor weight 
(mean ± SD, g) 
Inhibition of tumor 
growth (%) 
Control a - 0.582±0.16 - 
Pt-15b 30 0.086±0.06 ** 85.2 
Pt-16a 30 0.129±0.09 ** 77.8 
Cisplatin 1.5 0.073±0.03 ** 87.5 
Table 6. In vivo antitumor activity toward LLC. a vehicle (20% Cremophor EL (v/v), 20% PEG400 (v/v) 
and 60% saline solution (v/v)); ** p<0.01. 
For the assessment of the side effects, changes in the body weight of tumor-bearing mice were monitored 
at day 1 and every two days from day 7 to day 15. 
The time course of body weight changes, depicted in Figure 28, highlights that, despite the higher dose than 
the reference compound, treatment with Pt-15b and Pt-16a induced very low or no body weight loss, 
respectively, compared with cisplatin (which caused a substantial weight loss, about 27%). 
Even if these preliminary results seem to support our main goal, namely, the identification of effective 
antitumor metallo-agents able to interfere with DNA replication and to inhibit STAT3 signaling pathway. 
However, the molecular mechanism of these Pt(II) complexes (Pt-15b and Pt-16a) still needs to be clarified.  
Figure 28. The body weight changes of LLC-bearing C57BL mice treated with vehicle or 
tested compounds. Body weight was measured at day 1 and every two days from day 
7 and was taken as a parameter of systemic toxicity. The error bars indicate the SD. 
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3.4 Conclusions and perspectives 
This section of my research project was focused on the identification of platinum(II) complexes able to 
interfere with DNA replication and to inhibit STAT3 signaling cascade. 
STAT3 was chosen as additional target considering its overexpression in various cancer cell lines and its 
involvement in oncogenesis. Therefore, the structure of a known STAT3 inhibitor, AVS-0288, was modified 
in order to obtain a ligand able to chelate platinum and characterized by antiproliferative activity due to this 
dual mechanism of action. The 3-aminomethyl-1,2,5-oxadiaxole scaffold was functionalized by different 
substituents, allowing the modulation of both cytotoxicity and affinity/selectivity for STAT3 and among the 
synthesized derivatives, Pt-15b and Pt-16a were selected for in vivo studies. The chemotherapy with these 
compounds reduced the tumor mass similarly to cisplatin and, despite the higher dose, they seemed to be 
better tolerated than the reference compound. 
There are several opportunities for the future. Firstly, a deep investigation of the binding mode: 
 regarding platinum complexes, as reported in Section 1.3.1, they could target thiol-containing 
proteins. Therefore, Prof. Asai’s research group will repeat the AlphaScreen-based assay using a Cys 
blocking reagent. Indeed, even if there are not cysteine residues in STAT3-SH2 domain, it was shown 
that their alkylation could inhibit the formation of the STAT3:STAT3 protein dimer complex [106]; 
 if platinum interaction with cysteine is proven, a mass spectrometry method will be developed to 
investigate which cysteines are involved; 
 as for ligands and the hypothesis they could interact as enol, Molecular Dynamics simulation will be 
performed. Furthermore, thermodynamic and kinetic studies on the keto/enol equilibrium by 
computational methods could justify how the different substituents affect its rate and compound 
stability. 
From a pharmacological point of view, our results agree with literature evidences [44,45] confirming that this 
dual targeting approach could be very promising. Therefore, further information could be achieved by: 
 co-administration of 15b with cisplatin; 
 the use of 15b as axial ligands in a platinum(IV) complex. Besides the advantages of this prodrug (see 
Section 1.3.2), this could confer additional cytotoxicity upon their release inhibiting STAT3 
dimerization. 
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4.1 Research project 
Dithiolethiones (DTTs) and methanethiosulfonates (MTTSs) were recently reported to exert 
chemopreventive and anticancer activities. These electrophilic moieties could react with thiol groups, and 
therefore, hypothetically, with cysteines of biologically important peptides and proteins. 
In light of this data, in collaboration with Prof. A. Sparatore’s research group (as part of the PRIN research 
project, grant no. 20105YY2H_007, and, consequently, of another PhD thesis [107]), we designed and 
synthesized a new series of sulfurated compounds (17a,b,e and 18a-e), characterized by having the DTT and 
MTTS systems linked to a differently substituted 1,2,5-oxadiazole ring through an ester (17a, 18a and 18c) or 
an amidic bond (17e, 18d and 18e) (Figure 29). In addition, we synthesized the bioisosteric analogues of 17a 
and 18a, by replacing the oxadiazole with a 4,5-disubstituted N-methylimidazole (17b and 18b, respectively). 
  
Figure 29. Structures of the newly synthesized dithiolethione and methanethiosulfonate derivatives. 
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4.2 Synthetic chemistry 
The final products 17a,b,e and 18a-e were prepared [107,108] by condensation of the suitable intermediate with 
ACS48 or ACS4871, in presence of different coupling reagents (Scheme 12). 
The procedure for the synthesis of 1mg and 1ds is reported in Section 2.2, while compound 125 is described 
in Section 3.2. The synthesis of intermediates 132 and 133 was performed by Dr. Rimoldi’s and Prof. Romeo’s 
research groups, respectively. 
  
Scheme 12. Reagents and conditions: i) ACS48 or ACS71, EDC.HCl, DMAP, dry DMF, rt, 24h or 20h; ii) ACS48 or ACS71, 
DCC, DMAP, dry THF or dry CH2Cl2 or dry DMF, rt, 4h or 20h; iii) ACS48 or ACS71, TBTU, NMM, dry DMF, rt, 20h. 
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4.3 Conclusions 
This part of my PhD project was performed in collaboration with Prof. A. Sparatore’s research group and it 
aimed at the identification of potential dual inhibitors, able to covalently link cysteines of two transcription 
factors, STAT3 and NF-кB. [108] 
In order to achieve this goal, I synthetized differently substituted 1,2,5-oxadiazole derivatives which were 
coupled with DTT and MTTS systems by Dr. Elena Gabriele [107]. 
These compounds were evaluated for their affinity for STAT3 and NF-кB and for the antiproliferative activity. 
The results showed that MTTS derivatives (18b-e) could strongly disrupt STAT3 dimerization, whereas the 
corresponding DTTs (17a,b,e) possessed lower affinity, independently from the nature of the linked 
heterocyclic scaffold. On the other hand, none of them was able to inhibit the NF-кB transcriptional activity 
and the MTT assay, performed on HCT-116, highlighted that only 18a,b,e exhibited a moderate 
antiproliferative activity. 
The physicochemical properties of these compounds could be the discriminating factor to explain the low 
correspondence between cytotoxicity and STAT3 inhibition (tested in a cell-free assay). Based on these data, 
the MTTS moiety appears worth of further investigation, as promising ligand of STAT3-SH2 domain. 
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5.1 Research project 
The aim of this branch of my PhD project was the identification of new chemical scaffolds endowed with 
antiproliferative activity by targeting STAT3-SH2 domain. 
In order to achieve this goal, computationally driven drug design was performed employing a fragment-based 
drug design (FBDD) approach. Starting from small chemical fragments, this method allowed to find potential 
lead compounds, characterized by enhanced activity and suitable drug-like properties. 
 
The STAT3:STAT3-DNA ternary complex crystal structure (PDB code 1BG1) revealed the structural 
composition and topology of the SH2 domain binding hot spots. [25] 
Analyzing STAT3 direct inhibitors reported in the literature, a set of privileged fragments were selected 
(Database A) and, on the basis of their docking score, the most interesting ones were heterogeneously 
merged. The linked compounds (Database B) were docked in a region of 12 Å around the Arg609 and ranked 
by binding energies and binding modes. Unfortunately, the docking calculations were not useful to identify 
new chemical scaffolds, because the selected combinations of two fragments were strictly related to some 
substructures already known in literature to be STAT3 binders. Although this result could appear a failure, 
this first study proved that the computational protocol could be used to build scaffolds with potential activity 
on STAT3. 
 
Therefore, I decided to apply the same strategy on a different and larger base set of fragments, created by 
filtering PubChem database (Database C) with the aim to increase the chemical space. This new pool of 
fragments was docked and selected according to the ligand efficiency. Subsequently, the different possible 
poses were analyzed in order to identify two different groups of fragments depending on the region of 
interaction: region A (Arg609 – Ser636 – Lys 591) or B (Arg595 – Ser636 – Lys 591). The most interesting ones 
were heterogeneously merged (one fragment of each group) and searched in structures reported in literature 
or commercially available. These compounds (Database D) were docked and analyzed. 
 
In this way, I could easily obtain a pool of chemical entities with high structural diversity which underwent in 
vitro binding assays for the purpose of evaluating their affinity for the target. 
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5.2 STAT3 structure 
STAT proteins are monomeric structure which can be associated with other monomers to create homo or 
heterodimer. They consist of 750-850 amino acids and, through biochemical and mutagenic assays, a 
common primary structure, with highly conserved regions, was identified. In detail: 
 The N-terminal domain (ND, 125 residues) is a well conserved sequence. It is fundamental for the 
formation of the tetrameric STAT complex, involved in STAT-DNA interaction. [109] The deletion of the 
N-terminal domain and, in particular, of a conserved residue of tryptophan, crucial for the interaction 
between the two dimers, prevents tetramer formation. [110] This complex regulates the 
transcriptional induction, influencing receptor recognition, monomer phosphorylation, nuclear 
translocation and dephosphorylation. [111] 
 The coiled-coil domain (CCD, from 135 to 315 residues) is a region presenting four α-helices 
connected by short loops. This domain is characterized by a large hydrophilic surface which can 
interact with transcription factors and other regulatory proteins, while the central region of the 
helices is hydrophobic and includes residues of leucine, isoleucine and valine. As for the N-terminal 
domain, the coiled-coil domain acts as a protein-protein interaction site, allowing potential contacts 
between transcriptional factors and other regulatory proteins. [112] 
 The DNA binding domain (DBD, from 320 to 490 residues) is constituted by β-sheet structure. It is 
folded as the analogous sequence in the DNA-binding domains of tumor protein p53 and nuclear-
factor kappaB (NF-кB). [111] This region is also involved in the interaction between STAT and DNA and 
it modulates the nuclear import and export. [5] 
 The linker domain (LK, from 490 to 580 residues) is composed of a series of α helices and guarantee 
the suitable conformation between the DBD and the SH2 domain. Mutations cause instability in DNA 
and STAT binding. [113] 
 The Src homology 2 domain (SH2, from 580 to 680 residues) is the most highly conserved domain. 
This sequence is also common in other signaling molecules. In STAT activation pathway, it is essential 
for the recruitment of STATs, their activation mediated by JAK proteins and the dimerization of two 
activated monomers (through reciprocal interactions between the SH2 domain and the pTyr). [7] The 
SH2 domain also seems to be involved in dimer formation of unphosphorylated STAT (non-canonical 
pathway), interacting with the N-terminal domain. [114] 
 The tyrosine activation domain includes a conserved tyrosine, usually near residue 700, whose 
phosphorylation by JAKs activates STATs. Besides, its interaction with the SH2 domain of the other 
monomer stabilizes the association as dimer. [113] 
 The C-terminal Transcriptional Activation Domain (TAD) presents several crucial elements for STAT 
activation. For instance, this domain is involved in transcriptional activation of STAT regulated genes, 
because it contains a conserved residue of serine (Ser727), which can be phosphorylated to enhance 
transcriptional activity through the recruitment of co-activators. [7] Deletion experiments have shown 
that each STAT isoform possesses a different amino acid sequence in the primary residues of the TAD 
domain, which is essential for its function. [115] 
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As previously mentioned, SH2 domain is crucial for the dimerization of both the phosphorylated and 
unphosphorylated STAT3. [116] Using the STAT3:STAT3-DNA ternary complex crystal structure (PDB code 
1BG1), Shahani and coworkers identified three subpockets in the SH2 domain, which revealed its structural 
composition and topology. In particular, subpocket A has a key role in the dimerization since it hosts the key 
pTyr705 of the other monomer and it is characterized by polar and basic residues Lys591, Ser611, Ser613 and 
Arg609 which are engaged as hydrogen bond donors (HBD) or hydrogen bond acceptors (HBA) with the 
inhibitors. [25] 
From a topological point of view, a central βBβCβD anti-parallel β-sheet, flanked by adjacent α helices, 
characterizes the SH2 domain. The crucial arginine (Arg609) is located on the central βB strand, forming two 
positive charges on the pTyr-recognition site. Besides, the side chain of another arginine residue (Arg595, on 
the αA) determines the distinct hydrophobic side pocket on the side of pTyr705 and the Leu706 binding 
subpockets, which are absent in other STAT SH2 domains. [117] 
  
Figure 30. The active binding site of the STAT3 protein. [103] The 
four recognized domains are shown: the coiled-coil domain 
(green), the DNA binding domain (red), the linker domain 
(orange), and the SH2 domain (cyan). The detailed view 
highlighted the dimer interface and the two tail segments are 
magenta and yellow 
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5.3 Computational methods 
This section reports the main computational methods that were used in this phase of my research study. It 
is not supposed to be a comprehensive compendium on this matter, but only a summary on the main topics. 
5.3.1 Conformational analysis and molecular mechanics 
The steric and energetic features have to be well parameterized in the score functions. Therefore, 
conformational analysis has to be performed in order to study the relationship between the energy of a given 
molecular system and the variation of relevant torsion angles. The calculation of the total energy of the 
molecule can be achieved by three methods: 
 quantum or ab initio methods are very accurate but also costly in terms of computation time since 
they allow the calculation of the electronic distribution within the molecular orbitals by the 
Schrödinger equation; 
 semi-empirical methods are based on the calculation of the electronic distribution of molecular 
orbitals but consider only the valence electrons, leading to a significant increase in computing 
performance; they cannot yet be applied to biomacromolecular systems; 
 molecular mechanics considers atoms as partially charged rigid spheres with a radius corresponding 
to that of Van der Waals and connected by springs (bonds) endowed with appropriate elastic 
constants. These approximations imply that the electrons are not explicitly considered, and therefore 
it is not possible to simulate charge transfer, break and formation of a covalent bond during a 
chemical reaction or consider the effect of a single charge on the distribution of electrons in orbital. 
Methods based on these assumptions have the advantage of being markedly less demanding than 
the previous ones. The calculated potential energy has a relative value that allows to compare only 
the conformers of the same molecule. Furthermore, the considerable speed of the method means 
that it can be applied to complex systems such as proteins and nucleic acids. 
In this research work, the only viable option was the use of the molecular mechanics, in order to have 
acceptable calculation times. 
5.3.2 Molecular docking 
Molecular docking is based on computational methods that allow the study of the interactions between a 
generic ligand and a known three-dimensional biomacromolecule (protein or nucleic acid). The interaction 
between the two partners takes into account both the steric complementarity between the ligand (usually 
with low molecular weight) and the binding region of the target as well as the chemical and physical 
complementarity between the two molecules. These steric and energetic features are well parameterized in 
the score functions, used in all docking programs to assess the quality of a ligand-receptor complex (the term 
"receptor" is used here in a broad sense). Based on the size and/or molecular weight (MW) of the two 
partners of the simulated interaction, several cases may arise: 
 high MW receptor-low MW ligand is the most common case, when a drug that typically have a 
molecular weight less than 500 D, must interact with its target (protein or nucleic acid);  
 high MW receptor-high MW ligand is the typical case that occurs considering the quaternary 
structure of proteins, how a protein interacts with its receptor (docking protein-protein) or how a 
nucleic acid (RNA or DNA) interacts with an enzyme or, more generally, with a protein (docking 
DNA/RNA-protein); 
 low MW receptor-low MW ligand such as studying the formation of host-guest complexes. 
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5.3.2.1 PLANTS software 
In particular, in this research, it was necessary to perform calculations of molecular docking studies on “high 
MW receptor - low MW ligand” and the docking software chosen for this virtual screening study was PLANTS 
(Protein-Ligand ANT System). [118-121] This software is based on a particular class of stochastic optimization 
algorithms called Ant Colonization Optimization (ACO). These are inspired by the natural ants’ behaviour, 
consisting in the search for the shortest path between their anthill and the food supplies. The ants use an 
indirect form of communication based on the pheromones traces through which every single ant marks its 
own path. Molecular docking exploits an artificial "ant colony" to evaluate the lowest energy conformation 
of the ligand in the binding site: the virtual ants mime their real behaviour marking the most favourable 
conformations with "artificial pheromones". 
Ligands are considered completely flexible by PLANTS, in particular they have 6+r degrees of freedom: 3 
translational, 3 rotational and r degrees due to the torsion flexible angles whose number depends on the 
structure of the molecule (Figure 31). By contrast, the receptor is considered fixed or partially fixed. 
The degrees of freedom, by definition, are continuous functions, but the ACO was developed to be applied 
to combinatorial problems and so to discrete systems. For this reason, in PLANTS the degrees of freedom 
have been "discretized", considering a step of 0,1 Å for translations and of 1° for rotations. Hence, to each 
degree of freedom i is assigned a "pheromone vector" ττ; for example, for a torsional angle, the vector can 
assume discrete values between 1 and 360. 
The software is based on MAX-MIN Ant System (MMAS) that allows the virtual ants to choose the most 
favorable poses of the ligands, exploring the potential of each conformation, which is determined by the 
values associated to the degrees of freedom. Through this approach, it is also possible to calculate the 
probability that an ant chooses the right values and to avoid the construction of high energy conformations. 
The software assigns a score to the sampled potential space using a scoring function, which considers 
different interaction parameters, then, applying the algorithm criteria, only the poses with a negative score 
are selected. PLANTS uses three scoring functions PLP, CHEMPLP and PLP 95 that consider and evaluate 
different patterns of interactions. 
Once the poses have been generated, they are optimized by the application of local search algorithms 
designed by Nelder and Mead, and a clustering method was used to facilitate the analysis of the results: the 
software automatically ranks the poses according to the scoring function values, then extracts a given 
number of ranking structures, usually ten, which have an RMSD larger than 2 Å.   
Figure 31. Degrees of freedom of the ligand. The original system coordinates are 
shown as a sphere and the arrows indicate where and how the ligand can be moved 
in the space. 
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5.3.3 Preparation of the STAT-SH2 domain structure 
The X-ray crystallographic structure of STAT3-SH2 domain used for the docking studies was the STAT3:STAT3-
DNA ternary complex, downloaded from the Protein Data Bank (PDB code 1BG1). 
PDB [122] is a central archive including the 3D structures of biological molecules: it contains thousands of 
proteins, nucleic acids and complex assemblies which come from experiments in X-ray crystallography, 
nuclear magnetic resonance and electron microscopy. Besides, PDB includes several other additional 
information such as ID, author, bibliographic notes, organization of origin, data on the methods used, primary 
structure. 
The 1BG1 structure, composed of a pTyr705-STAT3 dimer which is linked to the DNA, was dimerized applying 
the transformation matrix as reported in the PDB file. The model was completed by adding the hydrogens in 
two steps: 1) to STAT3, applying the algorithm for proteins; 2) to DNA, applying the algorithm for nucleic 
acids. Atom charges (Gasteiger - Marsili method [123]) and potentials (CHARMM 22 for proteins and nucleic 
acids [124]) were assigned to the obtained structure. Finally, the model was optimized through a conjugate 
gradients minimization (50.000 steps) in order to reduce the high-energy sterical interactions. To preserve 
the experimental data, atom constraints were applied to protein and DNA backbones. The model preparation 
and the energy minimization were carried out respectively by NAMD 2 [125] and VEGA ZZ [82,83] programs. 
Therefore, I retrieved the docking area selecting a region of 8-12 Å around the Arg609 from a pTyr705-STAT3 
monomer, according to the size of the considered ligand and/or the selection of specific sub-pockets. 
5.3.4 Preparation of the dataset of fragments and compounds 
For the docking calculations, compounds were drawn by using ChemDraw [81] program and VEGA ZZ suite or 
downloaded from PubChem [126]. PubChem is a large database of small molecules collected according to their 
chemical structure and physicochemical properties including molecular weight, XLogP, and hydrogen bond 
donor and acceptor count, and their biological activities. The collection is managed by the National Center 
for Biotechnology Information (NCBI), which is a department of the United States National Institutes of 
Health (NIH). PubChem can be accessed for free and consists of three dynamically growing primary 
databases: 
 Compounds, containing pure and characterized chemical compounds (2D and/or 3D); 
 Substances, containing mixtures, extracts, complexes and uncharacterized substances; 
 BioAssay, including bioactivity results from HTS programs with several million values. 
 
The compounds, selected for the docking studies, were grouped in four databases: 
 Database A is composed of fragments selected starting from known STAT3 inhibitors; 
 Database B includes compounds obtained by combing two fragments from Database A; 
 Database C comes from PubChem dataset, converted and filtered according to various properties, 
the synthesizability and the stability; 
 Database D is a collection of compounds, reported in literature or commercially available, bearing at 
least two fragments of Database C. 
 
All molecules included in the databases underwent the same computational protocol consisting in the 
attribution of atom types (SP4 force field), the calculation of the atomic charges (Gasteiger-Marsili method), 
the energy minimization by molecular mechanics calculation (AMMP software [127], conjugate gradients 
minimizer, RMSD value of 0.01 as convergence criterion). Finally, each structure was significantly optimized 
by MOPAC 2016 [128] (PM7 hemiltonian method), a semi empirical quantum chemistry program. 
Weak acids and bases were considered ionized at physiological pH.  
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5.4 Results and discussion 
5.4.1 Virtual screening 
The aim of this research project was the identification of new chemical scaffolds capable of disrupting STAT3-
PPI (Protein-Protein Interaction) and characterized by an increased activity and suitable drug-like properties. 
Among the different approaches to STAT3-targeted drug design (inhibitors directly targeting the SH2 domain 
or the DNA-binding domain and antisense approaches using oligonucleotides to inhibit STAT3 transcription), 
I focused on analyzing SH2 domain direct inhibitors since it is the most feasible approach to design small 
molecules, especially with a structure-based computer-aided drug design strategy. [129] In order to achieve 
this goal, I employed a fragment-based drug design (FBDD) approach. 
Considering all STAT3 inhibitors reported in literature, the first problem I observed was that several 
compounds were presented as direct inhibitors on the basis of antiproliferative assays and computational 
studies but without any direct binding test. 
As previously mentioned (see Section 5.2), the crystal structure of STAT3:STAT3-DNA ternary complex (PDB 
code 1BG1) allowed to describe the structural composition and topology of the SH2 domain binding hot 
spots. In particular, the polar and basic residues (Lys591, Ser611, Ser613 and Arg609) of a region (labeled as 
subpocket A) of the SH2 domain could be engaged as hydrogen bond donors (HBD) or as hydrogen bond 
acceptors (HBA) with the direct STAT3 inhibitors. 
Using this model, two new different subpockets (Figure 32) were recognized:  
- subpocket A, defined by Arg609, Lys591 and Ser636; 
- subpocket B, lined by Arg595, Lys591 and Ser636. 
The analysis of the different scaffolds, supported by their proposed binding poses, highlighted that all the 
selected compounds interacted mainly with subpocket A. Therefore, I focused my attention on the pTyr-
mimetic fragments, such as 4-phosphonodifluoromethyl-cinnamate [20, 21], arylsulfonamide [22], 4-amino and 
4- hydroxyl salicyclic acid [23], the catechol structure [24] or the purine scaffold [25] (Figure 33a). Each fragment 
Figure 32. Subpockets A and B. 
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was docked in a region of 12 Å around the Arg609, using PLANTS software (ChemPLP scoring function, speed1 
as exhaustiveness of docking search, 10 poses for each docked ligand). 
 
I analyzed the ligand efficiency, calculated as ratio between ChemPLP docking score and the number of heavy 
atoms, and the different possible poses by visual inspection. This kind of analysis was required because in 
some cases different poses of the same ligand don’t have significant differences in ligand efficiency values 
but involve pockets lined by a different set of aminoacids. 
Afterwards, I considered region B with the aim to capitalize the interaction with Lys591 and Arg595, applying 
multiple ligand simultaneous docking of multiple fragments (Figure 33b) in a concerted way to A and B 
binding hot spots. Hence, I obtained virtual template compounds by linking docked fragments of these two 
groups using various chemical tethers such as amide, amine, ether and ester. The purpose was to investigate 
how various linkers could: 
 influence the flexibility of the scaffold (and if fragments maintained their poses in the binding sites); 
 enhance binding affinity; 
 modulate biophysical features such as water solubility. 
The linked compounds were finally docked (Figure 33c,d), ranked by binding energies and binding modes, 
and their drug properties were calculated. 
Figure 33. a. Some examples of pTyr-mimetic fragments; b. Example of multiple ligand simultaneous docking of two 
fragments; c. and d. Docking pose of one of the most interesting linked compounds. 
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Considering that the best virtual template compounds were strictly related to substructures already reported 
in the literature as STAT3 inhibitors, these docking calculations were not useful to identify new chemical 
scaffolds. However, this result was not a failure, it proved that the computational protocol could be used to 
build up scaffolds with potential activity on STAT3. Therefore, I decided to apply the same strategy on a 
different base set of fragments (Figure 34). 
PubChem compounds were filtered considering various characteristics such as molecular weight 
(80<MW<200), XLogP (less than 2), number of hydrogen bond donors and hydrogen bond acceptors 
(HBD+HBA>0). In this way, a smaller pool of fragments (4717 cpds) was identified and docked by PLANTS 
(CHEMPLP scoring function) in a region of 8 Å around Arg609, generating 10 poses for each one. 
The results were ranked according to the ligand efficiency (energy barrier -7.5 Kcal/mol) and divided into two 
groups, considering the region of interaction. This last division was performed considering the barycenter of 
each fragment: 
 Group A (641 fragments): the barycenter was far from the barycenter of region A (Arg609 - Ser 636 - 
Lys 591) less than 6 Å; 
 Group B (370 fragments): the barycenter was far from the barycenter of region B (Arg595 - Ser 636 - 
Lys 591) less than 9 Å but more than 6 Å from the barycenter of region A. 
Therefore, 89 fragment from group A and 114 from group B were selected by visual inspection considering 
their structural characteristics, stability and synthesizability. 
Due to the low molecular weight, each fragment weakly binds the biological target, but their combination 
could result in higher ligand efficiency. 
Hence, I could choose two different strategies for their heterogeneous merging (at least two of these 
fragments, one for each region of interaction): 
 linking through various chemical tethers such as amide, amine, ether and ester; 
 searching through structures reported in literature or commercially available. 
Following the first approach, the advantage would have been the possibility to investigate how various linkers 
could: 
 influence the flexibility of the scaffold; 
 arrange fragments in the binding sites; 
 enhance binding affinity; 
 modulate biophysical properties such as water solubility.  
Figure 34. Flowchart showing the main steps of the docking studies involving the fragments 
selected from PubChem collection. 
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The disadvantage would have been the need to build up new synthetic strategies for each compound. For 
this reason, I firstly decided to perform the second approach in order to capitalize cost and time.  
The interaction energy with STAT3 of all the possible combinations (10 146) of one fragment from group A 
and one from group B were recalculated using different scoring functions such as Van der Waals energy based 
on CHARMM 22 force field, distance-dependent electrostatic energy according to Coulomb’s equation 
(ElectDD), hydrophilic/hydrophobic complementarity (MLPInS = Molecular Lipophilic Potential Interaction 
Score), and ChemPLP ligand efficiency as implemented in PLANTS software. All these scores were also 
combined as consensus in order to build a new ranked list of scaffolds taking into account the scores all 
together. Considering the first 3 000 combinations of this list and applying <-16.9 Kcal/mol as energetic 
threshold, the best 734 couples were chosen. Their structures were delivered in cluster groups and the most 
representative fragments of each cluster underwent a literature search which pointed out 38 molecules. 
They were docked in a region of 12 Å around Arg609 and the best poses were selected according to the ligand 
efficiency (<-3.5 Kcal/mol) and the right orientation in the SH2 domain (it had to interact with both the 
regions) to give 9 candidates (Figure 35). The synthesized compounds (19-24) and the commercially available 
ones (25-27) were evaluated by in vitro binding assay (AlphaScreen-based assay). 
  
Figure 35. Synthesized (19-24) and commercially available (25-27) compounds. 
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5.4.2 Synthetic chemistry 
The synthesis of compounds 19 and 20 (Scheme 13 [130,131]) started from a Knoevenagel condensation 
between methyl cyanoacetate and butanale in acetic acid and piperidine. Intermediate 134 underwent an 
intramolecular cyclization by treatment with phosphoryl chloride (135), followed by a palladium catalyzed 
hydrogenation in order to remove the chlorine atom leading to compound 136. The bromination of the side 
chain, using N-bromosuccinimide in presence of benzoyl peroxide, and its nucleophilic substitution with a 
hydroxyl group led to intermediate 138. Finally, its treatment with 3-(2-bromoethyl)-indole gave the 
corresponding quaternary ammonium salt (139) which underwent a palladium catalyzed hydrogenation 
affording the tetrahydropyridine compounds (19 and 20), whose pairs of diastereoisomers were separated. 
Compounds 21-23 were synthesized according to a slightly modified literature procedure [132] as shown in 
Scheme 14-16, respectively. 
D-pantothenic acid calcium salt was firstly protected by acylation in presence of acetic anhydride and then 
the anhydride moiety was selectively hydrolyzed to give intermediate 140. Its coupling with methylamine 
(141) and a subsequent cold basic treatment led to the final compound 21 (Scheme 14). 
  
Scheme 13. Reagents and conditions: i) piperidine, AcOH, 24h, rt; ii) a. POCl3, dry DMF, 2h, 0°C to 80°C; b. 
H2O, 12h, rt; iii) H2, Pd/C, NaOAc, MeOH, 20h, rt; iv) NBS, benzoyl peroxide, CCl4, 3h, reflux; v) H2O/acetone 
(10:4), 20h, reflux; vi) 3-(2-bromoethyl)-indole, MeOH, 90 min, reflux; vii) H2, Pd/C, Et3N, MeOH, rt, 16h. 
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For the synthesis of compound 22, intermediate 140 reacted with Meldrum’s acid (2,2-dimethyl-1,3-dioxane-
4,6-dione), in presence of 4-dimethylaminopyridine and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride, affording the corresponding derivate 142. The latter was refluxed in methanol (143) and 
deprotected in basic condition resulting in the final methyl β-ketoester 22 (Scheme 15). 
 
Methyl 6-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)-3-oxohexanoate (21) was synthesized 
starting from intermediate 140 which was coupled with tert-butyl-γ-amino butanoate hydrochloride leading 
to the corresponding amide 144. The tert-butyl group was removed upon treatment with trifluoroacetic acid 
(145) and the reaction with Meldrum’s acid afforded the corresponding derivate 146 which was refluxed in 
methanol to obtain the methyl β-ketoester (147). Finally, the cold basic treatment led to the deprotection of 
the hydroxyl groups resulting in the final compound 23 (Scheme 16).  
Scheme 14. Reagents and conditions: i) Ac2O, I2, 2h at 0°C and then 18h at rt; b.H2O/THF (2:1), 16h, 
rt; ii) a. CH3NH2, HOBt, Et3N, dry CH2Cl2, 10 min, 0°C, N2; b. EDC.HCl, 30 min at 0°C and then 14h at 
rt; iii) K2CO3, dry MeOH, 210 min, 0°C. 
Scheme 15. Reagents and conditions. i) a. Meldrum’s acid, DMAP, dry CH2Cl2, 10 min, rt, N2; b. EDC.HCl, 
4h, rt; ii) dry MeOH, 18h, reflux; iii) K2CO3, dry MeOH, 210 min, 0°C. 
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For the synthesis of compound 24 (Scheme 17), 3-substituted acylindole 148, obtained by refluxing 
cyanoacetic acid with indole in acetic anhydride solution [133], underwent a microwave-assisted condensation 
with N,N-dimethylformamide dimethyl acetal leading to the α,β-unsaturated-α-cianoketone (149) whose 
cyclization in presence of guanidine hydrochloride and sodium ethoxide [134] afforded the pyrimidine nucleus 
formation (24). 
 
  
Scheme 16. Reagents and conditions: i) a. tert-butyl-γ-aminobutanoate hydrochloride, HOBt, Et3N, dry CH2Cl2, 10 min, 
0°C, N2; b. EDC.HCl, 30 min at 0°C and then 14h at rt; ii) TFA, dry CH2Cl2, 4h, rt; iii) a. Meldrum’s acid, DMAP, dry CH2Cl2, 
10 min, rt, N2; b. EDC.HCl, 4h, rt; iv) dry MeOH, 18h, reflux; v) K2CO3, dry MeOH, 210 min, 0°C. 
 Scheme 17. Reagents and conditions: i) cyanoacetic acid, Ac2O, 30 min, reflux; ii) N,N-dimethylformamide 
dimethyl acetal, toluene, 45 min, 120°C, mw; iii) guanidine hydrochloride, NaOEt, EtOH, 40 min, 120°C, mw. 
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5.4.3 AlphaScreen-based assay 
Thanks to a collaboration with Prof. A. Asai (University of Shizuoka, Japan), the effect of compounds 19-27 
on STAT3 dimerization was evaluated by using the AlphaScreen-based assay (Table 7). 
 
 
AlphaScreen (IC50, µM) 
STAT3 
19 >100 
20 >100 
21 >100 
22 >100 
23 >100 
24 >100 
25 >100 
26 26.3 ± 4.95 
27 >100 
Table 7. AlphaScreen-based Assay results. The ability to disrupt the binding of STAT3 to the cognate 
pTyr–peptide (5-carboxyfluorescein (FITC)-GpYLPQTV) is expressed as IC50. 
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5.5 Conclusions and perspectives 
In this section, I employed computationally driven drug design and investigated new chemical scaffolds able 
to disrupt STAT3 dimerization. The computational protocol was firstly validated and then applied on a larger 
base set of fragments leading to nine drug candidates. The synthesized compounds and the commercial ones 
were evaluated by an in vitro binding assay to determine their affinity for the target and compound 26 
displayed an interesting activity in inhibiting STAT3-PPI (IC50 value of 26.3 ± 4.95 µM). 
Therefore, considering these results, the next step of this study will concern a deeper literature search on 
the active compound aimed at: 
 evaluating known properties, both from a chemical and biological point of view; 
 a further optimization of the synthetic plan; 
 investigating the presence of analogues already characterized; 
 considering intellectual property implication and action potential. 
According to these data, SAR studies on compound 26 will be performed. 
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Thanks to the available national and international collaborations network, I had the chance to develop my 
PhD project through a multidisciplinary approach. 
Since the selectivity for cancer cells is one of the most important characteristics of anticancer agents, my 
efforts were mainly pointed to the discovery of molecularly targeted potential chemotherapic agents. 
In order to achieve this goal, I employed different combined synthetic-computational methods. 
On the one hand, a computationally driven drug design approach allowed me to identify nine potential STAT3 
inhibitors, which were synthetized and tested. This led to the identification of a new chemical entity which 
could be the starting point for further optimization. 
On the other hand, working on MD77 and a wild pool of its derivatives, I started the search for their potential 
target using Cresset Forge as software. The preliminary data suggested the main structural-activity 
relationships along this series of compounds which will be useful for designing new molecules. In addition, 
the obtained disparity matrix might shed light on the search of the potential target. 
Moreover, considering that cancer is a multifactorial disease, often caused by mutation or loss of several 
genes, whose treatment is highly restricted by the appearance of resistance, I followed a multitarget strategy, 
which could result in better therapeutic effects. In particular, I focused my attention on DNA, STAT3 and NF-
kB, considering their well-documented involvement in oncogenesis. 
In light of the above, besides several STAT3 and NF-kB inhibitors, I identified platinum(II) complexes, 
endowed with the 1,2,5-oxadiazole scaffold and a dual mechanism of action, e.g. inhibition of DNA replication 
and STAT3 signaling pathway. Preliminary in vivo studies showed that they possessed an activity similar to 
cisplatin but a better tolerance. 
 
In conclusion, my PhD project supported the potentiality of a multitarget approach and paved the way to 
further investigation on structural-activity relationships and molecular mechanisms of several interesting 
compounds, herein described. 
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Materials and methods 
Reagents and solvents were purchased from Sigma-Aldrich and used without further purification. Some 
reactions involving air-sensitive reagents were performed under nitrogen atmosphere and anhydrous 
solvents were used when necessary. Reactions were monitored by thin layer chromatography analysis on 
aluminum-backed Silica Gel 60 plates (70-230 mesh, Merck), using an ultraviolet fluorescent lamp at 254 nm 
and 365 nm. Visualization was aided by opportune staining reagents. Purification of intermediates and the 
final compounds was performed by flash chromatography using Geduran® Si 60 (40-63 µm, Merck). The 
Biotage Initiator microwave synthesizer was used. 
 
Physical measurements 
1H and 13C NMR spectra were recorded in CDCl3, CD3OD, acetone-d6, DMSO-d6 or DMF-d7 on Bruker DRX 
Avance 300 MHz or on a Varian 300 MHz Oxford equipped with a non-reverse probe at 25° C. Chemical shifts 
are expressed as δ (ppm). Multiplicity is reported as s (singlet), br s (broad singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet), dd (doublet of doublets), dt (doublet of triplets). The coupling constants (J-values) 
are given in Hertz (Hz). All spectroscopic data match the assigned structures. Melting points were determined 
in open capillary tubes on a Büchi Melting Point B-540. FTIR spectra were collected by using a Perkin Elmer 
(MA, USA) FTIR Spectrometer “Spectrum One” in a spectral region between 4000 and 450 cm-1 and analyzed 
by transmittance technique with 32 scansions and 4 cm-1 resolution. ESI-MS analyses were performed by 
using a Thermo Finnigan (MA, USA) LCQ Advantage system MS spectrometer with an electrospray ionization 
source and an ‘Ion Trap’ mass analyzer. The MS spectra were obtained by direct infusion of a sample solution 
in MeOH under ionization, ESI positive. Log Pow’s values and purity were evaluated with Partisil C18-ODS 
reversed-phase HPLC column with Merck-Hitachi L-7100 equipped with Detector UV6000LP. Elemental 
analyses were performed using a Perkin Elmer SeriesII/CHNS/O 2400 Analyzer. ICP-MS data were recorded 
with BRUKER Aurora M90 ICP-MS (MA, USA). 
 
Crystallization, data collection and structural determination 
The crystals of 1ag and 1da were obtained by crystallization from methanol as colorless prisms, while single 
crystals of Pt-13 were obtained as small yellow needles by slow evaporation of a solution 33% w/V in MeOH 
at room temperature. Crystals of 1ag were mounted on an Enraf-Nonius CAD-4 diffractometer, while those 
of 1da and Pt-13 on a Bruker-Axs CCD-based three circle diffractometer, both working at ambient 
temperature with graphite-monochromatized using MoKa (lambda=0.71073Å) radiation. 
The structures were solved by direct methods (SIR-97 [135]) and completed by iterative cycles of full-matrix 
least squares refinement on Fo2 using the SHELXL-97 [136] program (WinGX suite). [84] All non-H-atoms were 
refined anisotropically. The H-atoms positions were introduced in calculated positions in their described 
geometries and allowed to ride on the attached carbon atom with fixed isotropic thermal parameters.  
Geometrical calculations were carried out with the program PARST. [137] CCDC-1496339 (1ag), CCDC-1496338 
(1da) and CCDC-1478539 (Pt-13) contains the supplementary crystallographic data. These data can be 
obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge 
Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK; fax: ++44 1223 336 033; or 
deposit@ccdc.cam.ac.uk). 
 
Crystal data 1ag: C16 H10 F3 N3 O2, Mr = 333.27g/mol, orthorhombic, Space group Pbc21 a = 4.982 (2) Å, b = 
14.446 (3) Å, c = 20.630 (5) Å, V = 1484.6 (8) Å3, Z = 4, Dcalc = 1.491 Mg/m3, F(000) = 680, R = 0.0985 (reflections 
collected = 1163), wR2 = 0.229, T = 293(2) K, GOF = 1.219. The reflections were collected in the range 2.82° 
≤ θ ≤ 25.97° (limiting indices = -1 ≤ h ≤ 6, -1 ≤ k ≤ 17, -1 ≤ l ≤ 25) employing a 0.65 x 0.52 x 0.42 mm3 crystal. 
The residual positive and negative electron densities in the final map were 0.386 and -0.244 eÅ-3.  
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Crystal data 1da: C15 H10 Cl N3 O2, Mr = 299.71 g/mol, orthorhombic, Space group Pbc21 a = 13.768 (3) Å, b = 
5.074 (2) Å, c = 19.460 (3) Å, V = 1382.5 (5) Å3, Z = 4, Dcalc = 1.44 Mg/m3, F(000) = 616, R = 0.028 (reflections 
collected = 10460), wR2 = 0.059, T = 293(2) K, GOF = 0.929. The reflections were collected in the range 2.08° 
≤ θ ≤ 27.12° (limiting indices = -17 ≤ h ≤ 17, -6 ≤ k ≤ 6, -25 ≤ l ≤ 25) employing a 0.55 x 0.22 x 0.02 mm3 crystal. 
The residual positive and negative electron densities in the final map were 0.129 and –0.159 eÅ-3. 
 
Crystal data Pt-13: C4 H7 O1 Pt1 Cl2 N3, Mr = 379.01 g/mol, trigonal, Space group R-3 a = 39.836 (2) Å, c = 6.724 
(3) Å, V = 9240.8 (5) Å3, Z = 12, Dcalc = 2.439 Mg/m3, F(000) = 6120, R = 0.026 (reflections collected/unique = 
3614/3228), wR2 = 0.031, T = 293(2) K, GOF = 1.057. The reflections were collected in the range 1.02° ≤ θ ≤ 
25.03° (limiting indices = -47 ≤ h ≤ 47, -47 ≤ k ≤ 47, -8 ≤ l ≤ 7) employing a 0.01 x 0.02 x 0.01 mm3 crystal. The 
residual positive and negative electron densities in the final map were 0.950 and –0.540 eÅ-3. 
 
Stability test 
The stability study of complexes (Pt-13, Pt-14 and Pt-15b) was performed under physiological conditions 
through UV-vis spectroscopy at their respective λmax. Stock solutions were diluted to a final concentration of 
100 μM with 1 % DMF. The UV-vis peak profile of the sample was monitored for 48 hours at 4 hour intervals. 
 
Log Pow determination 
RP-HPLC analysis were performed to correlate the hydrophobicity of the compounds and the platinum(II) 
complexes with their retention time. The chromatograms were registered using Partisil C18-ODS reversed-
phase HPLC column at 25°C and water/acetonitrile (60:40) as mobile phase with KI as internal standard (flow 
rate: 1 mL/min; λ= 230 nm). 
For platinum complexes the same column was used and water (15 mM HCOOH)/MeOH (70:30) mobile phase 
with KI as internal standard (flow rate of 1 mL/min, λ= 210 nm). [96-98,138] The calibration curve was realized in 
comparison with reference compounds chosen in OECD guideline. [139] 
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General procedures for the synthesis of 
4-phenyl-1,2,5-oxadiazol-3-amines (105a-d,g-j,l,r) 
Procedure a 
 
Reagents and conditions: i) a. NaOH, 12h, 0° C; b. NaNO2, 20% HClO4, 14h, rt; c. NH2OH . HCl, NaOH, 2h, 
reflux; d. urea, 3h, reflux. 
 
A one-pot reaction [63] on ethyl benzoylacetate afforded 4-phenyl-1,2,5-oxadiazol-3-amine, 105a 
intermediate. 
 
Procedure b 
 
Reagents and conditions: i) NH2OH . HCl, NaHCO3, MeOH, 2h, reflux; ii) NCS, DMF, 12h, rt; iii) KCN, 
Et2O/H2O, 5h, rt; iv) NH2OH . HCl, NaHCO3, MeOH, 12h, reflux; v) 2N NaOH, 12h, reflux. 
 
The key intermediates 105b-d,g-j,l and 105r were obtained according to a literature method [59] starting from 
the appropriate benzaldehyde. 
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 4-phenyl-1,2,5-oxadiazol-3-amine (105a) 
 Procedure a: yield 34 % as white solid (m.p. 99.5-100.5°C). TLC: petroleum ether/ethyl 
acetate (7:3) - Rf: 0.45. Purified by flash chromatography (eluent: petroleum ether/ 
ethyl acetate (7:3). Molecular formula: C8H7N3O. Molecular weight: 161.16 g/mol. 1H 
NMR (300 MHz, CDCl3): δ 7.70-7.81 (m, 2H, ArH), 7.51-7.59 (m, 3H, ArH), 4.20 (br s, 
2H, NH2 exchanged with D2O) ppm. 13C NMR (75 MHz, CDCl3): δ 154.30, 146.94, 
130.58, 129.42, 127.57, 125.49 ppm. 
 
 4-(2-chlorophenyl)-1,2,5-oxadiazol-3-amine (105b) 
 Procedure b: yield 60 % (starting from 15 mmol of 2-chlorobenzaldehyde, 9 mmol of 
105b were obtained) as light yellow solid (m.p. 59.1-59.7°C). TLC: petroleum ether/ 
ethyl acetate (8:2) - Rf: 0.18. Molecular formula: C8H6ClN3O. Molecular weight: 195.61 
g/mol. 1H NMR (300 MHz, CDCl3): δ 7.33-7.57 (m, 4H, ArH), 4.22 (br s, 2H, NH2 
exchanged with D2O) ppm. 13C NMR (75 MHz, CDCl3): δ 154.99, 146.46, 133.48, 
132.29, 132.22, 130.54, 127.77, 124.78 ppm. 
 
 4-(3-chlorophenyl)-1,2,5-oxadiazol-3-amine (105c) 
 
Procedure b: yield 41 % (starting from 15 mmol of 3-chlorobenzaldehyde, 6.15 mmol 
of 105c were obtained) as light yellow solid (m.p. 132.6-132.9°C). TLC: petroleum 
ether/ethyl acetate (7:3) - Rf: 0.48. Molecular formula: C8H6ClN3O. Molecular weight: 
195.61 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.74 (t, J = 1.6 Hz, 1H, ArH), 7.63 (dt, J1 = 
1.6 Hz, J2 = 6.9 Hz, 1H, ArH), 7.45-7.54 (m, 2H, ArH), 4.22 (br s, 2H, NH2 exchanged 
with D2O) ppm. 13C NMR (75 MHz, acetone-d6): δ 155.41, 146.24, 134.74, 131.12, 
130.44, 128.36, 127.74, 126.55 ppm. 
 
 4-(4-chlorophenyl)-1,2,5-oxadiazol-3-amine (105d) 
 Procedure b: yield 19 % (starting from 15 mmol of 4-chlorobenzaldehyde, 2.85 mmol 
of 105d were obtained) as white solid (m.p. 140.3-143.8°C). TLC: petroleum ether/ 
ethyl acetate (7:3) - Rf: 0.59. Molecular formula: C8H6ClN3O. Molecular weight: 195.61 
g/mol. 1H NMR (300 MHz, CDCl3): δ 7.69 (d, J = 8.1 Hz, 2H, ArH), 7.52 (d, J = 8.1 Hz, 
2H, ArH), 4.21 (br s, 2H, NH2 exchanged with D2O) ppm. 13C NMR (75 MHz, acetone-
d6): δ 155.10, 146.20, 135.77, 129.44, 129.31, 124.95 ppm. 
 
 4-(4-trifluoromethyl)-1,2,5-oxadiazol-3-amine (105g) 
 
Procedure b: yield 25 % (starting from 15 mmol of 4-trifluoromethylbenzaldehyde, 
3.75 mmol of 105g were obtained) as light brown solid (m.p. 107.2-109.3°C). TLC: 
cyclohexane/ethyl acetate (8:2) - Rf: 0.30. Molecular formula: C9H6F3N3O. Molecular 
weight: 229.16 g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.04 (d, J = 8.7 Hz, 2H, ArH), 
7.91 (d, J = 8.7 Hz, 2H, ArH), 5.74 (s, 2H, NH2 exchanged with D2O) ppm. 13C NMR (75 
MHz, acetone-d6): δ 155.27, 146.11, 131. 53, 130.18, 128.58, 125.97 (q, J = 2.9 Hz), 
122.28 ppm. 19F NMR (282 MHz, acetone-d6): δ 63.47 (s, CF3) ppm. 
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 4-(4-bromophenyl)-1,2,5-oxadiazol-3-amine (105h) 
 Procedure b: yield 18 % (starting from 15 mmol of 4-bromobenzaldehyde, 2.70 mmol 
of 105h were obtained) as light brown solid (m.p. 143.8-144.8°C). TLC: cyclohexane/ 
ethyl acetate (8:2) - Rf: 0.53. Molecular formula: C8H6BrN3O. Molecular weight: 240.06 
g/mol. 1H NMR (300 MHz, CDCl3): δ 7.68 (d, J = 8.3 Hz, 2H, ArH), 7.62 (d, J = 8.3 Hz, 2H, 
ArH), 4.20 (br s, 2H, NH2 exchanged with D2O) ppm. 13C NMR (75 MHz, CDCl3): δ 
154.56, 146.70, 135.68, 129.38, 125.89, 125.02 ppm. 
 
 4-(4-methylphenyl)-1,2,5-oxadiazol-3-amine (105i) 
 Procedure b: yield 8 % (starting from 15 mmol of 4-methylbenzaldehyde, 1.2 mmol 
of 105i were obtained) as white solid (m.p. 126.7-128.5°C). TLC: cyclohexane/ethyl 
acetate (7:3) - Rf: 0.40. Molecular formula: C9H9N3O. Molecular weight: 175.19 g/mol. 
1H NMR (300 MHz, CDCl3): δ 7.64 (d, J = 8.2 Hz, 2H, ArH), 7.36 (d, J = 8.2 Hz, 2H, ArH), 
4.26 (br s, 2H, NH2 exchanged with D2O), 2.38 (s, 3H, CH3) ppm. 13C NMR (75 MHz, 
CDCl3): δ 154.31, 146.92, 140.87, 130.09, 127.44, 122.58, 21.44 ppm. 
 
 4-(1,1'-biphenyl-4-yl)-1,2,5-oxadiazol-3-amine (105j) 
 
Procedure b: yield 19 % (starting from 15 mmol of 1,1’-biphenyl-4-carbaldehyde, 
2.85 mmol of 105j were obtained) as light yellow solid (m.p. 161.4-161.8°C). TLC: 
cyclohexane/ethyl acetate (8:2) - Rf: 0.30. Molecular formula: C14H11N3O. Molecular 
weight: 237.26 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.74-7.84 (m, 4H, ArH), 7.62-7.66 
(m, 2H, ArH), 7.38-7.52 (m, 3H, ArH), 4.24 (br s, 2H, NH2 exchanged with D2O) ppm. 
13C NMR (75 MHz, DMSO-d6): δ 156.09, 147.31, 142.55, 139.79, 129.79, 128.99, 
128.77, 128.00, 127.46, 125.25 ppm. 
 
 4-(4-benzyloxyphenyl)-1,2,5-oxadiazol-3-amine (105l) 
 
Procedure b: yield 21 % (starting from 15 mmol of 4-benzozyloxoxy-benzaldehyde, 
3.15 mmol of 105l were obtained) as white solid (m.p. 144.5-145.5°C). TLC: 
cyclohexane/ethyl acetate (7:3) - Rf: 0.45. Molecular formula: C15H13N3O. Molecular 
weight: 267.29 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.66 (d, J = 8.8 Hz, 2H, ArH), 7.32-
7.48 (m, 5H, ArH), 7.11 (d, J = 8.8 Hz, 2H, ArH), 5.14 (s, 2H, CH2), 4.19 (br s, 2H, NH2 
exchanged with D2O) ppm. 13C NMR (75 MHz, CDCl3): δ 160.67, 154.21, 146.79, 
136.49, 129.31, 128.95, 128.47, 127.69, 118.24, 116.01, 70.37 ppm. 
 
 4-(4-nitrophenyl)-1,2,5-oxadiazol-3-amine (105r) 
 Procedure b: yield 12 % (starting from 15 mmol of 4-nitrobenzaldehyde, 1.8 mmol of 
105r were obtained) as brown-red solid (m.p. 135.4-137.6°C). TLC: cyclohexane/ethyl 
acetate (9:1) - Rf: 0.48. Molecular formula: C8H6N4O3. Molecular weight: 206.16 g/mol. 
1H NMR (300 MHz, CDCl3): δ 8.40 (d, J = 8.9 Hz, 2H, ArH), 7.98 (d, J = 8.9 Hz, 2H, ArH), 
4.27 (br s, 2H, NH2 exchanged with D2O) ppm. 13C NMR (75 MHz, acetone-d6): δ 
155.28, 148.87, 145.76, 132.43, 129.09, 124.09 ppm. 
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Procedures for the synthesis of 
4-(4-chlorophenyl)-3-aminoisoxazole (109) 
Synthesis of ethyl 4-(4-chlorophenyl)isoxazole-3-carboxylate (106) 
 
 
Ethyl 5-amino-4-(4-chlorophenyl)isoxazole-3-carboxylate (0.750 mmol) was dissolved in a mixture of acetic 
acid (1.5 mL), H2O (1.5 mL) and THF (2 mL). NaNO2 (7.5 mmol) was slowly added and the reaction mixture 
was stirred at room temperature for 1 hour (TLC: petroleum ether/ethyl acetate (95:5) - Rf: 0.26). After 
evaporating the solvents, the residue was diluted with water and extracted with dichloromethane. The 
collected organic layers were washed with a saturated aqueous solution of sodium bicarbonate and with 
water. The organic phase was dried over anhydrous Na2SO4, filtered and then concentrated under reduced 
pressure. The crude product was purified by flash chromatography (eluting with petroleum ether/ethyl 
acetate from 95:5 to 9:1) to afford compound 106. Yield 71 % as colorless oil. Molecular formula: C12H10ClNO3. 
Molecular weight: 251.67 g/mol. 1H NMR (300 MHz, acetone-d6): δ 9.12 (s, 1H, ArH), 7.57 (d, J = 8.6 Hz, 2H, 
ArH), 7.46 (d, J = 8.6 Hz, 2H, ArH), 4.38 (q, J = 7.1 Hz, 2H, CH2), 1.30 (t, J = 7.1 Hz, 3H, CH3) ppm. 
 
 
Synthesis of 4-(4-cholophenyl)-3-hydrazinecarboxylisoxazole (107) 
 
 
NH2NH2 ∙ H2O (1.596 mmol) was added portion-wise at 0°C to a stirred solution of 106 (0.397 mmol) in ethanol 
(1.3 mL). The reaction mixture was warmed to 40°C for 90 minutes (TLC: dichloromethane/methanol (95:5) - 
Rf: 0.45) and then the solvent was evaporated under reduced pressure. The residue was extracted with water 
and ethyl acetate and the organic layers were collected, dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The intermediate 107 was used in the next step without any further 
purification. Yield 85 % as white solid. Molecular formula: C10H8ClN3O2. Molecular weight: 237.64 g/mol. 1H 
NMR (300 MHz, acetone-d6): δ 10.11 (br s, 1H, NH exchanged with D2O), 9.17 (s, 1H, ArH), 7.65 (d, J = 8.6 Hz, 
2H, ArH), 7.42 (d, J = 8.6 Hz, 2H, ArH), 3.02 (br s, 2H, NH2 exchanged with D2O) ppm. 
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Synthesis of 4-(4-chlorophenyl)-3-acylazideisoxazole (108) 
 
 
The acyl hydrazine 107 (0.420 mmol) was dissolved in a 1:1 mixture of acetone/10% HCl (1.8 mL). After 
cooling at 0°C, a solution of NaNO2 (0.63 mmol) in water (1.8 mL) was added dropwise. The mixture was 
stirred for 40 minutes at room temperature and then quenched by slowly adding water. The resulting mixture 
was cooled and filtered obtaining compound 108 which was used without any further purification. Yield 86 
% as white solid. Molecular formula: C10H5ClN4O2. Molecular weight: 248.63 g/mol. 1H NMR (300 MHz, 
acetone-d6): δ 9.20 (s, 1H, ArH), 7.61 (d, J = 8.6 Hz, 2H, ArH), 7.48 (d, J = 8.6 Hz, 2H, ArH) ppm. 
 
 
Synthesis of 4-(4-chlorophenyl)-3-aminoisoxazole (109) 
 
 
The acylazide 108 (0.403 mmol) was suspended in a mixture of water/acetic acid (1:1, 6.4 mL) and the 
reaction was refluxed for 1 hour (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.25). Then the solvents were 
removed under vacuum and the residue was extracted with water and ethyl acetate, dried with anhydrous 
Na2SO4 and concentrated under reduced pressure obtaining 109. Quantitative yield as red foam. Molecular 
formula: C9H7ClN2O. Molecular weight: 194.62 g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.58 (s, 1H, ArH), 
7.57 (d, J = 8.5 Hz, 2H, ArH), 7.46 (d, J = 8.5 Hz, 2H, ArH), 5.10 (br s, 2H, NH2 exchanged with D2O) ppm. MS 
(ESI) m/z 194.9 [M + H]+. 
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Procedures for the synthesis of 
3-(4-chlorophenyl)-4-aminoisoxazole (114) 
Synthesis of 4- chlorobenzoylchloride oxime (102d) 
 
 
102d, an intermediate in the synthesis of 105d, was prepared according to literature procedure [59]: yield 87 
% (starting from 10 mmol of 4-chlorobenzaldehyde, 8.7 mmol of 102d were obtained) as light-yellow solid 
(m.p. 48-49°C). Molecular formula: C7H5Cl2NO. Molecular weight: 190.03 g/mol. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.60. 1H NMR (300 MHz, CDCl3): δ 7.74 (d, J = 8.7 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H), 2.88 (s, 
1H, OH, exchanged with D2O) ppm. 13C NMR (75 MHz, acetone-d6): δ 135.80, 135.71, 131.87, 128.66, 128.31 
ppm. 
 
 
Synthesis of ethyl (E)-3-pyrrolidin-1-yl acrylate (110) 
 
 
A solution of pyrrolidine (14.06 mmol) in toluene (2.4 mL) was added dropwise over 10 minutes to a solution 
of ethyl propiolate (14.06 mmol) in toluene (9.7 mL). The resulting mixture was stirred at room temperature 
for 16 hours (TLC: cyclohexane/ethyl acetate (9:1) - Rf: 0.11) and then the solvent was evaporated under 
reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The collected organic 
layers were dried over Na2SO4 and concentrated in vacuo to give pure 110. Quantitative yield as orange oil. 
Molecular formula: C9H15NO2. Molecular weight: 169.22 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.65 (d, J = 12.9 
Hz, 1H, CH), 4.48 (d, J = 12.9 Hz, 1H, CH), 4.13 (q, J = 7.1 Hz, 2H, CH2), 3.27 (br s, 4H, CH2), 1.93 (br s, 4H, CH2), 
1.26 (t, J =7.1, 3H, CH3) ppm. 
 
 
Synthesis of ethyl 3-(4-chlorophenyl)isoxazole-4-carboxylate (111) 
 
 
To a stirred solution of intermediate 102d (6.74 mmol) in anhydrous diethyl ether (13.4 mL) and 
trimethylamine (1.11 mL), a solution of 110 (6.74 mmol) in anhydrous diethyl ether was dripped at 0°C and 
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then the resulting mixture was stirred at room temperature for 18 hours under nitrogen atmosphere (TLC: 
cyclohexane/ethyl acetate (9:1) - Rf: 0.37). The orange suspension was partitioned between water and diethyl 
ether. The aqueous phase was extracted with further diethyl ether. The organic layers were combined, 
washed with 1M HCl, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The 
crude intermediate was purified by flash chromatography on silica gel (eluent: cyclohexane/ethyl acetate 
95:5) to afford 111. Yield 74 % as colorless oil. Molecular formula: C12H10ClNO3. Molecular weight: 251.67 
g/mol. 1H NMR (300 MHz, CDCl3): δ 8.96 (s, 1H, ArH), 7.70 (d, J = 8.7 Hz, 2H, ArH), 7.36 (d, J = 8.7 Hz, 2H, ArH), 
4.22 (q, J = 7.5 Hz, 2H, CH2), 1.24 (t, J = 7.5 Hz, 3H, CH3) ppm. 
 
 
Synthesis of 3-(4-chlorophenyl)isoxazole-4-carboxylic acid (112) 
 
 
A stirred solution of 111 (5.01 mmol) in acetic acid (21 mL) was treated with 6N HCl (35 mL) at reflux for 6 
hours (TLC: dichloromethane/methanol/acetic acid (98:2:0.02) - Rf: 0.25). After cooling, the reaction mixture 
was extracted with ethyl acetate. The concentrated organic layer was treated with sat. NaHCO3 and the 
aqueous solution was separated, cooled and acidified with 6N HCl. Intermediate 112 was extracted with ethyl 
acetate and the combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. Yield 96 % as white solid. Molecular formula: C10H6ClNO3. Molecular weight: 223.61 
g/mol. 1H NMR (300 MHz, CDCl3): δ 9.12 (s, 1H, ArH), 7.69 (d, J = 9 Hz, 2H, ArH), 7.49 (d, J = 9 Hz, 2H, ArH) 
ppm. 
 
 
Synthesis of [3-(4-chlorophenyl)isoxazol-4-yl]-carbamic acid tert-butyl ester (113) 
 
 
A mixture of 112 (2.94 mmol), diphenylphosphorylazide (2.94 mmol) and trimethylamine (0.41 mL) in dry 
tert-butanol (4 mL) was refluxed for 16 hours under nitrogen atmosphere (TLC: cyclohexane/ethyl acetate 
(7:3) - Rf: 0.28). Compound 113 was extracted with ethyl acetate. The combined organic phases were washed 
with 1M HCl and brine and dried over anhydrous Na2SO4. The crude was purified by flash chromatography 
on silica gel (eluent: cyclohexane/ethyl acetate from 8:2 to 7:3) to afford compound 113. Yield 53 % as brown 
solid (m.p. 160.5-163.2°C). Molecular formula: C14H15clN2O3. Molecular weight: 294.73 g/mol. 1H NMR (300 
MHz, CDCl3): δ 8.85 (s, 1H, ArH), 7.52 (d, J = 8.5 Hz, 2H, ArH), 7.45 (d, J = 8.6 Hz, 2H, ArH), 6.26 (br s, 1H, NH 
exchanged with D2O), 1.46 (s, 9H, C(CH3)3) ppm. 13C NMR (75 MHz, CDCl3): δ 152.62, 148.62, 136.27, 129.59, 
129.18, 126.14, 118.21, 81.71, 28.13 ppm.  
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Synthesis of 3-(4-chlorophenyl)-4-aminoisoxazole (114) 
 
 
To a stirred solution of 113 (1.076 mmol) in anhydrous dichloromethane (0.5 mL), trifluoracetic acid (0.5 mL) 
was slowly added and the reaction mixture was stirred at room temperature for 16 hours (TLC: 
cyclohexane/ethyl acetate (7:3) - Rf: 0.25) and then extracted with water. The collected acidic aqueous 
solutions were basified with a 4N NaOH and extracted with ethyl acetate. The organic layers were combined, 
dried over anhydrous Na2SO4, filtered and concentrated. The crude was purified by flash chromatography on 
silica gel (eluent: cyclohexane/ethyl acetate 7:3) to provide 114. Yield 84 % as yellow solid. Molecular 
formula: C9H7ClN2O. Molecular weight: 194.62 g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.30 (s, 1H, ArH), 
7.89 (d, J = 8.5 Hz, 2H, ArH), 7.53 (d, J = 8.5 Hz, 2H, ArH), 3.99 (s, 2H, NH2 exchanged with D2O) ppm. 
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Procedures for the synthesis of 
5-(4-chlorophenyl)-1-methyl-4-amino-imidazole (116) 
Synthesis of 5-(4-chlorophenyl)-1-methyl-4-nitro-imidazole (115) 
 
 
A mixture of 5-chloro-1-methyl-4-nitroimidazole (6.19 mmol), 4-cholorophenylboronic acid (6.19 mmol), 
Pd(PPh3)2Cl2 (0.19 mmol), K2CO3 (15.48 mmol) and TBAB (6.19 mmol) in water (10 mL) was stirred at 80°C for 
16 hours, under nitrogen atmosphere (TLC: dichloromethane/methanol (95:5) - Rf: 0.50). The resulting 
precipitate was filtered to obtained pure 115. Yield 92 % as yellow solid. Molecular formula: C10H8ClN3O2. 
Molecular weight: 237.64 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.48-7.55 (m, 3H, ArH), 7.34 (d, J = 8.5 Hz, 2H, 
ArH), 3.54 (s, 3H, CH3) ppm. MS (ESI) m/z 238.4 [M + H]+. 
 
 
Synthesis of 5-(4-chlorophenyl)-1-methyl-4-amino-imidazole (116) 
 
 
The intermediate 115 (0.42 mmol) was dissolved in dichloromethane/methanol (9:1, 3 mL) and Pd(OH)2 (0.07 
mmol) was added. The mixture was stirred under hydrogen atmosphere at room temperature overnight (TLC: 
dichloromethane/methanol (9:1) - Rf: 0.44) and then filtered on Celite®. The organic solvents were removed 
under vacuum to give the pure compound 116. Yield 91 % as brownish oil. Molecular formula: C10H10ClN3. 
Molecular weight: 207.66 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.41 (d, J = 8.5 Hz, 2H, ArH), 7.27 (d, J = 8.5 Hz, 
2H, ArH), 3.53 (s, 3H, CH3), 3.41 (br s, 2H, NH2 exchanged with D2O) ppm. MS (ESI) m/z 208.8 [M + H]+. 
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Procedures for the synthesis of 
ethyl 3-amino-4-(4-chlorophenyl)furan-2-carboxylate (118) 
Synthesis of 4-chlorophenyl-acrylonitrile sodium salt (117) 
 
 
Na (6.612 mmol) was suspended in ethanol (8 mL) and refluxed under nitrogen atmosphere. A solution of 4-
chlorophenylacetonitrile (3.306 mmol) and ethyl formate (4.98 mmol) in ethanol (2 mL) was added dropwise 
and the reaction mixture was stirred at reflux for 16 hours (TLC: dichloromethane/methanol (95:5) - Rf: 0.51). 
After cooling, diethyl ether was added and the resulting precipitate was collected by filtration, washed with 
diethyl ether and dried to give 4-chlorophenyl-acrylonitrile as sodium salt (117). Yield 78 % as white solid. 
Molecular formula: C9H5ClNNaO. Molecular weight: 201.58 g/mol. 1H NMR (300 MHz, DMSO-d6): δ 7.73 (d, J 
= 8.8 Hz, 2H, ArH), 7.06 (d, J = 8.8 Hz, 2H, ArH), 7.04 (s, 1H, CH) ppm. 
 
 
Synthesis of ethyl 3-amino-4-(4-chlorophenyl)furan-2-carboxylate (118) 
 
 
The intermediate 117 (2.48 mmol) was dissolved in dry DMF (3.97 mL) and diethyl chloromalonate (2.73 
mmol) was added. The reaction mixture was stirred for 5 hours at room temperature under nitrogen 
atmosphere (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.22) and then the solvent was removed under 
reduced pressure. The obtained orange solid was diluted with water and extracted with dichloromethane. 
The organic layer was dried over anhydrous Na2SO4, filtered and evaporated under vacuum. The resulting 
intermediate (diethyl 2-((2-(4-chlorophenyl)-2-cyanovinyl)oxy)malonate) was dissolved in dry ethanol (2.6 
mL) and 1,5-diazabicyclo-[4.3.0]-non-5-ene (2.73 mmol) was added under nitrogen atmosphere. After 
refluxing for 16 hours (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.51), the solution was concentrated and the 
residue was diluted with water and extracted with dichloromethane. The organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude was purified by silica gel 
chromatography (eluent: cyclohexane/ethyl acetate 9:1) to obtain 118. Yield 41 % as brownish solid. 
Molecular formula: C13H12ClNO3. Molecular weight: 265.69 g/mol. 1H NMR (300MHz, DMSO-d6): δ 7.87 (s, 1H, 
ArH), 7.41-7.56 (m, 4H, ArH), 5.54 (br s, 2H, NH2 exchanged with D2O), 4.22 (q, J = 7.1 Hz, 2H, CH2), 1.25 (t, J 
= 7.1 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 160.35, 142.29, 141.35, 133.85, 129.42, 128.82, 128.46, 
119.44, 60.13, 14.56 ppm.  
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Synthesis of 4’-chloro-[1,1-biphenyl]-2-amine (121) 
 
In a two-necked flask, 2-iodoaniline (1.14 mmol) was dissolved in dry toluene/ethanol (20:1, 20 mL) under 
nitrogen atmosphere. Then 4-chlorophenylboronic acid (1.256 mmol), 2M Na2CO3 (3.43 mmol) and Pd(PPh3)4 
(0.923 mmol) were added. The mixture was stirred at 70°C for 16 hours (TLC: cyclohexane/ethyl acetate (9:1) 
- Rf: 0.27). After solvent evaporation, water was added and the residue was extracted with ethyl acetate. The 
organic layers were collected, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The 
crude was purified by flash chromatography on silica gel (eluent: cyclohexane/ethyl acetate, 9:1) to afford 
121. Yield 81 % as orange oil. Molecular formula: C12H10ClN. Molecular weight: 203.67 g/mol. 1H NMR (300 
MHz, CDCl3): δ 7.34-7.46 (m, 4H, ArH), 7.06-7.21 (m, 2H, ArH), 6.72-6.89 (m, 2H, ArH), 3.75 (br s, 2H, NH2 
exchanged with D2O) ppm. 
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General procedures for the synthesis of N-aryl amides (1-5, 7-12) 
Procedure a 
 
In a microwave vessel, to a solution of the suitable 4-phenyl-1,2,5-oxadiazol-3-amine (0.255 mmol) and 4-
dimethylaminopyridine (0.306 mmol) in dry dichloroethane (1.5 mL), the opportune benzoyl chloride (0.306 
mmol) was added at room temperature under nitrogen atmosphere. The reaction mixture was irradiated in 
a microwave synthesizer at 300 Watts and 120°C for 45 minutes. Upon completion, the solution was treated 
with water and extracted with dichloromethane and the collected organic phases were washed with 1N HCl. 
The organic layer was dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was 
purified by flash column chromatography. 
 
 
Procedure b 
 
In a microwave vial, the aryl amine (0.15 mmol) was dissolved in dry dichloromethane (4.29 mL) under 
nitrogen atmosphere. Then trimethylamine (0.378 mmol) and benzoyl chloride (0.15 mmol) were added. The 
reaction mixture was irradiated at 300 Watts for 40 minutes at 80°C in a microwave synthesizer. The crude 
was washed with 1M HCl, saturated bicarbonate solution and brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The residue was purified by flash chromatography. 
 
 
Procedure c 
 
In a two-necked flame-dried flask under nitrogen atmosphere, the suspension of 60% NaH mineral oil (0.3 
mmol) in dry DMF (3 mL) was cooled at 0°C and the appropriate aryl amine (0.25 mmol) was added. The 
mixture was stirred for 30 minutes at 0°C. Then, the suitable commercially available acyl chloride (0.3 mmol) 
was added dropwise and the mixture was stirred at 60°C for 12 hours.  
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The reaction was quenched with water, and DMF was removed under vacuum. The residue was extracted 
with ethyl acetate; the collected organic layers were dried over Na2SO4 and evaporated. The crude product 
was purified by column chromatography to obtain the desired adduct. 
 
 
Procedure d 
 
In a two-necked flame-dried flask, the proper aryl amine (0.373 mmol) was dissolved in dry pyridine (0.54 
mL) under nitrogen atmosphere and cooled at 0°C. After 10 minutes, the suitable acyl chloride (0.341 mmol) 
was dripped and the mixture was stirred at room temperature until completion. The solvent was 
concentrated under reduced pressure and the residue was diluted with water and extracted with ethyl 
acetate. The organic layers were collected, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The pure 1,3,4-oxadiazol-2-yl-benzamide was isolated after flash chromatography. 
 
 
Procedure e 
 
In a two-necked flame-dried flask, the opportune aryl amine (0.48 mmol) and trimethylamine (0.96 mmol) 
were dissolved in dry dichloromethane under nitrogen atmosphere. The solution was cooled on an ice-bath 
and after 30 minutes the suitable acyl chloride (0.53 mmol) was added dropwise. The reaction was stirred 
for 90 minutes at different temperatures for each substrate. After cooling, the reaction was quenched with 
water and extracted with dichloromethane. The collected organic layers were firstly washed with 1M HCl and 
then with brine. The resulting solution was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The final benzamide was obtained as pure product by flash chromatography or precipitation as hydrochloride 
salt. 
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 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl)benzamide 
(MD77) 
 
Procedure c: yield 27 % as white solid (m.p. 111-114°C). Starting compounds: 
105d and 4-(trifluoromethyl)benzoyl chloride. TLC: petroleum ether/ethyl 
acetate (9:1) - Rf: 0.37. Purified by flash chromatography (eluent: cyclohexane/ 
ethyl acetate 8:2). Molecular formula: C16H9ClF3N3O2. Molecular weight: 367.71 
g/mol. 1H NMR (300 MHz, CD3OD): δ 8.12 (d, J = 8.6 Hz, 2H, ArH), 7.86 (d, J = 
8.6 Hz, 2H, ArH), 7.75 (d, J = 8.4 Hz, 2H, ArH), 7.50 (d, J = 8.4 Hz, 2H, ArH) ppm. 
13C NMR (75 MHz, acetone-d6): δ 165.16, 150.73, 149.77, 136.23, 129.27, 
129.22, 128.92, 125.72 (q, J = 3.5 Hz), 124.67 ppm. 19F NMR (282 MHz, CDCl3): 
δ -64.03 (s, CF3) ppm. 
 
 N-(4-phenyl-1,2,5-oxadiazol-3-yl)benzamide (1aa) 
 
Procedure a: yield 13 % as white solid (m.p. 139-140°C). Starting compounds: 
105a and benzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.28. 
Purified by flash chromatography (eluent: cyclohexane/ethyl acetate from 9:1 
to 6:4). Molecular formula: C15H11N3O2. Molecular weight: 265.27 g/mol. 1H 
NMR (300 MHz, CDCl3): δ 8.00-8.22 (m, 4H, ArH), 7.56-7.66 (m, 2H, ArH), 7.39-
7.53 (m, 4H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 172.56, 133.82, 133.12, 
130.76, 130.21, 129.34, 129.24, 128.97, 128.47, 127.76, 127.57 ppm. 
 
 4-(chloro)-N-(4-phenyl-1,2,5-oxadiazol-3-yl)benzamide (1ad) 
 
Procedure c: yield 10 % as yellow solid (m.p. 193.3-193.5°C). Starting 
compounds: 105a and 4-chlorobenzoyl chloride. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.43. Purified by flash chromatography (eluent: cyclohexane/ 
ethyl acetate 9:1). Molecular formula: C15H10ClN3O2. Molecular weight: 299.71 
g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.27 (br s, 1H, NH exchanged with 
D2O), 7.92 (d, J = 8.1 Hz, 2H, ArH), 7.66-7.73 (m, 2H, ArH), 7.47 (d, J = 8.1 Hz, 
2H, ArH), 7.33-7.41 (m, 3H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 164.15, 
148.55, 139.73, 130.90, 130.40, 129.39, 129.01, 127.56, 125.21, 109.99 ppm. 
 
 4-(trifluoromethyl)-N-(4-phenyl-1,2,5-oxadiazol-3-yl)benzamide (1ag) 
 
Procedure a: yield 9 %. Procedure c: yield 34 %. White solid (m.p. 198.5-
199.0°C). Starting compounds: 105a and 4-(trifluoromethyl)benzoyl chloride. 
TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.50. Purified by flash 
chromatography (eluent: cyclohexane/ethyl acetate 7:3). Molecular formula: 
C16H10F3N3O2. Molecular weight: 333.27 g/mol. 1H NMR (300 MHz, acetone-d6): 
δ 10.53 (br s, 1H, NH exchanged with D2O), 8.26 (d, J = 8.1 Hz, 2H, ArH), 7.92 (d, 
J = 8.1 Hz, 2H, ArH), 7.83-7.86 (m, 2H, ArH), 7.50-7.54 (m, 3H, ArH) ppm. 13C 
NMR (75 MHz, CDCl3): δ 165.20, 151.59, 149.74, 136.25, 133.64, 133.21, 
130.63, 129.04, 128.87, 127.51, 125.72 (q, J = 3.7 Hz), 122.11 ppm. 19F NMR 
(282 MHz, CDCl3): δ -63.58 (s, CF3) ppm. 
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 N-(4-(2-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1ba) 
 
Procedure c: yield 7 % as white solid (m.p. 101.0-104°C). Starting compounds: 
105b and benzoyl chloride. TLC: cyclohexane/ethyl acetate/dichloromethane 
(8:1:1) - Rf: 0.28. Purified by flash chromatography (eluent: cyclohexane/ethyl 
acetate from 9:1 to 6:4). Molecular formula: C15H10ClN3O2. Molecular weight: 
299.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.23 (br s, 1H, NH exchanged with 
D2O), 7.78-7.84 (m, 2H, ArH), 7.55-7.63 (m, 2H, ArH), 7.41-7.53 (m, 5H, ArH) ppm. 
13C NMR (75 MHz, CDCl3): δ 156.98, 134.46, 133.80, 130.20, 129.91, 129.85, 
129.33, 128.47, 128.05, 126.00 ppm. 
 
 4-(trifluoromethyl)-N-(4-(2-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1bg) 
 
Procedure c: yield 24 % as white solid (m.p. 122.1-122.3°C). Starting compounds: 
105b and 4-(trifluoromethyl)benzoyl chloride. TLC: petroleum ether/ethyl 
acetate (9:1) - Rf: 0.21. Purified by flash chromatography (eluent: petroleum 
ether/ethyl acetate 8:2). Molecular formula: C16H9ClF3N3O2. Molecular weight: 
367.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.37 (br s, 1H, NH exchanged with 
D2O), 7.94 (d, J = 8.4 Hz, 2H, ArH), 7.76 (d, J = 8.1 Hz, 2H, ArH), 7.60-7.63 (m, 1H, 
ArH), 7.42-7.52 (m, 3H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 163.73, 149.33, 
148.92, 135.60, 135.10, 134.66, 132.94, 132.42, 132.18, 130.23, 128.33, 127.90, 
126.33 (q, J = 3.7 Hz), 125.30 ppm. 19F NMR (282 MHz, CDCl3): δ -63.83 (s, CF3) 
ppm. 
 
 N-(4-(3-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1ca) 
 
Procedure c: yield 7 % as white solid (m.p. 119.0-120.7°C). Starting compounds: 
105c and benzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.20. 
Purified by flash chromatography (eluent: cyclohexane/ethyl acetate/ 
dichloromethane 8:1:1 and 1% acetic acid). Molecular formula: C15H10ClN3O2. 
Molecular weight: 299.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.16 (br s, 1H, NH 
exchanged with D2O), 7.88 (d, J = 7.3 Hz, 2H, ArH), 7.74 (t, J = 1.6 Hz, 1H, ArH), 
7.68-7.37 (m, 6H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 166.02, 149.42, 148.98, 
135.16, 133.80, 133.27, 130.81, 130.41, 130.17, 128.99, 128.48, 127.73, 125.50 
ppm. 
 
 4-(trifluoromethyl)-N-(4-(3-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1cg) 
 
Procedure c: yield 32 % as white solid (m.p. 196.2-196.3°C). Starting compounds: 
105c and 4-(trifluoromethyl)benzoyl chloride. TLC: cyclohexane/ ethyl acetate 
(8:2) - Rf: 0.35. Purified by flash chromatography (eluent: cyclohexane/ethyl 
acetate 75:25). Molecular formula: C16H9ClF3N3O2. Molecular weight: 367.71 
g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.25 (d, J = 8.1 Hz, 2H, ArH), 7.94 (d, J = 
8.4 Hz, 2H, ArH), 7.86 (s, 1H, ArH), 7.80 (d, J = 6.6 Hz, 1H, ArH), 7.52-7.62 (m, 2H, 
ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.45, 150.76, 149.90, 136.41, 
134.58, 133.93, 133.49, 131.06, 130.80, 129.13, 128.06, 127.63, 126.35, 125.88 
(q, J = 3.8 Hz) ppm. 19F NMR (282 MHz, acetone-d6): δ -63.43 (s, CF3) ppm. 
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 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1da) 
 
Procedure a: yield 12 %. Procedure c: yield 32 %. Brown solid (m.p. 177.4-
178.7°C). Starting compounds: 105d and benzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (8:2) - Rf: 0.28. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C15H10ClN3O2. Molecular 
weight: 299.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.20 (br s, 1H, NH exchanged 
with D2O), 7.81 (d, J = 7.6 Hz, 2H, ArH), 7.62-7.52 (m, 3H, ArH), 7.42-7.50 (m, 
2H, ArH), 7.39 (d, J = 8.5 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 
166.49, 151.07, 150.34, 136.37, 133.06, 132.74, 129.45, 129.42, 128.96, 
128.27, 125.10 ppm. 
 
 4-chloro-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1dd) 
 
Procedure a: yield 15 % as white solid (m.p. 155-160°C). Starting compounds: 
105d and 4-chlorobenzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 
0.44. Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 8:2). 
Molecular formula: C15H9Cl2N3O2. Molecular weight: 334.16 g/mol. 1H NMR 
(300 MHz, CDCl3): δ 8.07 (br s, 1H, NH exchanged with D2O), 7.81 (d, J = 8.2 Hz, 
2H, ArH), 7.64 (d, J = 8.2 Hz, 2H, ArH), 7.51 (d, J = 8.7 Hz, 2H, ArH), 7.46 (d, J = 
8.7 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 166.69, 140.26, 139.97, 
135.43, 130.07, 129.59, 129.49, 129.02, 128.86, 128.79, 126.27 ppm. 
 
 2-(trifluoromethyl)-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide 
(1de) 
 
Procedure c: yield 56 % as light gray solid (m.p. 197.1-199.8°C). Starting 
compounds: 105d and 2-(trifluoromethyl)benzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (8:2) - Rf: 0.27. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C16H9ClF3N3O2. Molecular 
weight: 367.71 g/mol. 1H NMR (300 MHz, CD3OD): δ 7.85-7.67 (m, 6H, ArH), 
7.55 (d, J = 8.5 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, CD3OD): δ 149.07, 136.79, 
132.38, 130.90, 129.67, 129.39, 129.14, 128.44, 127.69, 127.26, 126.65 (q, J = 
5.1 Hz), 125.57, 124.31, 121.96 ppm. 19F NMR (282 MHz, CD3OD): δ -60.30 (s, 
CF3) ppm. 
 
 3-(trifluoromethyl)-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1df) 
 
Procedure c: yield 60 % as light gray solid (m.p. 112.6-115.1°C). Starting 
compounds: 105d and 3-(trifluoromethyl)benzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (8:2) - Rf: 0.36. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C16H9ClF3N3O2. Molecular 
weight: 367.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.54 (br s, 1H, NH exchanged 
with D2O), 8.14 (s, 1H, ArH), 8.06 (d, J = 7.9 Hz, 1H, ArH), 7.89 (d, J = 7.9 Hz, 1H, 
ArH), 7.71-7.60 (m, 3H, ArH), 7.49-7.40 (m, 2H, ArH) ppm. 13C NMR (75 MHz, 
CDCl3): δ 164.54, 149.88, 148.85, 137.44, 132.74, 132.25, 131.81, 131.07, 
130.17, 130.08, 129.82, 129.03, 124.96 (q, J = 3.7 Hz), 124.03 ppm. 
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 4-bromo-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1dh) 
 
Procedure a: yield 11 % as brown solid (m.p. 195.5-197.0°C). Starting 
compounds: 105d and 4-bromobenzoyl chloride (synthesized refluxing 4-
bromobenzoic acid (1eq) with thionyl chloride (4eq) in dry dichloromethane 
for 16 hours). TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.40. Purified by flash 
chromatography (eluent: cyclohexane/ethyl acetate 8:2). Molecular formula: 
C15H9BrClN3O2. Molecular weight: 378.61 g/mol. 1H NMR (300 MHz, CDCl3): δ 
8.18 (br s, 1H, NH exchanged with D2O), 7.76 (d, J = 8.1 Hz, 2H, ArH), 7.68 (d, 
J = 8.7 Hz, 2H, ArH), 7.65 (d, J = 8.7 Hz, 2H, ArH), 7.47 (d, J = 8.1 Hz, 2H, ArH) 
ppm. 
 
 4-methyl-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1di) 
 
Procedure c: yield 24 % as brown solid (m.p. 163.5-164°C). Starting 
compounds: 105d and 4-methylbenzoyl chloride (synthesized refluxing 4- 
methylbenzoic acid (1eq) with thionyl chloride (4eq) in dry dichloromethane 
for 3 hours). TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.30. Purified by flash 
chromatography (eluent: cyclohexane/ethyl acetate 8:2). Molecular formula: 
C16H12ClN3O2. Molecular weight: 313.74 g/mol. 1H NMR (300 MHz, CDCl3): δ 
8.07 (br s, 1H, NH exchanged with D2O), 7.70 (d, J = 8.6 Hz, 2H, ArH), 7.58 (d, 
J = 8.6 Hz, 2H, ArH), 7.38 (d, J = 8.4 Hz, 2H, ArH), 7.25 (d, J = 8.4 Hz, 2H, ArH), 
2.37 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 165.50, 149.75, 149.13, 
144.59, 137.27 130.06, 129.79, 129.17, 129.06, 127.89, 124.31, 21.91 ppm. 
 
 4-methoxy-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1dk) 
 
Procedure c: yield 70 % as white solid (m.p. 161-168°C). Starting compounds: 
105d and 4-methoxybenzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - 
Rf: 0.20. Purified by flash chromatography (eluent: cyclohexane/ 
dichloromethane/ethyl acetate 7:2:1). Molecular formula: C16H12ClN3O3. 
Molecular weight: 329.74 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.23 (br 
s, 1H, NH exchanged with D2O), 8.02 (d, J = 8.7 Hz, 2H, ArH), 7.83 (d, J = 8.4 
Hz, 2H, ArH), 7.53 (d, J = 8.4 Hz, 2H, ArH), 7.06 (d, J = 8.7 Hz, 2H, ArH), 3.89 (s, 
3H, CH3) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.65, 163.46, 150.84, 
150.28, 136.05, 130.11, 129.15, 129.13, 124.97, 124.55, 113.91, 55.09 ppm. 
 
 4-nitro-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1dr) 
 
Procedure c: yield 46 % as yellow solid (m.p. 229.9-230.2°C). Starting 
compounds: 105d and 4-nitrobenzoyl chloride. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.21. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate from 98:2 to 7:3). Molecular formula: C15H9ClN4O4. 
Molecular weight: 344.71 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.79 (br 
s, NH, 1H exchanged with D2O), 8.41(d, J = 8.7 Hz, 2H, ArH), 8.30 (d, J = 8.7 Hz, 
2H, ArH), 7.88 (d, J = 8.4 Hz, 2H, ArH), 7.57 (d, J = 8.4 Hz, 2H, ArH) ppm. 13C 
NMR (75 MHz, acetone-d6): δ 164.87, 150.85, 150.56, 149.79, 138.06, 136.37, 
129.56, 129.31, 129.22, 124.74, 123.73 ppm. 
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 4-cyano-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1dt) 
 
Procedure c: yield 60 % as white solid (m.p. 212.3-212.8°C). Starting 
compounds: 105d and 4-cyanobenzoyl chloride. TLC: cyclohexane/ethyl acetate 
(8:2) - Rf: 0.27. Purified by flash chromatography (eluent: dichloromethane/ 
cyclohexane 98:2). Molecular formula: C16H12ClN3O3. Molecular weight: 329.74 
g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.64 (br s, NH, 1H exchanged with 
D2O), 8.21 (d, J = 9.0 Hz, 2H, ArH), 8.00 (d, J = 9.0 Hz, 2H, ArH), 7.86 (d, J = 7.8 
Hz, 2H, ArH), 7.56 (d, J = 7.8 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, acetone-d6): 
δ 165.22, 150.95, 149.87, 136.58, 136.46, 132.85, 129.52, 129.47, 129.12, 
124.89, 117.87, 116.32 ppm. 
 
 4-trifluoromethyl-N-(4-(4-bromophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1hg) 
 
Procedure c: yield 20 % as off-white solid (m.p. 242.5-244.8°C). Starting 
compounds: 105h and 4-trifluoromethylbenzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (7:3) - Rf: 0.11. Purified by flash chromatography (eluent: from 
cyclohexane/ethyl acetate 9:1 to 5:5). Molecular formula: C16H9BrF3N3O2. 
Molecular weight: 412.17 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.15 (br s, NH, 1H 
exchanged with D2O), 8.00 (d, J = 8.2 Hz, 2H, ArH), 7.81 (d, J = 8.2 Hz, 2H, ArH), 
7.64 (d, J = 8.7 Hz, 2H, ArH), 7.57 (d, J = 8.7 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, 
CDCl3): δ 170.08, 151.41, 135.63, 135.42, 135.19, 133.18, 129.25, 129.22, 
126.33 (q, J = 3.7 Hz), 125.12, 122.76, 121.50 ppm. 19F NMR (282 MHz, CDCl3): 
δ -63.63 (s, CF3) ppm. 
 
 4-trifluoromethyl-N-(4-(4-trifluoromethylphenyl)-1,2,5-oxadiazol-3-
yl)benzamide (1gg) 
 
Procedure a: yield 6 % as off-white solid (m.p. 210.9-212.1°C). Starting 
compounds: 105g and 4-trifluoromethylbenzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (7:3) - Rf: 0.60. Purified by flash chromatography (eluent: 
cyclohexane/dichloromethane 3:7). Molecular formula: C17H9F6N3O2. Molecular 
weight: 401.27 g/mol. 1H NMR (300 MHz, CD3OD): δ 8.12 (d, J = 8.4 Hz, 2H, ArH), 
7.95 (d, J = 8.4 Hz, 2H, ArH), 7.86 (d, J = 8.1 Hz, 2H, ArH), 7.80 (d, J = 8.1 Hz, 2H, 
ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 169.85, 149.20, 142.35, 130.75, 128.65 
(q, J = 3.6 Hz), 128.27 (q, J = 3.6 Hz), 128.06, 126.32, 126.27, 126.22, 126.10, 
125.91, 125.86 ppm. 19F NMR (282 MHz, CD3OD): δ -64.90 (s, CF3), -65.43 (s, CF3) 
ppm. 
 
 4-chloro-N-(4-(4-trifluoromethylphenyl)-1,2,5-oxadiazol-3-yl)benzamide (1gd) 
 
Procedure c: yield 8 % as yellow solid (m.p. 200.0-201.0°C). Starting compounds: 
105g and 4-chlorobenzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 
0.42. Purified by flash chromatography (eluent: cyclohexane /ethyl acetate 8:2). 
Molecular formula: C16H9ClF3N3O2. Molecular weight: 367.71 g/mol. 1H NMR 
(300 MHz, CDCl3): δ 8.11 (br s, 1H, NH exchanged with D2O), 7.81-7.85 (m, 4H, 
ArH), 7.74 (d, J = 8.4 Hz, 2H, ArH), 7.51-7.54 (m, 2H, ArH) ppm. 13C NMR (75 
MHz, CDCl3): δ 165.09, 149.15, 140.56, 132.69, 130.17, 129.71, 129.46, 129.17, 
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 128.22, 126.27 (q, J = 3.7 Hz), 125.64, 121.92 ppm. 19F NMR (282 MHz, 
CDCl3): δ -63.08 (s, CF3) ppm. 
 
 4-trifluoromethyl-N-(4-(p-tolyl)-1,2,5-oxadiazol-3-yl)benzamide (1ig) 
 
Procedure c: yield 19 % as gray solid (m.p. 118.8-121.5°C). Starting 
compounds: 105i and 4-trifluoromethylbenzoyl chloride. TLC: 
cyclohexane/ethyl acetate (7:3) - Rf: 0.64. Purified by flash chromatography 
(eluent: cyclohexane/ethyl acetate 7:3). Molecular formula: C17H12F3N3O2. 
Molecular weight: 347.30 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.12 (br s, 
1H, NH exchanged with D2O), 7.98 (d, J = 8.6 Hz, 2H, ArH), 7.79 (d, J = 8.6 
Hz, 2H, ArH), 7.57 (d, J = 8.2 Hz, 2H, ArH), 7.36 (d, J = 8.2 Hz, 2H, ArH), 2.44 
(s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 165.78, 150.20, 148.57, 
141.66, 130.45, 130.29, 128.32, 127.69, 126.45 (q, J = 3.7 Hz), 125.78, 
125.69, 122.31, 31.15 ppm. 19F NMR (282 MHz, CDCl3): δ -63.75 (s, CF3) 
ppm. 
 
 N-(4-([1,1'-biphenyl]-4-yl)-1,2,5-oxadiazol-3-yl)benzamide (1ja) 
 
Procedure c: yield 23 % as white solid (m.p. 168.8-170.8°C). Starting 
compounds: 105j and benzoyl chloride. TLC: cyclohexane/ethyl acetate 
(8:2) - Rf: 0.30. Purified by flash chromatography (eluent: dichloromethane/ 
cyclohexane 8:2). Molecular formula: C21H15N3O2. Molecular weight: 
341.37 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.31 (br s, 1H, NH exchanged 
with D2O), 7.83 (d, J = 7.5 Hz, 2H, ArH), 7.73 (d, J = 8.9 Hz, 2H, ArH), 7.66 (d, 
J = 8.9 Hz, 2H, ArH), 7.50-7.57 (m, 3H, ArH), 7.30-7.49 (m, 5H, ArH) ppm. 13C 
NMR (75 MHz, CDCl3): δ 165.16, 149.68, 148.67, 143.67, 139.74, 133.24, 
132.03, 129.12, 128.93, 128.06, 128.00, 127.59, 127.13, 124.00 ppm. 
 
 4-(trifluoromethyl)-N-(4-([1,1'-biphenyl]-4-yl)-1,2,5-oxadiazol-3-yl) 
benzamide (1jg) 
 
Procedure c: yield 14 % as white solid. Starting compounds: 105j and 4-
trifluoromethylbenzoyl chloride. TLC: cyclohexane/ethyl acetate (7:3) - Rf: 
0.60. Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 
8:2). Molecular formula: C22H14F3N3O2. Molecular weight: 409.37 g/mol. 1H 
NMR (300 MHz, acetone-d6): δ 10.59 (br s, 1H, NH exchanged with D2O), 
8.30 (d, J = 8.1 Hz, 2H, ArH), 7.90-7.97 (m, 4H, ArH), 7.82 (d, J = 8.4 Hz, 2H, 
ArH), 7.70 (d, J = 8.7 Hz, 2H, ArH), 7.37-7.50 (m, 3H, ArH), ppm. 13C NMR 
(75 MHz, CDCl3): δ 165.27, 151.31, 149.79, 143.13, 139.67, 136.29, 133.21, 
128.98, 128.93, 128.24, 128.09, 128.02, 127.45, 126.90, 125.75 (q, J = 3.45 
Hz), 124.63 ppm. 19F NMR (282 MHz, CDCl3): δ -63.58 (s, CF3) ppm. 
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 4-trifluoromethyl-N-(4-(4-benzyloxyphenyl)-1,2,5-oxadiazol-3-yl)benzamide 
(1lg) 
 
Procedure c: yield 30 % as gray solid (m.p. 217.9-220.5°C). Starting 
compounds: 105l and 4-trifluoromethylbenzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (7:3) - Rf: 0.54. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C23H16F3N3O3. Molecular 
weight: 439.39 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.11 (br s, 1H, NH 
exchanged with D2O), 7.99 (d, J = 8.7 Hz, 2H, ArH), 7.79 (d, J = 8.7 Hz, 2H, ArH), 
7.64 (d, J = 9.0 Hz, 2H, ArH), 7.35-7.44 (m, 5H, ArH), 7.09 (d, J = 9.0 Hz, 2H, 
ArH), 5.12 (s, 2H, CH2) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.23, 160.76, 
151.23, 149.56, 136.92, 136.28, 133.60, 133.17, 129.08, 128.88, 128.43, 
127.90, 127.63, 125.73 (q, J = 3.9 Hz), 117.90, 115.34, 69.68 ppm. 19F NMR 
(282 MHz, CDCl3): δ -63.58 (s, CF3) ppm. 
 
 4-trifluoromethyl-N-(4-(4-nitrophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1rg) 
 
Procedure c: yield 23 % as pale yellow solid (m.p. 101.8-104.7°C). Starting 
compounds: 105r and 4-trifluoromethylbenzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (8:2) - Rf: 0.37. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C16H9F3N4O4. Molecular 
weight: 378.27 g/mol. 1H NMR (300 MHz, CD3OD): δ 8.35 (d, J = 8.9 Hz, 2H, 
ArH), 8.12 (d, J = 8.2 Hz, 2H, ArH), 8.00 (d, J = 8.9 Hz, 2H, ArH), 7.86 (d, J = 8.2 
Hz, 2H, ArH). 13C NMR (75 MHz, CD3OD): δ 180.32, 166.46, 150.20, 149.92, 
149.27, 135.98, 132.45, 128.80, 128.70, 128.13, 125.70 (q, J = 3.7 Hz), 123.90 
ppm. 19F NMR (282 MHz, CD3OD): δ -65.10 (s, CF3) ppm. 
 
 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)cyclohexanecarboxamide (2) 
 
Procedure c: yield 61 % as white solid (m.p. 167.5-167.9°C). Starting 
compounds: 105d and cyclohexanecarbonyl chloride. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.46. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 9:1). Molecular formula: C15H16ClN3O2. Molecular 
weight: 305.76 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.51 (d, 2H, J = 8.4 Hz, 
ArH), 7.41 (d, 2H, J = 8.4 Hz, ArH), 7.29 (br s, 1H, NH exchanged with D2O), 
1.18-1.92 (m, 10H, CH, CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 174.81, 149.49, 
148.79, 137.31, 129.73, 129.16, 124.07, 45.24, 29.92, 29.39, 25.58 ppm. 
 
 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)heptanamide (3) 
 
Procedure c: yield 43 % as white solid (m.p. 115.5-115.8°C). Starting 
compounds: 105d and n-heptanoyl chloride. TLC: cyclohexane/ethyl acetate 
(8:2) - Rf: 0.30. Purified by flash chromatography (eluent: cyclohexane/ethyl 
acetate 85:15). Molecular formula: C15H18ClN3O2. Molecular weight: 307.78 
g/mol. 1H NMR (300 MHz, CDCl3): δ 7.65 (br s, 1H, NH exchanged with D2O), 
7.59 (d, 2H, J = 8.7 Hz, ArH), 7.47 (d, 2H, J = 8.7 Hz, ArH), 2.48 (t, 2H, J = 6.9 
Hz, CH2), 1.62-1.72 (m, 2H, CH2), 1.25-1.39 (m, 6H, CH2), 0.89 (t, 3H, J = 6.9 Hz, 
CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 172.27, 150.63, 149.94, 136.28, 129.68, 
129.31, 125.00, 35.71, 31.60, 29.95, 24.94, 22.52, 13.64 ppm. 
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 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)butyramide (4) 
 
Procedure c: yield 98 % as white solid (m.p. 138.7-139.8°C). Starting 
compounds: 105d and n-butyryl chloride. TLC: cyclohexane/ethyl acetate (8:2) 
- Rf: 0.26. Purified by flash chromatography (eluent: cyclohexane/ 
dichloromethane/ethyl acetate 4:5:1). Molecular formula: C12H12ClN3O2. 
Molecular weight: 265.70 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.53 (d, 2H, J = 
8.1 Hz, ArH), 7.42 (d, 2H, J = 8.1 Hz, ArH), 7.31 (br s, 1H, NH exchanged with 
D2O), 2.42 (t, 2H, J = 7.5 Hz, CH2), 1.61-1.73 (m, 2H, CH2), 0.93 (t, 3H, J = 7.4 Hz, 
CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 172.17, 149.17, 148.68, 137.42, 129.81, 
129.26, 123.81, 38.32, 18.60, 13.66 ppm. 
 
 N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)acetamide (5) 
 
Procedure c: yield 32 % as white solid (m.p. 167.9-168.7°C). Starting 
compounds: 105d and acetyl chloride. TLC: cyclohexane/ethyl acetate (6:4) - 
Rf: 0.24. Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 
7:3). Molecular formula: C10H8ClN3O2. Molecular weight: 237.64 g/mol. 1H 
NMR (300 MHz, CDCl3): δ 7.51 (d, 2H, J = 8.1 Hz, ArH), 7.43 (d, 2H, J = 8.1 Hz, 
ArH), 7.38 (br s, 1H, NH exchanged with D2O), 2.23 (s, 3H, CH3) ppm. 13C NMR 
(75 MHz, CDCl3): δ 175.98, 149.10, 148.41, 137.69, 130.03, 129.30, 123.91, 
22.40 ppm. 
 
 N-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)benzamide (7da) 
 
Procedure d: reaction time 3 hours at room temperature, yield 24 % as pink 
solid (m.p. 188-189°C). Starting compounds: 2-amino-5-(4-chlorophenyl)-
1,3,4-oxadiazole and benzoyl chloride. TLC: cyclohexane/ethyl acetate (7:3) - 
Rf: 0.14. Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 
7:3). Molecular formula: C15H10ClN3O2. Molecular weight: 299.71 g/mol. 1H 
NMR (300 MHz, DMSO-d6): δ 12.23 (br s, 1H, NH exchange with D2O), 8.02 (d, 
J = 7.5 Hz, 2H, ArH), 7.96 (d, J = 8.5 Hz, 2H, ArH), 7.51-7.72 (m, 5H, ArH) ppm. 
 
 4-trifluoromethyl-N-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)benzamide (7dg) 
 
Procedure d: reaction time 16 hours at room temperature, yield 33 % as red 
solid (m.p. 234-235°C). Starting compounds: 2-amino-5-(4-chlorophenyl)-
1,3,4-oxadiazole and 4-trifluoromethylbenzoyl chloride. TLC: 
dichloromethane/methanol/ethyl acetate (95:2.5:2.5) - Rf: 0.34. Purified by 
flash chromatography (eluent: dichloromethane/methanol/ethyl acetate 
95:2.5:2.5 to 90:5:5). Molecular formula: C16H9ClF3N3O2. Molecular weight: 
367.71 g/mol. 1H NMR (300 MHz, CDCl3): δ 11.99 (br s, 1H, NH exchange with 
D2O) 8.33 (d, J = 7.0 Hz, 2H, ArH), 7.97 (d, J = 8.0 Hz, 2H, ArH), 7.73 (d, J = 7.0 
Hz, 2H, ArH), 7.52 (d, J = 8.0 Hz, 2H, ArH) ppm. 19F NMR (282 MHz, CDCl3): δ -
63.08 (s, CF3) ppm. 
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 N-(4-(4-chlorophenyl)-isoxazol-3-yl)benzamide (8da) 
 
Procedure e: at 40°C, yield 26 % as viscous brownish solid (m.p. 150.3-158.9°C). 
Starting compounds: 109 and benzoyl chloride. TLC: cyclohexane/ethyl acetate 
(75:25) - Rf: 0.37. Purified by flash chromatography (eluent: petroleum ether/ 
ethyl acetate 85:15 to 7:3). Molecular formula: C16H11ClN2O2. Molecular 
weight: 298.05 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.49 (s, 1H, ArH), 8.23 (br s, 
1H, NH exchanged with D2O), 7.84 (d, J = 7.6 Hz, 2H, ArH), 7.59 (t, J = 8.0 Hz, 
1H, ArH), 7.43-7.53 (m, 2H, ArH), 7.31-7.41 (m, 4H, ArH) ppm. 13C NMR (75 MHz, 
CDCl3): δ 165.14, 156.62, 134.47, 132.82, 132.63, 129.48, 129.39, 128.95, 
128.84, 128.78, 127.49, 126.63 ppm. 
 
 4-trifluoromethyl-N-(4-(4-chlorophenyl)-isoxazol-3-yl)benzamide (8dg) 
 
Procedure e: at 40°C, yield 10 % as light yellow solid (m.p. 171.4-173.0°C). 
Starting compounds: 109 and 4-trifluoromethylbenzoyl chloride. TLC: 
cyclohexane/ethyl acetate (7:3) - Rf: 0.45. Purified by flash chromatography 
(eluent: cyclohexane/ethyl acetate 7:3). Molecular formula: C17H10ClF3N2O2. 
Molecular weight: 366.04 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.17 (br 
s, 1H, NH exchanged with D2O), 9.08 (s, 1H, ArH), 8.22 (d, J = 8.4 Hz, 2H, ArH), 
7.90 (d, J = 8.4 Hz, 2H, ArH), 7.59 (d, J = 8.6 Hz, 2H, ArH), 7.41 (d, J =8.6 Hz, 2H, 
ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.01, 158.22, 155.66, 136.93, 
133.19, 132.84, 128.85, 128.78, 128.70, 127.80, 125.59 (q, J = 3.8 Hz), 122.17, 
117.33 ppm. 19F NMR (282 MHz, acetone-d6): δ -63.56 (s, CF3) ppm. MS (ESI) 
m/z 367.0 [M + H]+. 
 
 N-(3-(4-chlorophenyl)-isoxazol-4-yl)benzamide (9da) 
 
Procedure c: yield 39 % as gray solid (m.p. 162.7-165.6°C). Starting compounds: 
114 and benzoyl chloride. TLC: cyclohexane/ethyl acetate (75:25) - Rf: 0.30. 
Purified by flash chromatography (eluent: petroleum ether/ethyl acetate 
75:25). Molecular formula: C16H11ClN2O2. Molecular weight: 298.73 g/mol. 1H 
NMR (300 MHz, acetone-d6): δ 9.28 (br s, 1H, NH exchanged with D2O), 9.28 (s, 
1H, ArH), 7.98 (d, J = 7.2 Hz, 2H, ArH), 7.82 (d, J = 8.5 Hz, 2H, ArH), 7.46-7.63 
(m, 5H, ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.67, 155.72, 152.43 
135.38, 133.60, 131.94, 129.73, 129.18, 128.48, 127.65, 127.26, 117.95 ppm. 
 
 4-trifluoromethyl-N-(3-(4-chlorophenyl)-isoxazol-4-yl)benzamide (9dg) 
 
Procedure c: yield 53 % as off-white solid (m.p. 162.0-168.8°C). Starting 
compounds: 114 and 4-trifluoromethylbenzoyl chloride. TLC: cyclohexane/ 
ethyl acetate (7:3) - Rf: 0.58. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 75:25). Molecular formula: C17H10ClF3N2O2. 
Molecular weight: 366.04 g/mol. 1H NMR (300 MHz, acetone-d6): δ 9.57 (br s, 
1H, NH exchanged with D2O), 9.31 (s, 1H, ArH), 8.19 (d, J = 8.2 Hz, 2H, ArH), 
7.87 (d, J = 8.2 Hz, 2H, ArH), 7.82 (d, J = 8.5 Hz, 2H, ArH), 7.57 (d, J = 8.5 Hz, 2H, 
ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 164.64, 155.70, 152.68, 135.46, 
132.96, 132.54, 129.78, 129.18, 128.56, 127.07, 125.46 (q, J = 3.8 Hz), 122.18, 
117.69 ppm. 19F NMR (282 MHz, acetone-d6): δ -63.49 (s, CF3) ppm. 
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 N-(5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-yl)benzamide hydrochloride 
(10da . HCl) 
 
Procedure e: at 0°C, yield 32 % as brown foam. Starting compounds: 116 and 
benzoyl chloride. TLC: dichloromethane/methanol (9:1) - Rf: 0.52. Purified by 
precipitation as hydrochloride salt with 2M HCl in Et2O. Molecular formula: 
C17H15Cl2N3O. Molecular weight: 348.23 g/mol. 1H NMR (300 MHz, CD3OD): δ 
9.00 (s, 1H, ArH), 7.88 (d, J = 8.4 Hz, 2H, ArH), 7.46-7.65 (m,7H, ArH), 3.84 (s, 
3H, CH3) ppm. 13C NMR (75 MHz, CD3OD): δ 168.77, 136.42, 133.52, 132.62, 
132.08, 131.47, 131.41, 129.23, 129.18, 128.43, 127.57, 123.07, 34.08 ppm. 
 
 4-trifluoromethyl-N-(5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-
yl)benzamide hydrochloride (10dg . HCl) 
 
Procedure e: at 0°C, yield 25 % as brown oil. Starting compounds: 116 and 4-
trifluoromethylbenzoyl chloride. TLC: dichloromethane/methanol (9:1) - Rf: 
0.55. Purified by precipitation as hydrochloride salt with 2M HCl in Et2O. 
Molecular formula: C18H14Cl2F3N3O. Molecular weight: 416.23 g/mol. 1H NMR 
(300 MHz, CD3OD): δ 8.96 (s, 1H, ArH), 8.04 (d, J = 8.2 Hz, 2H, ArH), 7.83 (d, J = 
8.2 Hz, 2H, ArH), 7.60 (d, J = 8.6 Hz, 2H, ArH), 7.55 (d, J = 8.6 Hz, 2H, ArH), 3.84 
(s, 3H, CH3) ppm. 13C NMR (75 MHz, CD3OD): δ 167.29, 136.53, 135.79, 135.77, 
133.57, 133.51, 131.55, 129.28, 128.41, 126.67, 125.39 (q, J = 3.7 Hz), 125.14, 
122.91, 34.12 ppm. 19F NMR (282 MHz, CD3OD): δ -64.52 (s, CF3) ppm. 
 
 ethyl 3-N-benzamido-4-(4-chlorophenyl)furan-2-carboxylate (119da) 
 
Procedure b: yield 42 % as off-white solid (m.p. 158.5-160.5°C). Starting 
compounds: 118 and benzoyl chloride. TLC: petroleum ether/ethyl acetate 
(9:1) - Rf: 0.14. Purified by flash chromatography (eluent: petroleum ether/ 
ethyl acetate from 9:1 to 7:3). Molecular formula: C20H16ClNO4. Molecular 
weight: 369.80 g/mol. 1H NMR (300 MHz, CDCl3): δ 9.10 (s, 1H, NH exchanged 
with D2O), 7.87 (d, J = 7.0 Hz, 2H, ArH), 7.58 (s, 1H, ArH), 7.42-7.57 (m, 3H, 
ArH), 7.34 (d, J = 9.0 Hz, 2H, ArH), 7.30 (d, J = 9.0 Hz, 2H, ArH), 4.40 (q, J = 7.1 
Hz, 2H, CH2), 1.39 (t, J = 7.1 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 
165.08, 159.77, 142.90, 133.87, 133.52, 133.26, 132.44, 132.33, 130.11, 
128.80, 128.73, 128.19, 127.52, 124.21, 61.30, 14.31 ppm. 
 
 ethyl 3-N-(4-trifluoromethylbenzamide)-4-(4-chlorophenyl)furan-2-
carboxylate (119dg) 
 
Procedure b: yield 47 % as brownish solid (m.p. 166.0-168.1°C). Starting 
compounds: 118 and 4-trifluoromethylbenzoyl chloride. TLC: petroleum 
ether/ ethyl acetate (9:1) - Rf: 0.16. Purified by flash chromatography (eluent: 
petroleum ether/ethyl acetate 9:1). Molecular formula: C21H15ClF3NO4. 
Molecular weight: 437.80 g/mol. 1H NMR (300 MHz, CDCl3): δ 9.20 (s, 1H, NH 
exchanged with D2O), 7.99 (d, J = 8.2 Hz, 2H, ArH), 7.74 (d, J = 8.2 Hz, 2H, ArH), 
7.59 (s, 1H, ArH), 7.30-7.35 (m, 4H, ArH), 4.42 (q, J = 7.1 Hz, 2H, CH2), 1.41 (t,  
J = 7.1 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 162.77, 158.89, 141.96,  
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 135.43, 133.31, 132.87, 132.71, 131.10, 128.95, 127.79, 127.25, 126.99, 
124.89 (q, J = 3.7 Hz), 123.16, 120.69, 60.46, 13.31 ppm. 19F NMR (282 MHz, 
CDCl3): δ -63.11 (s, CF3) ppm. 
 
 N-(4-chloro-[1,1-biphenyl]-2-yl)benzamide (12da) 
 
Procedure c: yield 55 % as white solid (m.p. 167-169°C). Starting compounds: 
121 and benzoyl chloride. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.44. 
Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 9:1). 
Molecular formula: C19H14ClNO. Molecular weight: 307.78 g/mol. 1H NMR 
(300 MHz, CDCl3): δ 8.46 (d, J = 7.9 Hz, 1H, ArH), 7.83 (br s, 1H, NH exchanged 
with D2O), 7.63 (d, J = 7.0 Hz, 2H, ArH), 7.35-7.54 (m, 8H, ArH), 7.19-7.30 (m, 
2H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 164.13, 135.57, 133.75, 133.62, 
133.29, 130.86, 130.44, 129.67, 129.02, 128.39, 127.92, 127.84, 125.78, 
123.68, 120.88 ppm. MS (ESI) m/z 308.0 [M + H]+. 
 
 4-trifluoromethyl-N-(4-chloro-[1,1-biphenyl]-2-yl)benzamide (12dg) 
 
Procedure c: yield 40 % as brown solid (m.p. 169-170°C). Starting compounds: 
121 and 4-trifluoromethylbenzoyl chloride. TLC (petroleum ether/ethyl 
acetate 9:1) - Rf: 0.28. Purified by flash chromatography (eluent: petroleum 
ether/ethyl acetate 9:1). Molecular formula: C20H13ClF3NO. Molecular weight: 
375.78 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.39-8.47 (m, 1H, ArH), 7.82 (br s, 
1H, NH exchanged with D2O), 7.66-7.76 (m, 4H, ArH), 7.42-7.52 (m, 3H, ArH), 
7.35-7.41 (m, 2H, ArH), 7.26-7.29 (m, 2H, ArH) ppm. 19F NMR (282 MHz, 
CDCl3): δ -63.09 (s, CF3) ppm. 
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Synthesis of N-benzyl-4-(4-chlorophenyl)-1,2,5-oxadiazol-3-amine (6) 
 
To a solution of 105d (0.153 mmol) in acetic acid (4 mL), benzaldehyde (0.306 mmol) was added and the 
solution was stirred for 3 hours at room temperature. The reaction was cooled at 0°C and NaBH4 (0.306 
mmol) was added. The mixture was stirred for 1 hour. When the reaction was complete (TLC: 
cyclohexane/ethyl acetate (95:5) - Rf: 0.42), a solution of 2M NaOH was added, the mixture was extracted 
with ethyl acetate, dried over Na2SO4, filtered and concentrated in vacuo. Upon purification by flash 
chromatography (eluent: cyclohexane/ethyl acetate 9.5:0.5) compound 6 was obtained. Yield 67 % as brown 
solid (m.p. 147.5-147.7°C). Molecular formula: C15H12ClN3O. Molecular weight: 285.73 g/mol. 1H NMR (300 
MHz, CDCl3): δ 7.65 (d, J = 8.6 Hz, 2H, ArH), 7.38 (d, J = 8.6 Hz, 2H, ArH), 7.25-7.45 (m, 5H, ArH), 4.58 (s, 1H, 
CH2), 4.52 (s, 1H, CH2), 4.20 (br t, 1H, NH exchanged with D2O) ppm. 13C NMR (75 MHz, acetone-d6): δ 155.99, 
146.08, 138.95, 136.06, 129.93, 129.54, 128.50, 128.02, 127.34, 125.03, 48.47 ppm. 
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Synthesis of 4-hydroxy-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl) 
benzamide (1dm) 
 
A solution of 1M BBr3 in dry dichloromethane (2.26 mmol) was added dropwise to a solution of 1dk (0.430 
mmol) in dry dichloromethane (5 mL) at room temperature, under nitrogen atmosphere. The mixture was 
stirred for 12 hours and, upon completion (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.20), the solution was 
treated with water and the organic layer was separated. Then the aqueous phase was extracted with ethyl 
acetate and the collected organic phase was washed with brine. The organic layer was dried over Na2SO4, 
filtered and evaporated under reduced pressure giving a crude, which was purified by flash chromatography 
(eluent: cyclohexane/ethyl acetate 7:3) to afford 1dm. Yield 35 % as white solid (m.p. 225-225.5°C). 
Molecular formula: C15H10ClN3O3. Molecular weight: 315.71 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.16 
(br s, 1H, NH exchanged with D2O), 9.23 (br s, 1H, OH exchanged with D2O), 7.94 (d, J = 8.7 Hz, 2H, ArH), 7.83 
(d, J = 8.5 Hz, 2H, ArH), 7.54 (d, J = 8.5 Hz, 2H, ArH), 6.96 (d, J = 8.7 Hz, 2H, ArH), 2.78 (br s, 1H, OH exchanged 
with D2O) ppm. 13C NMR (75 MHz, CD3OD): δ 167.77, 162.38, 150.75, 150.07, 136.58, 130.30, 129.12, 128.87, 
124.89, 123.05, 115.31 ppm. 
  
Chapter 7 – Experimental Part: Chemistry 
 
102 
Synthesis of N-((4-(4-hydroxyphenyl)-1,2,5-oxadiazol-3-yl)-4-
trifluoromethylbenzamide (1mg) 
 
A solution of 1lg (0.54 mmol) and a catalytic amount of palladium on carbon (10 % w/w) in ethyl acetate (9 
mL) and methanol (1 mL) was hydrogenated at room temperature for 24 hours (TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.13). The resulting mixture was filtered and extracted with diethyl ether. The organic layer 
was dried over Na2SO4, filtered and evaporated in vacuo. The crude oil was purified by flash chromatography 
eluting with cyclohexane/ethyl acetate (7:3) to afford 1mg. Yield: 91.5 % as white solid. Molecular formula: 
C16H10F3N3O3. Molecular weight: 349.27 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.43 (br s, 1H, NH 
exchanged with D2O), 8.98 (br s, 1H, OH exchanged with D2O), 8.26 (d, J = 8.1 Hz, 2H, ArH), 7.93 (d, J = 8.1 Hz, 
2H, ArH), 7.71 (d, J = 8.7 Hz, 2H, ArH), 6.95 (d, J = 8.7 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, acetone-d6): δ 
165.52, 159.90, 151.61, 149.69, 136.60, 129.44, 129.08, 125.95 (q, J = 3.7 Hz), 116.78, 116.20 ppm. 19F NMR 
(282 MHz, CDCl3): δ -63.97 (s, CF3) ppm. 
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Synthesis of dibenzyl phenylphosphates (1dn,ng) 
 
In a two-necked flask, the suitable phenol (0.143 mmol) was dissolved in dry acetonitrile (1 mL) under 
nitrogen atmosphere and the mixture was cooled to -10°C with an ice-acetone bath. CCl4 (0.07 mL) was added 
followed by N,N-diisopropylethylamine (0.301 mmol) and N,N-dimethylaminopyridine (0.014 mmol). 
Dibenzylphosphite (0.208 mmol) was added dropwise and, keeping the temperature at -10°C, the mixture 
was stirred for 3 hours. When the reaction was complete, an aqueous solution of 0.5 M KH2PO4 was added 
and the system was allowed to warm at room temperature. The mixture was extracted with ethyl acetate 
and the combined organic phases were washed with water and brine, dried over Na2SO4, filtered and 
concentrated in vacuo. The product was purified by flash chromatography. 
 
 dibenzyl (4-((4-(4-chlorophenyl)-1,2,5-oxadiazol-3-
yl)carbamoyl)phenyl) phosphate (1dn) 
 
Yield 45 % as brown solid. Starting compound: 1dm. TLC: 
dichloromethane/methanol (98:2) - Rf: 0.3. Eluent for flash 
chromatography dichloromethane/methanol 98:2. Molecular 
formula: C29H23ClN3O6P. Molecular weight: 575.94 g/mol. 1H NMR 
(300 MHz, CD3OD) δ 7.95 (d, J = 8.8 Hz, 2H, ArH), 7.74 (d, J = 8.7 Hz, 
2H, ArH), 7.50 (d, J = 8.8 Hz, 2H, ArH), 7.34-7.39 (m, 5H, ArH), 7.27 
(d, J = 8.7 Hz, 2H, ArH), 5.21 (s, 2H, CH2), 5.18 (s, 2H, CH2) ppm. 
 
 dibenzyl (4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-
yl)phenyl) phosphate (1ng) 
 
Yield 49 % as off-white solid. Starting compound: 1mg. TLC: 
cyclohexane/ethyl acetate (9:1) - Rf: 0.5. Eluent for flash 
cyclohexane/ethyl acetate 9:1. Molecular formula: C30H23F3N3O6P. 
Molecular weight: 609.50 g/mol. 1H NMR (300 MHz, acetone-d6): δ 
10.59 (br s, 1H, NH exchanged with D2O), 8.27 (d, J = 8.1 Hz, 2H, 
ArH), 7.93 (d, J = 8.1 Hz, 2H, ArH), 7.85 (d, J = 8.7 Hz, 2H, ArH), 7.30-
7.45 (m, 9H, ArH), 5.22 (s, 2H, CH2), 5.17 (s, 2H, CH2) ppm. 19F NMR 
(282 MHz, acetone-d6): δ -63.80 (s, CF3) ppm. 
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Synthesis of phenyl dihydrogenphosphates (1do,og) 
 
A solution of the proper dibenzyl phenylphosphate (0.044 mmol) and palladium on carbon (10 % w/w) in 
methanol (2.54 mg) was hydrogenated at room temperature for 3 hours. After completion of the reaction, 
the catalyst was filtered off on Celite® and the filtrate was concentrated under reduced pressure to afford 
the final compound. The product was purified on semipreparative RP-HPLC. 
 
 4-((4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)carbamoyl)phenyl 
dihydrogen phosphate (1do) 
 
Yield 69 % as light brown solid. Starting compound: 1dn. RP-HPLC 
condition: Kinetex® 2.6 µm C18 column, 100 Å, 30 x 2.1 mm, 80 % H2O/ 
20 % acetonitrile and 1/1000 of trifluoroacetic acid, flow: 0.8 mL/min 
flow rate and UV detector. Molecular formula: C15H11ClN3O6P. Molecular 
weight: 395.69 g/mol. 1H NMR (300 MHz, CD3OD): δ 7.84 (d, J = 10.3 Hz, 
2H, ArH), 7.63 (d, J = 9.7 Hz, 2H, ArH), 7.39 (d, J = 9.7 Hz, 2H, ArH), 7.26 
(d, J = 10.3 Hz, 2H, ArH) ppm. MS (ESI) m/z 396.1 [M + H]+. 
 
 4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-yl)phenyl 
dihydrogen phosphate (1og) 
 
Yield 57 % as light yellow solid. Starting compound: 1ng. RP-HPLC 
condition: Luna® 5 µm C8 column, 100 Å, 30 x 2 mm, 60 % H2O/ 40 % 
acetonitrile and 1/1000 of trifluoroacetic acid, flow: 0.8 mL/min flow rate 
and UV detector. Molecular formula: C16H11F3N3O6P. Molecular weight: 
429.25 g/mol. 1H NMR (200 MHz, CD3OD): δ 8.12 (d, J = 8.2 Hz, 2H, ArH), 
7.85 (d, J = 8.2 Hz, 2H, ArH), 7.77 (d, J = 8.7 Hz, 2H, ArH), 7.33 (d, J = 8.7 
Hz, 2H, ArH) ppm. MS (ESI) m/z 430.0 [M + H]+. 19F NMR (282 MHz, 
acetone-d6): δ -64.36 (s, CF3) ppm. 
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Synthesis of ethyl 2-(4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-
oxadiazol-3-yl)phenoxy)acetate (1pg) 
 
K2CO3 (0.177 mmol) and methyl chloroacetate (0.088 mmol) were added to a stirred solution of 1mg (0.088 
mmol) in dry DMF (0.7 mL) under nitrogen atmosphere. The reaction mixture was stirred at room 
temperature for 24 hours (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.42) and filtered. The filtrate was 
concentrated under vacuum and redissolved in ethyl acetate. The organic layer was washed with 1N NaOH 
and brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The pure 1pg was crystallized 
from dichloromethane. Yield: 89 % as off-white solid. Molecular formula: C20H16F3N3O5. Molecular weight: 
435.36 g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.38-8.49 (m, 4H, ArH), 7.71 (d, J = 8.5 Hz, 2H, ArH), 7.09 (d, 
J = 9.0 Hz, 2H, ArH), 4.81 (s, 2H, CH2), 4.23 (q, J = 7.1 Hz, 2H, CH2), 2.81 (br s, 1H, NH exchanged with D2O), 
1.26 (t, J = 7.1 Hz, 3H, CH3) ppm. 19F NMR (282 MHz, CDCl3): δ -63.59 (s, CF3) ppm. 
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Synthesis of 4-aminophenyl derivatives (1ds,sg) 
 
To a solution of the suitable nitrophenyl derivative (0.062 mmol) in ethyl acetate (4 mL), tin(II) chloride (0.310 
mmol) was added and the mixture was refluxed for 7 hours. After quenching by addition of a saturated 
aqueous NaHCO3 until pH=7-8, the precipitated tin salts were eliminated by filtration and the aqueous phase 
was extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered and evaporated under 
vacuum. The crude residue was purified by flash chromatography to provide the final compound. 
 
 
 4-amino-N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1ds) 
 
Yield 70 % as yellow solid (m.p. 153.5-154°C). Starting compound: 1dr. TLC: 
cyclohexane/ethyl acetate (6:4) - Rf: 0.22. Eluent for flash chromatography 
cyclohexane/ethyl acetate 6:4. Molecular formula: C15H11ClN4O2. Molecular 
weight: 314.73 g/mol. 1H NMR (300 MHz, acetone-d6): δ 9.82 (br s, NH, 1H 
exchanged with D2O), 7.64-7.70 (m, 4H, ArH), 7.40 (d, J = 8.7 Hz, 2H, ArH), 6.60 
(d, J = 8.4 Hz, 2H, ArH), 5.35 (br s, 2H, NH2 exchanged with D2O) ppm. 13C NMR 
(75 MHz, acetone-d6): δ 166.09, 153.41, 151.15, 150.88, 136.17, 130.26, 
129.36, 129.30, 125.46, 119.84, 113.35 ppm. 
 
 4-trifluoromethyl-N-(4-(4-aminophenyl)-1,2,5-oxadiazol-3-yl)benzamide (1sg) 
 
Yield: 78 % as brown solid. Starting compound: 1rg. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.30. Eluent for flash chromatography: from cyclohexane/ 
ethyl acetate 8:2 to 6:4. Molecular formula: C16H11F3N4O2. Molecular weight: 
348.29 g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.15 (br s, 1H, NH exchanged 
with D2O), 8.14 (d, J = 8.2 Hz, 2H, ArH), 7.80 (d, J = 8.2 Hz, 2H, ArH), 7.43 (d, J 
= 8.8 Hz, 2H, ArH), 6.60 (d, J = 8.8 Hz, 2H, ArH), 5.03 (br s, 2H, NH2 exchanged 
with D2O) ppm. 13C NMR (75 MHz, acetone-d6): δ 165.21, 151.60, 151.02, 
149.25, 136.49, 128.81, 128.64, 128.34, 125.72 (q, J = 3.5 Hz), 119.99, 114.09, 
112.63 ppm. 19F NMR (282 MHz, CDCl3): δ -63.99 (s, CF3) ppm. 
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General procedures for the nitrile or ester hydrolysis 
under basic conditions (1du,qg, 120da,dg) 
Procedure a 
 
3N NaOH (2 mL) was added at room temperature to a solution of 1dt (0.066 mmol) in ethanol (5 mL). The 
reaction mixture was heated at reflux for 3 hours. The mixture was cooled to room temperature and 
concentrated under vacuum. The residue was diluted with water and extracted with ethyl acetate. The 
aqueous phase, containing the sodium salt of 1du, was acidified with a solution of 3N HCl until pH = 2 and 
extracted with ethyl acetate. The organic layer was dried over Na2SO4, filtered and evaporated under reduced 
pressure. 
 
 
Procedure b 
 
The suitable ethyl carboxylate (0.27 mmol) was dissolved in tetrahydrofuran/ethanol (1:1, 4 mL) and 1N 
NaOH (1 mL) was added dropwise. The reaction was refluxed until completion and the solvents were 
removed under reduced pressure. The residue was diluted with water and washed with dichloromethane. 
The aqueous layer, containing the sodium salt of the final compound, was acidified with 1N HCl and extracted 
with ethyl acetate. The organic layers were dried and concentrated under reduced pressure, affording the 
pure carboxylic acid. 
 
 
 4-(N-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)carbamoyl)benzoic acid 
(1du) 
 
Procedure a: yield 81 % as white solid (m.p. 297-298°C). Starting 
compound: 1dt. TLC: dichloromethane/methanol (9:1) - Rf: 0.21. 
Molecular formula: C16H10ClN3O4. Molecular weight: 343.72 g/mol. 1H 
NMR (300 MHz, DMSO-d6): δ 8.02-8.09 (m, 4H, ArH), 7.78 (d, J = 8.4 
Hz, 2H, ArH), 7.59 (d, J = 8.7 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, 
DMSO-d6): δ 167.26, 166.52, 151.32, 150.66, 136.37, 136.31, 135.23, 
130.20, 130.01, 129.85, 129.10, 124.78 ppm. 
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 2-(4-(4-(4-(trifluoromethyl)benzamido)-1,2,5-oxadiazol-3-
yl)phenoxy)acetic acid (1qg) 
 
Procedure b. Reaction time: 30 minutes. Yield 93 % as light yellow 
foam. Starting compound: 1pg. TLC: dichloromethane/methanol (8:2) 
- Rf: 0.21. Molecular formula: C18H12F3N3O5. Molecular weight: 407.31 
g/mol. 1H NMR (300 MHz, acetone-d6): δ 10.44 (br s, 1H, OH 
exchanged with D2O), 8.26 (d, J = 8.1 Hz, 2H, ArH), 7.93 (d, J = 8.1 Hz, 
2H, ArH), 7.81 (d, J = 9.0 Hz, 2H, ArH), 7.08 (d, J = 9.0 Hz, 2H, ArH), 4.80 
(s, 2H, CH2), 2.81 (br s, 1H, NH exchanged with D2O) ppm. 19F NMR 
(282 MHz, CDCl3): δ -63.61 (s, CF3) ppm. 
 
 3-benzamido-4-(4-chlorophenyl)furan-2-carboxylic acid (120da) 
 
Procedure b. Reaction time: 60 minutes. Yield 86 % as white solid 
(m.p. 181.6-184.2°C). Starting compound: 119da. TLC: dichloro-
methane/methanol (8:2) - Rf: 0.28. Molecular formula: C18H12ClNO4. 
Molecular weight: 341.75 g/mol. 1H NMR (300 MHz, CD3OD): δ 7.97 
(s, 1H, ArH), 7.90 (d, J = 7.4 Hz, 2H, ArH), 7.58 (t, J = 7.4 Hz, 1H, ArH), 
7.42-7.53 (m, 4H, ArH), 7.34 (d, J = 8.7 Hz, 2H, ArH) ppm. 13C NMR (75 
MHz, CD3OD): δ 168.02, 159.77, 142.85, 138.89, 133.55, 133.28, 
131.90, 129.32, 128.86, 128.43, 128.37, 128.29, 127.33, 125.82 ppm. 
 
 4-(4-chlorophenyl)-3-(4-(trifluoromethyl)benzamido)furan-2-
carboxylic acid (120dg) 
 
Procedure b. Reaction time: 60 minutes. Yield 71 % as yellow-brown 
solid (m.p. 187.9-191.1°C). Starting compound: 119dg. TLC: dichloro-
methane/methanol (8:2) - Rf: 0.26. Molecular formula: C19H11ClF3NO4. 
Molecular weight: 409.75 g/mol. 1H NMR (300 MHz, CD3OD): δ 8.09 
(d, J = 8.0 Hz, 2H, ArH), 7.79 (d, J = 8.0 Hz, 2H, ArH), 7.72 (s, 1H, ArH), 
7.44 (d, J = 8.5 Hz, 2H, ArH), 7.31 (d, J = 8.5 Hz, 2H, ArH) ppm. 13C NMR 
(75 MHz, CD3OD): δ 166.53, 165.74, 141.43, 140.42, 137.04, 132.62, 
130.55, 128.13, 128.11, 128.09, 125.84, 125.57, 125.14 (q, J = 3.5 Hz), 
124.17, 121.97 ppm. 19F NMR (282 MHz, CD3OD): δ -64.49 (s, CF3) 
ppm. 
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Synthesis of ethyl 4-((4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl) 
carbamoyl)benzoate (1dv) 
 
In a two-necked flask equipped with a magnetic stirring bar, dry MgCl2 (0.0087mmol), diethylcarbonate 
(0.087 mmol) and 1du (0.087 mmol) were dissolved in ethanol (3 mL) under argon atmosphere. The mixture 
was stirred at 40°C for 12 hours (TLC: petroleum ether/ethyl acetate (8:2) - Rf: 0.45). The reaction mixture 
was diluted with H2O, concentrated and extracted with ethyl acetate. The organic layer was dried over 
Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography 
with petroleum ether/ethyl acetate (8:2) to provide 1dv. Yield 15 % as white solid. Molecular formula: 
C18H14ClN3O4. Molecular weight: 371.78 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.31 (br s, 1H, NH exchanged 
with D2O), 8.18 (d, J = 8.1 Hz, 2H, ArH), 7.94 (d, J = 8.1 Hz, 2H, ArH), 7.65 (d, J = 8.1 Hz, 2H, ArH), 7.47 (d, J = 
8.1 Hz, 2H, ArH), 4.43 (q, J = 7.2 Hz, 2H, CH2), 1.43 (t, J = 7.2 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 
165.56, 164.93, 149.82, 148.85, 137.44, 135.57, 135.01, 130.48, 129.85, 129.07, 127.86, 124.12, 61.93, 14.47 
ppm. 
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Synthesis of N-(4-(4-chlorophenyl)-furan-3-yl)benzamides (11da,dg) 
 
A mixture of the suitable carboxylic acid (0.293 mmol), Ag2CO3 (0.0293 mmol), acetic acid (0.015 mmol) in 
dry DMSO (0.29 mL) was stirred at 120°C under nitrogen atmosphere for 16 hours. After cooling to room 
temperature, ethyl acetate was added. The organic layer was washed with saturated sodium bicarbonate 
solution, water and brine, and dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure. The crude was purified by flash chromatography to give the final compound. 
 
 
 N-(4-(4-chlorophenyl)furan-3-yl)benzamide (11da) 
 
Yield 12.6 % as pale-yellow solid (m.p. 72.3-80.8°C). Starting compound: 
120da. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.45. Eluent for flash 
chromatography: cyclohexane/ethyl acetate from 95:5 to 8:2. Molecular 
formula: C17H12ClNO2. Molecular weight: 297.74 g/mol. 1H NMR (300 MHz, 
CDCl3): δ 8.37 (s, 1H, ArH), 7.76 (d, J = 7.0 Hz, 2H, ArH), 7.67 (br s, 1H, NH 
exchanged with D2O), 7.42-7.59 (m, 6H, ArH), 7.37 (d, J = 8.4 Hz, 2H, ArH) ppm. 
13C NMR (75 MHz, CDCl3): δ 164.47, 138.48, 134.19, 134.13, 133.50, 132.05, 
129.78, 129.37, 129.05, 128.92, 126.84, 122.30, 119.11 ppm. 
 
 4-trifluoromethyl-N-(4-(4-chlorophenyl)furan-3-yl)benzamide (11dg) 
 
Yield 25 % as yellow-orange solid (m.p. 115.1-116.4°C). Starting compound: 
120dg. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.58. Eluent for flash 
chromatography: cyclohexane/ethyl acetate (8:2). Molecular formula: 
C18H11ClF3NO2. Molecular weight: 365.74 g/mol. 1H NMR (300 MHz, CDCl3): δ 
8.28 (s, 1H, ArH), 7.79 (d, J = 8.1 Hz, 2H, ArH), 7.66 (d, J = 8.3 Hz, 2H, ArH), 7.62 
(br s, 1H, NH exchanged with D2O), 7.36-7.44 (m, 3H, ArH), 7.27 (d, J = 8.3 Hz, 
2H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 163.18, 138.63, 136.75, 134.48, 
134.31, 133.54, 129.83, 129.34, 128.83, 127.86, 127.35, 125.98 (q, J = 3.7 Hz), 
122.06, 119.01 ppm. 19F NMR (282 MHz, CDCl3): δ -63.11 (s, CF3) ppm. 
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Procedure for the synthesis of 1-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-
yl)methanamine hydrochloride (14 . HCl) 
Synthesis of ethyl 4-chlorocinnamate (122) 
 
 
The commercially available 4-chlorocinnamic acid (1 mmol) was suspended in absolute ethanol (5 mL) under 
nitrogen atmosphere and chlorotrimethylsilane (2.2 mmol) was dripped. The reaction was stirred at room 
temperature overnight (TLC: cyclohexane/ethyl acetate (9:1) - Rf: 0.36) and then the solvent was removed 
under reduced pressure. The crude was dissolved in ethyl acetate, washed with saturated NaHCO3, water 
and brine. Then the organic layers were collected, dried over Na2SO4 and concentrated to give the pure 122 
without any further purification. Yield 96 % as colorless oil. Molecular formula: C11H11ClO2. Molecular weight: 
210.66 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.60 (d, J = 16.0 Hz, 1H, CH), 7.42 (d, J = 8.3 Hz, 2H, ArH), 7.33 (d, 
J = 8.3 Hz, 2H, ArH), 6.38 (d, J = 16.0 Hz, 1H, CH), 4.25 (q, J = 7.1 Hz, 2H, CH2), 1.32 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (75 MHz, CDCl3): δ 166.64, 143.03, 136.05, 132.92, 129.14, 129.10, 118.84, 60.55, 14.26 ppm. 
 
 
Synthesis of 4-chlorocinnamyl alcohol (123) 
 
 
To a suspension of 122 (1 mmol) in dry toluene (2.5 mL), at -78°C under nitrogen, DIBAL-H (2.2 mmol, 1.2 M 
solution in toluene) was added dropwise. The reaction mixture was allowed to slowly warm to room 
temperature and then stirred for 5 hours (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.16). The reaction 
mixture was quenched with cold 0.1N HCl and filtered. The organic layer was separated and the aqueous 
layer was extracted with ethyl acetate. The combined organic layer was washed with brine and water, dried 
over Na2SO4 and concentrated under vacuum to afford the pure intermediate 123. Yield 94 % as white solid. 
Molecular formula: C9H9ClO. Molecular weight: 168.62 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.35-7.19 (m, 4H, 
ArH), 6.56 (d, J = 15.9 Hz, 1H, CH), 6.32 (dt, J1 = 15.9, J2 = 5.5 Hz, 1H, CH), 4.31 (d, J = 5.5 Hz, 2H, CH2) ppm. 13C 
NMR (75 MHz, CDCl3): δ 135.18, 133.22, 129.59, 129.19, 128.73, 127.63, 63.29 ppm. 
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Synthesis of 4-(4-chlorophenyl)-3-(hydroxymethyl)-1,2,5-oxadiazole 2-oxide (124) 
 
 
A solution of 4-chlorocinnamyl alcohol (1 mmol) in glacial acetic acid (5 mL) was cooled to 0°C and sodium 
nitrite (2 mmol) was added portion-wise. The reaction mixture was stirred at room temperature for 48 hours. 
After completion (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.35), the reaction mixture was quenched with 
ice water and extracted with ethyl acetate. The organic layer was washed with saturated NaHCO3, water, and 
brine. After drying over Na2SO4 and concentrating under reduced pressure, the residue was purified by flash 
chromatography (firstly with cyclohexane/ethyl acetate 7:3 and then with cyclohexane/chloroform 5:5) to 
obtain compound 124. Yield 50 % as brown oil. Molecular formula: C9H7ClN2O3. Molecular weight: 226.62 
g/mol. 1H NMR (300 MHz, CDCl3): δ 7.79 (d, J = 8.6 Hz, 2H, ArH), 7.53 (d, J = 8.6 Hz, 2H, ArH), 4.73 (s, 2H, CH2) 
ppm. 13C NMR (75 MHz, CDCl3): δ 155.81, 137.77, 129.74, 129.06, 124.62, 53.31 ppm. MS (ESI) m/z 227.01 
[M+H]+. 
 
 
Synthesis of 4-(4-chlorophenyl)-3-(hydroxymethyl)-1,2,5-oxadiazole (125) 
 
 
124 (1.26 mmol) was refluxed with trimethylphosphite (2.62 mL) for 24 hours (TLC: 
cyclohexane/dichloromethane/ethyl acetate (50:45:5) - Rf: 0.26) in a flame-dried flask under nitrogen. After 
cooling, 1N HCl (26.2 mL) was added to the reaction mixture which was extracted with diethyl ether. The 
combined organic layers were washed with saturated NaHCO3, and then with brine, dried and evaporated 
under vacuum. Flash chromatography (cyclohexane/ethyl acetate 8:2) was performed to afford 125. Yield: 
15 % as yellow solid (m.p. 74.8-76.5°C). Molecular formula: C9H7ClN2O2. Molecular weight: 210.62 g/mol. 1H 
NMR (300 MHz, CDCl3): δ 7.86 (d, J = 8.4 Hz, 2H, ArH), 7.51 (d, J = 8.4 Hz, 2H, ArH), 4.98 (s, 2H, CH2) ppm. 13C 
NMR (75 MHz, acetone-d6): δ 153.42, 153.21, 136.29, 130.19, 129.28, 124.73, 52.89 ppm. IR ν = 3369, 2963, 
2929, 1692, 1453, 1415, 1260, 1095, 799 cm-1. MS (ESI) m/z 233.6 [M+Na]+. 
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Synthesis of 4-(4-chlorophenyl)-3-(azidomethyl)-1,2,5-oxadiazole (126) 
 
 
A solution of 125 (1 mmol) in CCl4/DMF (1:4, 5 mL), with sodium azide (1.2 mmol) and PPh3 (1 mmol), was 
heated at 90°C for 5 hours (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.59). After cooling, the reaction mixture 
was quenched with water and extracted with diethyl ether. The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure. The crude was purified by flash chromatography (cyclohexane/ethyl 
acetate 8:2) to afford 126. Yield: 36 % as orange foamy solid. Molecular formula: C9H6ClN5O. Molecular 
weight: 235.63 g/mol. 1H NMR (200 MHz, CDCl3): δ 7.73 (d, J = 8.5 Hz, 2H, ArH), 7.51 (d, J = 8.5 Hz, 2H, ArH), 
4.63 (s, 2H, CH2) ppm. 13C NMR (50 MHz, CDCl3): δ 153.14, 148.91, 137.66, 129.94, 129.82, 123.65, 43.26 
ppm. IR ν = 3435, 2961, 2921, 2110, 1449, 1412, 1350, 1096, 800 cm-1. MS (ESI) m/z 258.6 [M+Na]+. 
 
 
Synthesis of 1-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-methanamine hydrochloride (14 . HCl) 
 
 
Intermediate 126 (0.4 mmol) was dissolved in methanol (3 mL) and the solution was degassed by bubbling 
argon for 10 minutes. Pd/C (10 % w/w) was then added and the mixture was stirred at room temperature 
under hydrogen atmosphere (20 atm) for 4 hours. After completion, the reaction mixture was filtered 
through Celite® and the organic layer was evaporated under vacuum. The crude was cooled by an ice bath 
and suspended in 2 M HCl in Et2O (2 mL). The mixture was stirred for 10 minutes and then the precipitated 
brown solid 14 . HCl was filtered and washed with Et2O. Yield: 24 % as brown solid. Molecular formula: 
C9H6Cl2N3O. Molecular weight: 246.09 g/mol. 1H NMR (300 MHz, acetone-d6): δ 8.01 (d, J = 8.8 Hz, 2H, ArH), 
7.63 (d, J = 8.8 Hz, 2H, ArH), 5.29 (s, 2H, CH2) ppm. 13C NMR (50 MHz, acetone-d6): δ 153.57, 149.16, 136.74, 
130.93, 129.64, 124.08, 40.47 ppm. IR ν = 3436, 2874, 2711, 2019, 1603, 1557, 1497, 1465, 1261, 1095, 830, 
684 cm-1. MS (ESI) m/z 209.9 [M] +. 
  
Chapter 7 – Experimental Part: Chemistry 
 
114 
Procedure for the synthesis of 2-amino-2-(4-(4-chlorophenyl)-1,2,5-
oxadiazol-3-yl)-1-phenylethan-1-one hydrochlorides (15a-c . HCl) 
Synthesis of 1-(4-chlorophenyl)-2-(hydroxyimino)propan-1-one (127) 
 
 
In a flame-dried flask under argon atmosphere, a solution of 4-chloropropiophenone (15 mmol) in a mixture 
of dry tetrahydrofuran (3 mL) and dry dichloromethane (3 mL) was cooled to - 20°C. Chlorotrimethylsilane 
(15 mmol) and tert-butyl nitrite (19.5 mmol) were added dropwise. The solution was stirred at - 20°C for 30 
minutes and then at room temperature for 16 hours (TLC: cyclohexane/ethyl acetate (9:1) - Rf: 0.37). The 
solvent was evaporated under reduced pressure and the crude was firstly purified by flash chromatography 
with cyclohexane/ethyl acetate (95:5). Finally, intermediate 127 was recrystallized in chloroform/ 
cyclohexane (1:5). Yield: 81 % as white solid (m.p. 118.5-119°C). Molecular formula: C9H8ClNO2. Molecular 
weight: 197.62 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.89 (br s, 1H, NOH exchanged with D2O), 7.82 (dd, J1 = 
8.7 Hz, J2 = 2.5 Hz, 2H, ArH), 7.38 (dd, J1 = 8.7 Hz, J2= 2.5 Hz, 2H, ArH), 2.15 (s, 3H, CH3) ppm. 13C NMR (75 
MHz, CDCl3): δ 190.80, 157.08, 139.63, 134.74, 131.97, 128.71, 10.40 ppm. IR ν = 3292, 3242, 2917, 1664, 
1586, 1090, 997, 900, 840, 751 cm-1. MS (ESI) m/z 195.9 [M-H]-. 
 
 
Synthesis of 1-(4-chlorophenyl)propane-1,2-dione dioxime (128) 
 
 
To a solution of hydroxylamine hydrochloride (150 mmol) and sodium hydroxide (150 mmol) in water (30 
mL), a methanolic solution of 127 (11.6 mmol in 15 mL) was added and the mixture was heated to reflux for 
3 hours (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.28). After evaporation under reduced pressure of 
methanol, the remaining water layer was cooled with an ice-bath. The precipitated solid was collected by 
filtration and then washed with water and chloroform to give 128. Yield: 55 % as white solid (m.p. 103.5-
104°C). Molecular formula: C9H9ClN2O2. Molecular weight: 212.63 g/mol. 1H NMR (300 MHz, CD3OD) δ 7.89 
(d, J = 8 Hz, 2H, ArH), 7.43 (d, J1 = 8 Hz, 2H, ArH), 2.09 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CD3OD): δ 154.36, 
133.30, 130.66, 128.07, 127.81, 127.11, 8.62 ppm. IR ν = 3234, 3103, 2917, 1665, 1596, 1427, 1093, 982, 898, 
741 cm-1. MS (ESI) m/z 212.9 [M+H]+.   
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Synthesis of 3-(4-chlorophenyl)-4-methyl-1,2,5-oxadiazole (129) 
 
 
In a flame-dried flask, compound 128 (10 mmol) was added to a mixture of KOH (0.4 mmol) and Cs2CO3 (0.1 
mmol) in ethylene glycol (4 mL) under argon atmosphere and the reaction was heated to 160°C for 90 
minutes (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.75). The mixture was dry-loaded on silica eluting with 
cyclohexane to remove the ethylene glycol. Afterwards, a purification of the crude by flash chromatography 
(cyclohexane/ethyl acetate 9:1) was performed to obtain 129. Yield: 64 % as pale solid (m.p. 82-83°C). 
Molecular formula: C9H7ClN2O. Molecular weight: 194.62 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.61 (d, J = 8.4 
Hz, 2H, ArH), 7.42 (d, J = 8.4 Hz, 2H, ArH), 2.50 (s, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 153.12, 149.71, 
136.84, 129.62, 129.48, 124.75, 9.92 ppm. IR ν = 3436, 3100, 2917, 1920, 1603, 1445, 1386, 1096, 892, 729 
cm-1. MS (ESI) m/z 179.0 [M-CH3]-. 
 
 
General procedure for the synthesis of 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-phenylethan-1-ones 
(130a-c) 
 
 
A solution of 129 (5 mmol) in dry tetrahydrofuran (3 mL) was placed in a flame-dried flask under argon 
atmosphere and, after cooling to - 55°C, a solution of n-BuLi 2.7 M in heptane (5 mmol) was added dropwise. 
The reaction mixture was stirred for 20 minutes at -55°C and then the suitable methyl benzoate (5 mmol) 
was rapidly added. After 30 minutes the solution was allowed to warm to room temperature and stirred for 
90 minutes. After completion, a saturated solution of NH4Cl was added and then the solvent was evaporated 
under reduced pressure. The residue was diluted with water and extracted with dichloromethane. The 
organic phase was dried over Na2SO4, filtered and evaporated under vacuum. Purification of the crude 
residue by flash chromatography was performed to give the final product. 
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 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-(4-
trifluoromethyl)phenylethan-1-one (130a) 
 
Yield: 68 % as yellow solid. Starting compounds: 129 and methyl 4-
trifluoromethylbenzoate. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.57. 
Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 9:1). 
Molecular formula: C17H10ClF3N2O2. Molecular weight: 366.72 g/mol. 1H 
NMR (300 MHz, CDCl3): δ 8.10 (d, J = 8.2 Hz, 2H, ArH), 7.79 (d, J = 8.2 Hz, 2H, 
ArH), 7.56 (d, J = 8.7 Hz, 2H, ArH), 7.44 (d, J = 8.7 Hz, 2H, ArH), 4.64 (s, 2H, 
CH2) ppm. 13C NMR (75 MHz, CDCl3): δ 192.42, 153.89, 147.73, 137.89, 
137.00, 129.56, 129.33, 128.80, 126.09 (q, J = 3.6 Hz), 124.04, 34.16 ppm. 
19F NMR (282 MHz, CDCl3): δ -63.32 (s, CF3) ppm. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-phenylethan-1-one (130b) 
 
Yield: 89 % as light brown solid (m.p. 101.5-102°C). Starting compounds: 
129 and methyl benzoate. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.61. 
Purified by flash chromatography (eluent: cyclohexane/ethyl acetate 9:1). 
Molecular formula: C16H11ClN2O2. Molecular weight: 298.73 g/mol. 1H NMR 
(300 MHz, CDCl3): δ 8.00 (d, J = 7.3 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.48-7.60 
(m, 4H), 7.43 (d, J = 8.4 Hz, 2H), 4.64 (s, 2H) ppm. 13C NMR (75 MHz, CDCl3): 
δ 193.30, 153.95, 148.22, 136.83, 135.36, 134.29, 129.49, 129.39, 129.01, 
128.40, 124.25, 33.89 ppm. IR ν = 3436, 3349, 2929, 1683, 1451, 1093, 992, 
845, 689 cm-1. MS (ESI) m/z 320.9 [M+Na]+. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-(4-methoxy) 
phenylethan-1-one (130c) 
 
Yield: 40 % as orange solid. Starting compounds: 129 and methyl 4-
methoxybenzoate. TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.29. Purified 
by flash chromatography (eluent: cyclohexane/ethyl acetate 8:2). 
Molecular formula: C17H13ClN2O3. Molecular weight: 328.06 g/mol. 1H NMR 
(300 MHz, CDCl3): δ 7.95 (d, J = 9.0 Hz, 2H, ArH), 7.56 (d, J = 8.7 Hz, 2H, ArH), 
7.38 (d, J = 8.7 Hz, 2H, ArH), 6.95 (d, J = 9.0 Hz, 2H, ArH), 4.57 (s, 2H, CH2), 
3.87 (s, 3H, OCH3) ppm. 13C NMR (50 MHz, CDCl3): δ 191.94, 164.63, 154.18, 
148.75, 136.99, 131.03, 129.66, 128.67, 124.58, 114.40, 55.82, 33.73 ppm. 
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Synthesis of 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyimino)-1-phenylethan-1-ones (131a-c) 
 
 
In a flame-dried flask under argon atmosphere, a solution of the starting compound (1 mmol) in dry 
tetrahydrofuran (3 mL) was cooled at -20°C and chlorotrimethylsilane (1 mmol) was added. After dripping 
tert-butyl nitrite (1.3 mmol), the solution was stirred at - 20°C for 30 minutes and then at room temperature 
for 16 hours. The solvent was evaporated under reduced pressure and the purification of the crude was 
performed by flash chromatography to obtain the final product. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyimino)-1-(4-
trifluoromethyl)phenylethan-1-one (131a) 
 
Yield: 68 % as white solid. Starting compound: 130a. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.36. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C17H9ClF3N3O3. Molecular 
weight: 395.72 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.90 (br s, 1H, NOH 
exchanged with D2O), 8.16 (d, J = 8.2 Hz, 2H, ArH), 7.76 (d, J = 8.2 Hz, 2H, ArH), 
7.58 (d, J = 8.6 Hz, 2H, ArH), 7.42 (d, J = 8.6 Hz, 2H, ArH) ppm. 13C NMR (75 
MHz, CDCl3): δ 187.45, 153.42, 146.37, 144.44, 137.91, 137.63, 131.20, 
130.07, 129.82, 129.22, 129.00, 125.60 (q, J = 4.1 Hz), 123.82 ppm. 19F NMR 
(282 MHz, CDCl3): δ -63.82 (s, CF3) ppm. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyimino)-1-phenylethan-
1-one (131b) 
 
Yield: 76 % as white solid (m.p. 126.0-126.5°C). Starting compound: 130b. TLC: 
cyclohexane/ethyl acetate (8:2) - Rf: 0.20. Purified by flash chromatography 
(gradient elution, from 10% to 20% ethyl acetate/cyclohexane). Molecular 
formula: C16H10ClN3O3. Molecular weight: 327.72 g/mol. 1H NMR (300 MHz, 
CDCl3): δ 8.49 (br s, 1H, NOH exchanged with D2O), 8.09 (dd, J1 = 7.4 Hz, J2 = 
1.0 Hz, 2H, ArH), 7.58-7.70 (m, 3H, ArH), 7.47-7.54 (m, 2H, ArH), 7.42 (dd, J1 = 
8.6 Hz, J2 = 0.9 Hz, 2H, ArH) ppm. 13C NMR (75 MHz, CDCl3): δ 188.52, 153.22, 
145.85, 144.69, 137.24, 134.73, 134.27, 130.75, 129.50, 128.81, 128.53, 
123.62 ppm. IR ν = 3324, 3077, 2918, 1664, 1599, 1450, 1092, 878, 694 cm-1. 
MS (ESI) m/z 326.8 [M-H]-. 
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 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyimino)-1-(4-
trifluoromethyl)phenylethan-1-one (131c) 
 
Yield: 84 % as yellow solid. Starting compounds: 130c. TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.13. Purified by flash chromatography (eluent: 
cyclohexane/ethyl acetate 8:2). Molecular formula: C17H12ClN3O4. Molecular 
weight: 357.75 g/mol. 1H NMR (300 MHz, acetone-d6): δ 12.65 (br s, 1H, NOH 
exchanged with D2O), 8.16 (d, J = 9.0 Hz, 2H, ArH), 7.77 (d, J = 8.8 Hz, 2H, ArH), 
7.59 (d, J = 8.7 Hz, 2H, ArH), 7.10 (d, J = 9.0 Hz, 2H, ArH), 3.94 (s, 3H, OCH3) 
ppm. 13C NMR (50 MHz, acetone-d6): δ 186.54, 164.78, 153.65, 146.26, 
145.40, 136.94, 133.30, 129.75, 129.37, 128.20, 124.58, 114.40, 55.46 ppm. 
 
 
Synthesis of 2-amino-2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-phenylethan-1-one hydrochlorides 
(15a-c . HCl) 
 
 
To a solution of the suitable 2-(hydroxyimino)-1-phenylethan-1-one (0.15 mmol) in trifluoroacetic acid (1.5 
mL), zinc dust (0.81 mmol) was slowly added on an ice bath. The mixture was stirred at room temperature 
for 20-40 minutes. 
 
 
 2-amino-2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-(4-
trifluoromethyl)phenylethan-1-one hydrochloride (15a . HCl) 
 
Reaction time: 20 minutes. Work up: The reaction was cooled with an ice bath 
and a solution of 2 M HCl in Et2O was added. After 20 minutes, hexane was 
used for the precipitation of the hydrochloride salt. The solid was filtered and 
washed with Et2O (3 mL). Yield: 43 % as orange solid. Starting compound: 
131a. Molecular formula: C17H12Cl2F3N3O2. Molecular weight: 418.20 g/mol. 
1H NMR (300 MHz, CD3OD): δ 7.78 (d, J = 8.2 Hz, 2H, ArH), 7.57-7.70 (m, 6H, 
ArH), 6.79 (s, 1H, CH) ppm. 13C NMR (75 MHz, CD3OD): δ 187.07, 153.07, 
147.86, 136.55, 130.18, 129.64, 129.49, 129.36, 128.92, 128.11, 125.08 (q, J 
= 3.9 Hz), 122.64, 49.30 ppm. 19F NMR (282 MHz, CD3OD): δ -64.88 (s, CF3) 
ppm. MS (ESI) m/z 382.5 [M+H]+. 
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 2-amino-2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-phenylethan-1-one 
hydrochloride (15b . HCl) 
 
Reaction time: 40 minutes. Work up: the reaction was cooled with an ice bath 
and a solution of 2 M NaOH was added until pH=7-8. The insoluble material 
was removed by filtration and washed with dichloromethane (2 mL). The 
organic phase was separated, dried over dry Na2SO4, filtered and evaporated 
under reduced pressure. The obtained yellow oil was cooled and treated with 
2 M HCl in Et2O (2 mL) and the mixture was stirred for 10 minutes. The 
precipitated solid was filtered and washed with Et2O (3 mL) affording 15b as 
hydrochloride salt. Yield: 85 % as white solid. Starting compound: 131b. 
Molecular formula: C16H13Cl2N3O2. Molecular weight: 350.20 g/mol. 1H NMR 
(300 MHz, CD3OD): δ 7.55-7.70 (m, 7H, ArH), 7.32-7.38 (m, 2H, ArH), 6.69 (s, 
1H, CH) ppm. 13C NMR (75 MHz, CD3OD): δ 188.94, 153.08, 147.99, 137.60, 
134.83, 132.45, 130.20, 129.6, 128.85, 128.28, 122.35, 49.30 ppm. IR ν = 3411, 
3208, 2850, 1702, 1689, 1599, 1449, 1093, 995, 688 cm-1. MS (ESI) m/z 314.1 
[M + H]+. 
 
 2-amino-2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-1-(4-
methoxy)phenylethan-1-one hydrochloride (15c . HCl) 
 
Work up: The reaction was cooled with an ice bath and a solution of 2 M HCl 
in Et2O was added. The resulting precipitated solid was filtered and washed 
with Et2O (3 mL) affording 15c as hydrochloride salt. Yield: 79 % as light yellow 
solid. Starting compound: 131c. Molecular formula: C17H15Cl2N3O3. Molecular 
weight: 380.23 g/mol. 1H NMR (200 MHz, CD3OD): δ 7.58-7.67 (m, 4H, ArH), 
7.57 (d, J = 9.1 Hz, 2H, ArH), 6.86 (d, J = 9.0 Hz, 2H, ArH), 6.60 (s, 1H, CH), 3.84 
(s, 3H, OCH3) ppm. 13C NMR (50 MHz, CD3OD): δ 187.20, 165.61, 153.21, 
148.50, 137.74, 132.97, 130.45, 129.76, 125.26, 122.67, 114.35, 55.17, 48.83 
ppm. IR ν = 3413, 3193, 2931, 1692, 1670, 1601, 1428, 1259, 1094, 994, 827 
cm-1. MS (ESI) m/z 344.1 [M+H]+. 
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Synthesis of 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-
(hydroxyamino)-1-phenylethan-1-ones (16a-c) 
 
In a flame-dried flask under nitrogen atmosphere, a solution of 131a-c (0.05 mmol) in dry tetrahydrofuran (1 
mL) was cooled at -78°C and lithium triethylborohydride in tetrahydrofuran (1.7 M, 0.08 mL) was added. The 
solution was stirred at -78°C for 1-3 hours (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.26). A saturated 
solution of NH4Cl was added and the resulting mixture was filtered, dried over Na2SO4 and concentrated 
under reduced pressure. The crude was purified by flash chromatography (cyclohexane/ethyl acetate 7:3) 
affording the finale product. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyamino)-1-(4-
(trifluoromethyl)phenyl)ethan-1-one (16a) 
 
Reaction time: 3 hours. Yield: 97 % as white solid. Starting compound: 131a. 
Molecular formula: C17H11ClF3N3O3. Molecular weight: 397.74 g/mol. 1H NMR 
(300 MHz, CD3OD): δ 7.41-7.49 (m, 4H, ArH), 7.32-7.41 (m, 4H, ArH), 5.79 (s, 
1H, CH) ppm. 13C NMR (75 MHz, CD3OD): δ 153.35, 147.75, 145.75, 143.92, 
136.55, 130.00, 129.58, 129.20, 128.83, 126.86, 124.80 (d, J = 3.7 Hz), 124.36, 
73.43 ppm.  19F NMR (282 MHz, CD3OD): δ -64.44 (s, CF3) ppm. IR ν = 3469, 
2963, 2461, 1714, 1621, 1605, 1452, 1418, 1328, 1262, 1166, 1066, 802 cm-1. 
MS (ESI) m/z 395.9 [M - H]-. 
 
 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyamino)-1-
phenylethan-1-one (16b) 
 
Reaction time: 1 hour. Yield: 96 % as off-white solid. Starting compound: 
131b. Molecular formula: C16H12ClN3O3. Molecular weight: 329.74 g/mol. 1H 
NMR (300 MHz, CD3OD): δ 7.40 (d, J = 8.7 Hz, 2H, ArH), 7.33 (d, J = 8.7 Hz, 2H, 
ArH), 7.08-7.26 (m, 5H, ArH), 5.71 (s, 1H, CH) ppm. 13C NMR (75 MHz, CD3OD): 
δ 153.16, 147.94, 145.71, 139.18, 136.11, 128.94, 128.44, 127.80, 127.61, 
126.05, 124.30, 73.93 ppm. 
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 2-(4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl)-2-(hydroxyamino)-1-(4-
methoxyphenyl)ethan-1-one (16c) 
 
Reaction time: 2 hours. Yield: 74 % as grey solid. Starting compound: 131c. 
Molecular formula: C17H14ClN3O4. Molecular weight: 359.77 g/mol. 1H NMR 
(300 MHz, CD3OD): δ 7.36 (d, J = 8.6 Hz, 2H, ArH), 7.32 (d, J = 8.8 Hz, 1H, ArH), 
7.02 (d, J = 8.8 Hz, 1H, ArH), 6.64 (d, J = 8.6 Hz, 1H, ArH), 5.63 (s, 1H, CH), 3.70 
(s, 3H, OCH3) ppm. 13C NMR (75 MHz, CD3OD): δ 159.48, 153.15, 148.25, 
145.70, 136.05, 130.76, 129.04, 128.40, 127.21, 124.17, 113.12, 73.56, 54.19 
ppm. 
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General procedure for the synthesis of platinum complexes 
 
K2PtCl4 (1 mmol) was dissolved in 10 mL of distilled water. The ligand (1.1 mmol), when available in 
dihydrochloride form, was preventively neutralized with NaHCO3 aqueous solution and then dripped into the 
platinate solution. 4 M HCl (10 mmol) was added and the mixture was refluxed under nitrogen atmosphere 
for 12 hours. After cooling to room temperature, the product was filtered as a solid and washed extensively 
with water. The precipitate was then dissolved in diethyl ether and crystallized for slow diffusion of hexane. 
 
 
 Pt-13 
 
Yield: 62 % as pale-yellow solid. Starting compound: 13. Molecular formula: 
C4H7Cl2N3OPt. Molecular weight: 377.96 g/mol. 1H NMR (300 MHz, DMF-d7) δ 
6.72 (br, 2H), 4.34 (t, J = 6.3 Hz, 2H), 2.61 (s, 3H). 13C NMR (75 MHz, DMF-d7) 
163.18, 153.94, 42.79, 8.64. 195Pt NMR (300 MHz, DMF-d7) δ -2065. Elemental 
analysis for C4H7Cl2N3OPt: calculated C, 12.67; H, 1.86; N, 11.09; found C, 
12.72; H, 1.78; N, 10.98. MS (ESI) m/z 365.9 [M-Cl+Na]+. 
 
 Pt-14 
 
Yield: 45 % as brown solid. Starting compound: 14 . HCl. Molecular formula: 
C9H8Cl3N3OPt. Molecular weight: 473.94 g/mol. 1H NMR (300 MHz, DMF-d7) 
δ 7.98 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.8 Hz, 2H), 6.94 (br, 2H), 4.61 (t, J = 6.0 
Hz, 2H). 13C NMR (75 MHz, DMF-d7) 137.78, 130.49, 130.19, 125.25, 123.31, 
116.47, 44.35. 195Pt NMR (300 MHz, DMF-d7) δ -2075. Elemental analysis for 
C9H8Cl3N3OPt: calculated C, 22.73; H, 1.70; N, 8.84; found C, 23.01; H, 1.75; 
N, 8.89. MS (ESI) m/z 461.9 [M-Cl+Na]+. 
 
 Pt-15b 
 
Yield: 61 % as olive-green solid. Starting compound: 15b . HCl. Molecular 
formula: C16H12Cl3N3O2Pt. Molecular weight: 577.96 g/mol. 1H NMR (300 
MHz, CDCl3) δ 7.77 (d, J = 8.5 Hz, 2H), 7.50-7.44 (m, 5H), 7.25-7.21 (m, 2H), 
6.20 (t, J = 5.8Hz, 1H), 5.46-5.41 (m, 1H), 4.88-4.85 (m, 1H). 13C NMR (75 MHz, 
CDCl3) 191.27, 152.84, 149.45, 138.06, 135.09, 132.73, 130.44, 130.35, 
130.23, 130.19, 129.60, 129.51, 129.47, 129.32, 129.23, 128.93, 55.15. 195Pt 
NMR (300 MHz, CDCl3) δ -2068. Elemental analysis for C16H12Cl3N3O2Pt: 
calculated C, 33.15; H, 2.09; N, 7.25; found C, 33.58; H, 2.18; N, 7.54. MS (ESI) 
m/z 578.5 [M+H]+. 
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 Pt-15c 
 
Yield: 44 % as brown solid. Starting compound: 15c . HCl. Molecular formula: 
C17H14Cl3N3O3Pt. Molecular weight: 609.75 g/mol. Elemental analysis for 
C17H14Cl3N3O3Pt: calculated C, 33.49; H, 2.81; N, 6.89; found C, 33.78; H, 2.84; 
N, 6.67. MS (ESI) m/z 509.2 [M-2Cl-OCH3]+. 
 
 Pt-16a 
 
Yield: 37 % as brown solid. Starting compound: 16a. Molecular formula: 
C17H11Cl3F3N3O3Pt. Molecular weight: 663.72 g/mol. Elemental analysis for 
C17H11Cl3F3N3O3Pt: calculated C, 30.76; H, 1.67; N, 6.33; found C, 30.93; H, 
1.97; N, 6.54. MS (ESI) m/z 701.4 [M+K]+. 
 
 Pt-16b 
 
Yield: 51 % as brick-red solid. Starting compound: 16b. Molecular formula: 
C16H12Cl3N3O3Pt. Molecular weight: 595.72 g/mol. Elemental analysis for 
C16H12Cl3N3O3Pt: calculated C, 32.26; H, 2.03; N, 7.05; found C, 32.98; H, 2.66; 
N, 7.54. MS (ESI) m/z 596.5 [M+H]+. 
 
 Pt-16c 
 
Starting compound: 16c. Molecular formula: C17H14Cl3N3O4Pt. Molecular 
Weight: 625.75 g/mol. 
Its characterization is ongoing. 
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Procedures for the synthesis of methyl 1-(2-(1H-indol-3-yl)ethyl)-5-(1-
hydroxyethyl)-1,4,5,6-tetrahydropyridine-3-carboxylates (19,20) 
Synthesis of methyl 2-cyano-2-hexenoate (134) 
 
 
In a flame-dried flask, butyraldehyde (4.12 mmol), methyl cyanoacetate (4.04 mmol), acetic acid (9.52 mmol) 
and piperidine (0.162 mmol) were added under nitrogen atmosphere and stirred for 24 hours (TLC: 
cyclohexane/ethyl acetate (65:35) - Rf: 0.73). After water addition, the mixture was extracted with 
dichloromethane and the collected organic layers were dried over Na2SO4 and concentrated under reduced 
pressure to give 134. Yield 95 % as ocher oil. Molecular formula: C8H11NO2. Molecular weight: 153.18 g/mol. 
1H NMR (300 MHz, CDCl3): δ 7.62 (t, J = 7.9 Hz, 1H, CH), 3.82 (s, 3H, OCH3), 2.50 (q, J = 7.5 Hz, 2H, CH2), 1.56 
(dq, J1 = 14.7, J2 = 7.3 Hz, 2H, CH2), 0.96 (t, J = 7.4 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 163.85, 
161.71, 113.55, 109.51, 53.01, 33.73, 21.14, 13.60 ppm. 
 
 
Synthesis of methyl 2-chloro-5-ethylnicotinate (135) 
 
 
A solution of compound 134 (3.56 mmol) in dry N,N-dimethylformamide (2.28 mL) was cooled at 0°C and 
POCl3 (7.13 mmol) was dripped. The reaction mixture was heated at 80°C for 2 hours and then ice-water was 
added to the cooled solution which was stirred overnight at room temperature (TLC: cyclohexane/ethyl 
acetate (8:2) - Rf: 0.50). The mixture was extracted with ethyl acetate and concentrated in vacuo to give a 
black oil. The residue was purified by flash chromatography (eluting with cyclohexane/ethyl acetate 9:1) to 
obtain compound 135. Yield 16 % as light-brown oil. Molecular formula: C9H10ClNO2. Molecular weight: 
199.63 g/mol. 1H NMR (300 MHz, CDCl3): δ 8.35 (d, J = 2.5 Hz, 1H, ArH), 7.99 (d, J = 2.5 Hz, 1H, ArH), 3.95 (s, 
3H, OCH3), 2.69 (q, J = 7.6 Hz, 2H, CH2), 1.27 (t, J = 7.6 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 164.9, 
151.2, 146.7, 139.4, 138.1, 125.9, 52.6, 24.9, 14.7 ppm. 
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Synthesis of methyl 5-ethylnicotinate (136) 
 
 
The suspension of intermediate 135 (8.31 mmol), palladium on carbon (10%) and sodium acetate (10.39 
mmol) in methanol (55 mL) was hydrogenated for 20 hours (TLC: cyclohexane/ethyl acetate (8:2) - Rf: 0.18) 
at room temperature. The mixture was filtered on Celite® and concentrated under reduced pressure to give 
a white solid residue which was purified by flash chromatography (eluting with cyclohexane/ethyl acetate 
8:2) to give the product 136. Yield 87 % as light-yellow oil. Molecular formula: C9H11NO2. Molecular weight: 
165.19 g/mol. 1H NMR (300 MHz, CDCl3): δ 9.00 (d, J = 1.7 Hz, 1H, ArH), 8.57 (d, J = 1.7 Hz, 1H, ArH), 8.08 (t, J 
= 1.7 Hz, 1H, ArH), 3.90 (s, 3H, OCH3), 2.67 (q, J = 7.6 Hz, 2H, CH2), 1.24 (t, J = 7.6 Hz, 3H, CH3) ppm. 13C NMR 
(75 MHz, CDCl3): δ 165.97, 153.23, 148.27, 139.03, 136.12, 125.62, 52.27, 25.78, 15.03 ppm. 
 
 
Synthesis of methyl 5-(1'-bromoethyl)nicotinate (137) 
 
 
The solution of compound 136 (7.20 mmol), N-bromosuccinimide (9.58 mmol) and benzoyl peroxide (0.072 
mmol) in CCl4 (36 mL) was refluxed for 3 hours (TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.30). The 
precipitate was filtered and the solution was evaporated under vacuum. The residue was extracted with 
NaHCO3 and dichloromethane, and the organic layer was dried over Na2SO4 and concentrated under reduced 
pressure to give the product 137. Yield 65 % as orange oil. Molecular formula: C9H10BrNO2. Molecular weight: 
244.09 g/mol. 1H NMR (300 MHz, CDCl3): δ 9.11 (d, J = 1.7 Hz, 1H, ArH), 8.81 (d, J = 1.7 Hz, 1H, ArH), 8.36 (t, J 
= 1.7 Hz, 1H, ArH), 5.21 (q, J = 7.0 Hz, 1H, CH), 3.96 (s, 3H, CH3), 2.07 (d, J = 7.0 Hz, 3H, CH3) ppm. 13C NMR (75 
MHz, CDCl3): δ 165.2, 151.7, 150.2, 138.8, 135.2, 125.9, 52.4, 44.2, 26.2 ppm. 
 
 
Synthesis of methyl 5-(1'-hydroxyethyl)nicotinate (138) 
 
 
Intermediate 137 (4.72 mmol) was refluxed in a solution of water (157 mL) and acetone (63 mL) for 20 hours 
(TLC: cyclohexane/ethyl acetate (7:3) - Rf: 0.06). After cooling the mixture was extracted with 
dichloromethane and the collected layers concentrated under vacuum. The product was purified by flash 
chromatography (eluting with cyclohexane/ethyl acetate 7:3) to give the compound 138. Yield 74 % as 
colorless solid (m.p. 52-53°C). Molecular formula: C9H11NO3. Molecular weight: 181.19 g/mol. 1H NMR (300 
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MHz, CDCl3): δ 9.09 (d, J = 1.7 Hz, 1H, ArH), 8.76 (d, J = 1.7 Hz, 1H, ArH), 8.33 (t, J = 1.7 Hz, 1H, ArH), 5.02 (q, 
J = 6.5 Hz, 1H, CH), 3.95 (s, 3H, OCH3), 1.55 (d, J = 6.5 Hz, 3H, CH3) ppm. 
 
 
Synthesis of 1-(2-(1H-indol-3-yl)ethyl)-3-(1-hydroxyethyl)-5-(methoxycarbonyl)pyridin-1-ium bromide 
(139) 
 
 
The solution of compound 138 (1.28 mmol) and 3-(2-bromoethyl)-indole (1.38 mmol) in methanol (25 mL) 
was refluxed for 90 minutes. The solution was concentrated under reduced pressure and diethyl ether was 
added. The resulting yellow precipitate was filtered and recrystallized from methanol to give the pure salt 
139. Yield 95 % as yellow solid (m.p. 222-224°C). Molecular formula: C19H21BrN2O3. Molecular weight: 405.29 
g/mol. 1H NMR (300 MHz, CD3OD): δ 9.02 (s, 1H, ArH), 8.85 (s, 1H, ArH), 8.60 (s, 1H, ArH), 7.35 (dd, J1 = 8.1, 
J2 = 1 Hz, 1H, ArH), 7.22 (dd, J1 = 8.1, J2 = 1 Hz, 1H, ArH), 7.10 (dt, J1 = 8.1, J2 = 1 Hz, 1H, ArH), 6.99 (s, 1H, ArH), 
6.94 (dt, J1 = 8.1, J2 = 1.0 Hz, 1H, ArH), 4.97 (t, J = 6.3 Hz, 2H, CH2), 4.88 (q, J = 6.7 Hz, 1H, CH), 3.96 (s, 3H, 
OCH3), 3.47 (t, J = 6.3 Hz, 2H, CH2), 1.21 (d, J = 6.7 Hz, 3H, CH3) ppm. 13C NMR (75 MHz, CD3OD): δ 147.88, 
144.58, 143.59, 141.57, 136.63, 129.90, 126.66, 123.87, 121.63, 119.06, 116.71, 111.38, 107.64, 65.47, 63.08, 
26.73, 23.51 ppm. 
 
 
Synthesis of methyl 1-(2-(1H-indol-3-yl)ethyl)-5-(1-hydroxyethyl)-1,4,5,6-tetrahydropyridine-3-
carboxylates (19,20) 
 
 
The suspension of compound 139 (1.48 mmol), palladium on carbon (10 % w/w) and triethylamine (0.25 mL) 
in methanol (50 mL) was hydrogenated for 16 hours. The mixture was filtered on Celite® and concentrated 
in vacuo. The residue was purified by flash chromatography (eluting with dichloromethane/methanol 98:2) 
to give the couple of diastereoisomers (19 and 20). Yield 80 % (19/20: 1:1) as light-yellow solids. Molecular 
formula: C19H24N2O3. Molecular weight: 328.41 g/mol.  
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19 - TLC: dichloromethane/methanol (95:5) - Rf: 0.11. 1H NMR (300 MHz, CDCl3): δ 8.14 (br s, 1H, NH 
exchanged with D2O), 7.57 (d, J = 7.7 Hz, 1H, ArH), 7.35-7.38 (m, 2H, ArH), 7.21 (t, J = 7.3 Hz, 1H, ArH), 7.13 
(t, J = 7.3 Hz, 1H, ArH), 6.98 (d, J = 2.1 Hz, 1H, ArH), 3.70-3.80 (m, 1H; CH), 3.65 (s, 3H, OCH3), 3.44 (t, J = 7.3 
Hz, 2H, CH2), 2.90-3.09 (m, 4H, CH2 and NCH2), 2.49 (dd, J1 = 15.5, J2 = 3.6 Hz, 1H, CH2), 2.01 (dd, J1 = 15.6, J2 
= 10.3 Hz, 1H, CH2), 1.68-1.80 (m, 1H, CH), 1.65 (br s, 1H, OH exchanged with D2O), 1.17 (d, J = 6.4 Hz, 3H, 
CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 169.01, 145.99, 136.21, 127.13, 122.20, 122.01, 119.49, 118.54, 
112.56, 111.24, 70.00, 56.45, 50.52, 48.11, 39.68, 24.94, 23.40, 21.91 ppm. 
 
20 - TLC: dichloromethane/methanol (95:5) - Rf: 0.08. 1H NMR (300 MHz, CDCl3): δ 8.22 (br s, 1H, NH 
exchanged with D2O), 7.58 (d, J = 7.7 Hz, 1H, ArH), 7.34-7.37 (m, 2H, ArH), 7.20 (t, J = 7.4 Hz, 1H, ArH), 7.13 
(t, J = 7.4 Hz, 1H, ArH), 6.96 (d, J = 2.1 Hz, 1H, ArH), 3.65 (s, 3H, OCH3), 3.48-3.58 (m, 1H, CH), 3.44 (t, J = 7.0 
Hz, 2H, CH2), 3.32-3.38 (m, 1H, CH2), 2.92-3.09 (m, 4H, CH2 and OH exchanged with D2O), 2.38 (dd, J1 = 15.6, 
J2 = 4.9 Hz, 1H, CH2), 1.88 (dd, J1 = 15.5, J2 = 10.0 Hz, 1H, CH2), 1.62-1.72 (m, 1H, CH), 1.25 (d, J = 6.4 Hz, 3H, 
CH3) ppm. 13C NMR (75 MHz, CDCl3): δ 169.13, 147.01, 136.20, 127.02, 122.19, 122.00, 119.40, 118.49, 
112.40, 111.20, 69.05, 56.28, 50.41, 47.86, 38.40, 23.19, 23.14, 21.86 ppm. 
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General procedures for the synthesis of 21-23 
Synthesis of O,O’-diacetyl-D-pantothenic acid (140) 
 
 
A mixture of D-pantothenic acid calcium salt (1.10 mmol) and a catalytic amount of I2 (0.15 mmol) suspended 
in acetic anhydride (10 mL) was stirred at 0°C for 2 hours and then left at room temperature for 18 hours. 
The cooled solution was concentrated under reduced pressure by azeotrope with toluene. The obtained red 
oil was dissolved in dichloromethane (15 mL) and washed with sodium thiosulfate (5 mL). The organic layer 
was dried over Na2SO4 and concentrated under vacuum to give a yellow oil. The latter was dissolved in a 
solution of THF and water (2:1, 5 mL) and stirred at room temperature for 16 hours. The product was 
concentrated under reduced pressure to obtain 140. Yield 85 % as light-yellow oil. Molecular formula: 
C13H21NO7. Molecular weight: 303.31 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.80 (br s, 1H, COOH exchanged 
with D2O), 6.77 (br t, J = 5.7 Hz, 1H, NH exchanged with D2O), 4.91 (s, 1H, CH), 3.99 (d, J = 11.1 Hz, 1H, CH2), 
3.81 (d, J = 11.1 Hz, 1H, CH2), 3.33-3.62 (m, 2H, CH2), 2.57 (t, J = 5.5 Hz, 2H, CH2), 2.11 (s, 3H, CH3CO), 2.06 (s, 
3H, CH3CO), 1.04 (s, 3H, C(CH3)2), 1.00 (s, 3H, C(CH3)2) ppm. 13C NMR (75 MHz, CDCl3): δ 176.28, 171.17, 
170.00, 168.37, 76.84, 69.28, 37.16, 34.59, 33.57, 21.28, 20.80, 20.75, 20.64 ppm. 
 
 
Synthesis of O,O’-diacetyl-D-pantothenamides (141,144) 
 
 
The solution of compound 138 (1.60 mmol), the proper amine (1.92 mmol) and 1-hydroxybenzotriazole 
hydrate (1.92 mmol) in dry dichloromethane (9.31 mL) was stirred under nitrogen atmosphere in presence 
of triethylamine (3.21 mmol). The solution was cooled to 0°C and N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (1.60 mmol) was added. The reaction mixture was stirred at 0°C for 30 
minutes and then warmed to room temperature for 14 hours. The mixture was diluted with dichloromethane 
and washed firstly with 0.1 M HCl and then saturated NaHCO3. The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure to obtain an oil. 
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 methyl O,O’-diacetyl-D-pantothenamide (141) 
 
Yield: 79 % as off-white foamy solid. Starting compounds: 
140 and methylamine (2.0 M in THF). Molecular formula: 
C14H24N2O6. Molecular weight: 316.35 g/mol. 1H NMR (300 
MHz, CDCl3): δ 6.90 (br s, 1H, NH exchanged with D2O), 5.77 
(br s, 1H, NH exchanged with D2O), 4.92 (s, 1H, CH), 4.02 (d, J 
= 11.0 Hz, 1H, CH2), 3.83 (d, J = 11.0 Hz, 1H, CH2), 3.34-3.64 
(m, 2H, CH2), 2.79 (d, J = 4.5 Hz, 3H, NHCH3), 2.37 (t, J = 5.2 
Hz, 2H, CH2), 2.15 (s, 3H, CH3CO), 2.06 (s, 3H, CH3CO), 1.06 (s, 
3H, C(CH3)2), 1.02 (s, 3H, C(CH3)2). 
 
 tert-butyl N-(O,O’-diacetyl-D-pantothenoyl)- γ - 
aminobutanoate (144) 
 
Yield 89 % as grey oil. Starting compounds: 138 and tert-
butyl-γ-aminobutanoate hydrochloride. Molecular formula: 
C21H36N2O8. Molecular weight: 444.53 g/mol. 1H NMR (300 
MHz, CDCl3): δ 7.08 (br t, J = 5.7 Hz, 1H, NH), 6.56 (br t, J = 
5.4 Hz, 1H, NH), 4.80 (s, 1H, CH), 3.92 (d, J = 11.0 Hz, 1H, 
AcOCH2), 3.73 (d, J = 11.0 Hz, 1H, AcOCH2), 3.26-3.47 (m, 2H, 
CH2), 3.05-3.19 (m, 2H, CH2), 2.27 (t, J = 5.8 Hz, 2H, CH2), 
2.16 (t, J = 7.3 Hz, 2H, CH2), 2.04 (s, 3H, CH3CO), 1.95 (s, 3H, 
CH3CO), 1.62-1.71 (m, 2H, CH2), 1.33 (s, 9H, C(CH3)3), 0.96 (s, 
3H, (CH3)2), 0.91 (s, 3H, (CH3)2) ppm. 13C NMR (75 MHz, 
CDCl3): δ 172.57, 171.59, 170.79, 169.82, 168.05, 76.87, 
69.22, 38.81, 36.96, 35.22, 34.85, 32.88, 27.95, 24.59, 
21.29, 20.72, 20.64, 20.58 ppm. 
 
 
Synthesis of N-(O,O’-diacetyl-D-pantothenoyl)- γ -aminobutyric acid (145) 
 
 
To a solution of 144 (1.42 mmol) in dry dichloromethane (6.59 mL), trifluoroacetic acid (2.75 mL) was added 
and the reaction mixture was stirred for 4 hours at room temperature. The resulting mixture was 
concentrated under reduced pressure by azeotrope with toluene to remove TFA, checked by 19F NMR (282 
MHz, CDCl3) - absence of peak at -76.00 ppm) to obtain 145. Yield 98 % as amber oil. Molecular formula: 
C17H28N2O8. Molecular weight: 388.42 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.42 (br t, J = 5.5 Hz, 1H, NH), 7.22 
(br t, J = 5.1 Hz, 1H, NH), 4.85 (s, 1H, CH), 4.00 (d, J = 11.1 Hz, 1H, CH2), 3.83 (d, J = 11.1 Hz, 1H, CH2), 3.49-
3.53 (m, 2H, CH2), 3.20-3.34 (m, 2H, CH2), 2.54 (t, J = 5.7 Hz, 2H, CH2), 2.40 (t, J = 7.0 Hz, 2H, CH2), 2.11 (s, 3H, 
CH3CO), 2.05 (s, 3H, CH3CO), 1.79-1.88 (m, 2H, CH2), 1.02 (s, 3H, (CH3)2), 1.01 (s, 3H, (CH3)2) ppm. 13C NMR (75 
MHz, CDCl3): δ 176.35, 172.44, 171.12, 170.25, 168.90, 77.07, 69.25, 38.93, 37.03, 35.58, 35.03, 31.33, 24.26, 
21.26, 20.76, 20.62 ppm.  
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Synthesis of Meldrum’s acid derivatives (142,146) 
 
 
A solution of carboxylic acid (0.136 mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum’s acid, 0.136 mmol) 
and 4-dimethylaminopyridine (0.161 mmol) in dry dichloromethane (0.94 mL) was stirred for 15 minutes at 
room temperature. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.152 mmol) was 
added and the solution was left stirring for other 4 hours. After dilution with dichloromethane, the organic 
phase was washed with 0.1 M HCl, dried over sodium sulfate and concentrated in vacuo to give 142 and 146. 
 
 (R)-4-((3-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-3-
hydroxypropyl)amino)-2,2-dimethyl-4-oxobutane-1,3-diyl 
diacetate (142) 
 
Yield: 81 % as colorless oil. Starting compound: 140. 
Molecular formula: C19H27NO10. Molecular weight: 429.42 
g/mol. 1H NMR (300 MHz, CDCl3): δ 6.43 (br s, 1H, NH 
exchanged with D2O), 4.89 (s, 1H, CH), 3.97 (d, J = 11.0 Hz, 
1H, CH2), 3.75 (d, J = 11.0 Hz, 1H, CH2), 3.52-3.72 (m, 2H, 
CH2), 3.16-3.25 (m, 2H, CH2), 2.08 (s, 3H, CH3CO), 1.99 (s, 
3H, CH3CO), 1.68 (s, 6H, C(CH3)2), 0.99 (s, 3H, C(CH3)2), 
0.93 (s, 3H, C(CH3)2) ppm. 13C NMR (75 MHz, CDCl3): δ 
194.51, 170.81, 169.57, 168.21, 160.58, 105.35, 92.50, 
76.62, 69.12, 37.26, 35.96, 35.22, 26.73, 21.33, 20.74, 
20.63, 20.60 ppm. 
 
 N-[4-(2,2-dimethyl-4,6,-dioxo-1,3-dioxan-5-ylidene)-4-
hydroxybutyl]-O,O’-diacetyl-D-pantothenamide (146) 
 
Yield: 84 % as light-brown oil. Starting compound: 145. 
Molecular formula: C23H34N2O11. Molecular weight: 
514.53 g/mol. 1H NMR (300 MHz, CDCl3): δ 7.09 (br t, J = 
5.4 Hz, 1H, NH), 6.53 (br t, J = 5.2 Hz, 1H, NH), 4.81 (s, 
1H, CH), 3.95 (d, J = 11.0 Hz, 1H, CH2), 3.78 (d, J = 11.0 
Hz, 1H, CH2), 3.38-3.52 (m, 2H, CH2), 3.10-3.38 (m, 2H, 
CH2), 2.88-3.10 (m, 2H, CH2), 2.27-2.37 (m, 2H, CH2), 2.07 
(s, 3H, CH3CO), 1.99 (s, 3H, CH3CO), 1.85 (m, 2H, CH2), 
1.68 (s, 3H, CO(CH3)2), 1.67 (s, 3H, CO(CH3)2), 0.99 (s, 3H, 
(CH3)2), 0.96 (s, 3H, (CH3)2) ppm. 13C NMR (75 MHz, 
CDCl3): δ 196.98, 171.87, 170.77, 169.93, 168.09, 
161.00, 104.78, 91.44, 76.97, 69.21, 38.46, 36.96, 35.37, 
35.06, 26.99, 26.70, 26.64, 25.80, 21.26, 20.71, 20.65, 
20.58 ppm. 
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Synthesis of methyl β-ketoesters (143,147) 
 
 
Dry methanol (14.2 mL) was used to dissolve the starting compound (0.69 mmol) and this solution was 
refluxed for 18 hours. The solvent was removed by evaporation under reduced pressure and the methyl β-
ketoester was obtained. 
 
 
 (R)-4-((5-methoxy-3,5-dioxopentyl)amino)-2,2-dimethyl-
4-oxobutane-1,3-diyl diacetate (143) 
 
Yield: 87 % as light yellow oil. Starting compound: 142. 
Molecular formula: C16H25NO8. Molecular weight: 359.38 
g/mol. 1H NMR (300 MHz, CDCl3): δ 6.51 (t, J = 5.6 Hz, 1H, 
NH exchanged with D2O), 4.86 (s, 1H, CH), 3.97 (d, J = 
11.0 Hz, 1H, CH2), 3.77 (d, J = 11.0 Hz, 1H, CH2), 3.69 (s, 
3H, OCH3), 3.32-3.58 (m, 2H, CH2), 3.42 (s, 2H, CH2), 2.70-
2.77 (m, 2H, CH2), 2.09 (s, 3H, CH3CO), 2.02 (s, 3H, 
CH3CO), 1.01 (s, 3H, C(CH3)2), 0.97 (s, 3H, C(CH3)2) ppm. 
13C NMR (75 MHz, CDCl3): δ 202.73, 170.84, 169.80, 
168.02, 167.27, 76.97, 69.19, 52.39, 48.87, 42.06, 37.04, 
33.54, 21.28, 20.77, 20.70, 20.61 ppm. 
 
 O,O’-diacetylmalonylcarba(dethia)pantetheine 
methylester (147) 
 
Yield: 94 % as light yellow oil. Starting compound: 146. 
Molecular formula: C20H32N2O9. Molecular weight: 
444.48 g/mol. 1H NMR (300 MHz, CDCl3): δ 6.87 (br t, J 
= 5.4 Hz, 1H, NH), 5.89 (br t, J = 5.2 Hz, 1H, NH), 4.89 (s, 
1H, CH), 4.02 (d, J = 11.0 Hz, 1H, CH2), 3.83 (d, J = 11.0 
Hz, 1H, CH2), 3.73 (s, 3H, OCH3), 3.44-3.58 (m, 2H, CH2), 
3.48 (s, 2H, CH2), 3.21-3.33 (m, 2H, CH2), 2.62 (t, J = 6.8 
Hz, 1H, CH2), 2.35 (t, J = 5.8 Hz, 2H, CH2), 2.15 (s, 3H, 
CH3CO), 2.06 (s, 3H, CH3CO), 1.78-1.85 (m, 2H, CH2), 
1.07(s, 3H, CO(CH3)2), 1.03 (s, 3H, CO(CH3)2) ppm. 13C 
NMR (75 MHz, CDCl3): δ 202.5, 171.8, 170.9, 170.0, 
168.1, 167.7, 77.0, 69.3, 52.3, 48.8, 40.2, 38.7, 37.0, 
35.2, 35.1, 23.0, 20.8, 20.7, 20.6 ppm. 
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Deprotection of O,O’-diacetyl groups (21-23) 
 
 
Potassium carbonate (2.25 mmol) was added to a solution of the proper O,O’-diacetyl pantoic derivative 
(0.69 mmol) in dry methanol (23 mL) at 0°C. After 210 minutes, the solvent was concentrated under vacuum. 
Upon filtration, the supernatant was dried under reduced pressure. 
 
 
 (R)-2,4-dihydroxy-3,3-dimethyl-N-(3-(methylamino)-3-
oxopropyl)butanamide (21) 
 
Yield: 78% as colorless oil. Starting compound: 141. 
Molecular formula: C10H20N2O4. Molecular weight: 232.28 
g/mol. 1H NMR (300 MHz, CD3OD): δ 3.88 (s, 1H, CH), 
3.35-3.48 (m, 4H, CH2), 2.70 (s, 3H, NCH3), 2.40 (t, J = 6.7 
Hz, 2H, CH2), 0.90 (s, 6H, C(CH3)2) ppm. 
 
 methyl (R)-5-(2,4-dihydroxy-3,3-dimethylbutanamido)-
3-oxopentanoate (22) 
 
Yield: 64% as colorless oil. Starting compound: 143. 
Molecular formula: C12H21NO6. Molecular weight: 
275.30 g/mol. 1H NMR (300 MHz, D2O): δ 4.04 (s, 1H, 
CH), 3.74 (s, 3H, OCH3), 3.42-3.58 (m, 4H, CH2), 3.41 (s, 
2H, CH2), 2.73 (t, J = 5.9 Hz, 2H, CH2), 0.93 (s, 6H, C(CH3)2) 
ppm. 13C NMR (75 MHz, D2O): δ 204.5, 174.7, 169.8, 
76.3, 69.2, 52.4, 46.9, 40.8, 39.6, 36.3, 20.4 ppm. 
 
 malonyl carba(dethia)-pantetheine methylester (23) 
 
Yield: 70% as colorless oil. Starting compound: 143. 
Molecular formula: C16H28N2O7. Molecular weight: 
360.41 g/mol. 1H NMR (300 MHz, D2O): δ 3.98 (s, 1H, 
CH), 3.75 (s, 3H, OCH3), 3.43-3.56 (m, 2H, CH2), 3.51 (d, J 
= 11.0 Hz, 1H, CH2), 3.39 (d, J = 11.0 Hz, 1H, CH2), 3.34 (s, 
2H, CH2),3.17 (t, J = 7.0 Hz, 2H, CH2), 2.68 (t, J = 7.0 Hz, 
2H, CH2), 2.48 (t, J = 6.0 Hz, 2H, CH2), 1.72-1.80 (m, 2H, 
CH2), 0.92 (s, 3H, C(CH3)2), 0.88 (s, 3H, C(CH3)2) ppm. 13C 
NMR (75 MHz, D2O): δ 207.6, 175.0, 173.8, 170.1, 75.7, 
68.2, 52.7, 40.0, 38.5, 38.4, 35.4, 35.2, 22.3, 20.4, 18.9 
ppm. 
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Procedures for the synthesis of 2-amino-4-(1H-indol-3-yl) 
pyrimidine-5-carbonitrile (24) 
Synthesis of 3-(1H-Indol-3-yl)-3-oxo-propionitrile (148) 
 
 
Cyanoacetic acid (20 mmol) and acetic anhydride (20 mL) were heated at 85°C for 10 minutes. Then indole 
(20 mmol) was added and the reaction mixture was refluxed for 30 minutes. After cooling, the precipitate 
was filtered and washed with ice-water. The crude product was recrystallized several times from acetic acid 
to give compound 148. Yield 22 % as brown solid (m.p. 240-241°C). Molecular formula: C11H8N2O. Molecular 
weight: 184.20 g/mol. 1H NMR (300 MHz, DMSO-d6): δ 12.16 (br s, 1H, NH exchanged with D2O), 8.35 (d, J = 
3.3 Hz, 1H, ArH), 8.07-8.19 (m, 1H, ArH), 7.37-7.59 (m, 1H, ArH), 7.11-7.31 (m, 2H, ArH), 4.48 (s, 2H, CH2) ppm. 
13C NMR (75 MHz, DMSO-d6): δ 183.33, 137.06, 135.93, 125.59, 123.74, 122.76, 121.44, 116.87, 114.87, 
112.86, 29.86 ppm. 
 
 
Synthesis of (2Z)-3-(dimethylamino)-2-(1H-indole-3-carbonyl)acrylonitrile (149) 
 
 
Intermediate 148 (6.4 mmol) and N,N-dimethylformamide dimethyl acetal (10 mmol) were dissolved in dry 
toluene (15 mL). The mixture was irradiated by a microwave synthesizer at 300 Watts at 120°C for 45 minutes 
(TLC: dichlorometane /ethyl acetate (8:2) - Rf: 0.51). After cooling, the obtained yellow solid was filtered and 
recrystallized from ethanol to give pure 149. Yield 85 % as yellow prisms (m.p. 160-163°C). Molecular formula: 
C14H13N3O. Molecular weight: 239.28 g/mol. 1H NMR (300 MHz, DMSO-d6): δ 11.73 (br s, 1H, NH exchanged 
with D2O), 8.26 (s, 1H, ArH), 8.12 (d, J = 7.2 Hz, 1H, ArH), 7.98 (s, 1H, CH), 7.45 (d, J = 7.5 Hz, 1H, ArH), 7.05-
7.22 (m, 2H, ArH), 3.35 (s, 3H, CH3), 3.25 (s, 3H, CH3) ppm. 13C NMR (75 MHz, DMSO-d6): δ 182.18, 159.12, 
136.26, 131.59, 127.20, 122.93, 122.24, 122.19, 121.57, 115.12, 112.34, 78.04, 47.85 ppm. 
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Synthesis of 2-amino-4-(1H-indol-3-yl)pyrimidine-5-carbonitrile (24) 
 
 
A solution of compound 149 (1.11 mmol), guanidine hydrochloride (2.22 mmol) and sodium ethoxide (1.11 
mmol) in ethanol (6 mL) was irradiated by a microwave synthesizer at 300 Watts, at 120°C for 40 minutes. 
After cooling to room temperature, the precipitate was filtered and washed with ice-cold ethanol. The 
obtained yellow solid was recrystallized in ethanol to give pure compound 24. Yield 83 % as light-yellow solid 
(m.p. 258-259°C). Molecular formula: C13H9N5. Molecular weight: 235.25 g/mol. 1H NMR (300 MHz, DMSO-
d6): δ 11.95 (br s, 1H, NH exchanged with D2O), 8.66 (d, J = 8.0 Hz, 1H, ArH), 8.56 (s, 1H, ArH), 8.46 (s, 1H, 
ArH), 7.64 (br s, 1H, NH2 exchanged with D2O), 7.54 (br s, 1H, NH2 exchanged with D2O), 7.50 (d, J = 8.1 Hz, 
1H, ArH), 7.08-7.29 (m, 2H, ArH) ppm. 13C NMR (75 MHz, DMSO-d6) δ 163.77, 163.60, 163.56, 136.81, 130.44, 
126.17, 123.70, 123.19, 121.49, 120.26, 112.48, 111.95, 89.64 ppm. 
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8.1 Materials and methods 
8.1.1 MTT-assay 
The MTT assay was performed according to literature data. [85,86] 
HCT-116 cell line (colorectal cancer) were cultured in McCoy’s media, whereas the DLD-1 (colorectal cancer) 
and MCF-7 were cultured in Dulbecco’s modified eagle’s medium (DMEM) with glutamine. All the media were 
supplemented with penicillin (10,000 U/mL), streptomycin (10 mg/mL), nonessential amino acids and 10% 
Fetal Calf Serum (FCS). The same media was utilized for the experiments where cells were incubated with 
newly synthesized compounds dissolved in DMSO. The same volume of solvent was added to control 
conditions and did not exceed 0.5% v/v. 
8.1.2 AlphaScreen-based assay 
It is a bead-based nonradioactive assay system for detecting biomolecular interactions in a microtiter plate 
format. The binding of biological partners brings donor and acceptor beads into close proximity and as a 
result, a fluorescent signal between 520 and 620 nm is produced. The AlphaScreen-based assays [140-141] were 
performed in a final reaction volume of 25 μL of the assay buffer containing 10 mM HEPES–NaOH (pH 7.4), 
50 mM NaCl, 1 mM EDTA (pH 8.0), 0.1% NP-40, and 10 ng/μL BSA in a 96-well microtiter plate at 25°C. the 
phospho-Tyr (pTyr) peptide probes used in this study were 5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 
and (FITC)-GpYDKPHVL for STAT1. Firstly, 75 nM of each SH2-containing protein was incubated with the test 
compound for 15 min. Each protein sample was then incubated for 90 minutes with 50 nM of its 
corresponding FITC-pTyr peptide, and mixed with streptavidin coated donor beads and anti-FITC acceptor 
beads simultaneously before detection at 570 nm using EnVison Xcite (PerkinElmer). 
8.1.3 In vivo antitumor activity in Lewis Lung Carcinoma 
All experiments were performed according to D.L.G.S. 26/2014 which warrants care of experimental animals 
in Italy. The research project was approved by the Italian Health Department according to the art. 7 of the 
above mentioned D.L. The LLC cell line was purchased from ECACC, United Kingdom. The LLC cell line was 
maintained in DMEM (Euroclone) supplemented with 10% heat-inactivated fetal bovine serum (FBS; 
Euroclone), 10 mM L-glutamine, 100 U mL−1 penicillin, and 100 μg mL−1 streptomycin in a 5% CO2 air incubator 
at 37°C. The LLC was implanted intramuscularly (im) as a 2 × 106 cell inoculum into the right hind leg of 8 
week old male and female C57BL mice (24 ± 3 g body weight). After 24 hours from tumor implantation, mice 
were randomly divided into five groups (8 animals per group, 10 controls). From day 7 after tumor inoculation 
(visible tumor) animals were treated daily with a single dose of Pt-15b and of Pt-16a complex (30 mg kg−1 
dissolved in a vehicle solution composed of 20% Cremophor EL (v/v), 20% PEG400 (v/v) and 60% saline 
solution (v/v)) or with a daily ip dose of cisplatin (1.5 mg kg−1 in 0.9% NaCl solution). At day 15, animals were 
sacrificed, the legs were amputated at the proximal end of the femur, and the inhibition of tumor growth 
was determined according to the difference in weight of the tumor-bearing leg and the healthy leg of the 
animals expressed as a percentage referred to the control animals. Body weight was measured at day 1 and 
every two days from day 7, and was taken as a parameter for systemic toxicity. All the values are the means 
± SD of not less than three measurements. 
8.1.4 Determination of intracellular and DNA-bound Pt concentrations 
For the determination of total intracellular 195Pt concentrations, cells were homogenated with a lysis buffer 
containing 0.5% NP-40, 150 mM NaCl and 50 mM Tris-HCl at pH 7.5. The cell monolayer was treated three 
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times with PBS before the incubation with the lysis buffer for 30 minutes at 4°C. Cell lysates were then cleared 
by centrifugation at 14,000g for 10 min, and the 195Pt concentration was determined by ICP-MS. The data 
were normalized with the protein concentrations determined using the BCA protein assay (Thermo scientific, 
Rockford, IL USA). The 195Pt concentration bound to DNA was estimated from nuclear DNA, extracted as 
previously described. [86] The data were normalized with DNA concentrations determined by 
spectrophotometer determination with NanoDrop system. 
8.1.5 Binding study with 9-ethylguanine and GSH 
The binding studies were directly conducted in NMR tube preparing 1 eq. of Pt-15b in 20 % of 0.9 % w/v NaCl-
D2O solution in DMSO-d6. 1eq. of 9-ethylguanine or GSH was added to the solution. The samples were 
evaluated at different times by 1H NMR analysis. 
8.1.6 Western blot analysis 
Cells were washed twice with PBS and lysed by incubation with a solution of 50 mM Tris pH 7.5, 150 mM 
NaCl, 0.5% Nonidet-P40, containing a protease inhibitor cocktail (Sigma Aldrich, Milan, Italy) for 30 minutes 
on ice. Cell lysates were then cleared by centrifugation at 14,000 g for 10 minutes. [142] Protein samples were 
separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose membrane (GE Healthcare 
Little Chalfont, Buckinghamshire, UK) and subsequently immunoblotted with primary antibody, following the 
appropriate secondary fluorescently labeled antibody, and acquired with the Odissey FC system (LI-COR). 
Quantitative densitometric analyses were performed by Image Studio software (LI-COR). The following 
antibodies were utilized: monoclonal antibody anti p53 and β-tubulin (SIGMA), anti-pSTAT3 (Abcam) and 
anti-STAT3 (Santa-Cruz Biotechnology). 
8.1.7 RNA Preparation and Quantitative Real Time PCR 
Total RNA was extracted with the iScript Sample Preparation Buffer according to manufacturer’s instructions. 
Reverse transcription-polymerase first-strand cDNA synthesis was realized by using the iScript cDNA 
synthesis Kit (Bio-Rad). qPCR was then performed by using the Kit Thermo SYBR Green/ROX qPCR Master Mix 
(Carlo Erba Reagents) and specific primers for STAT3 and 18S. The analyses were carried out with the ABI 
Prism® 7000 Sequence Detection System (Applied Biosystems; Life Technologies Europe BV). PCR cycling 
conditions were as follows: 94°C for 10 minute, 40 cycles at 94°C for 15 seconds, and 60°C for 1 minute. Data 
were expressed as Ct values and used for the relative quantification of targets by Ct calculation. [143] 
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9-EtG, 9-ethylguanine 
11β-HSD1, 11β-hydroxysteroid dehydrogenase type 1 
 
A2780, human ovarian cancer cell line 
A549, lung carcinoma cell line 
Ac2O, acetic anhydride 
ACO, Ant Colonization Optimization 
AcOEt, ethyl acetate 
AcOH, acetic acid 
AMMP, Automated Molecular Mechanics Optimization 
ATP7B, copper-transporting P-type ATPase 
 
Bcl-2, B-cell lymphoma 2 
Boc2O, di-tert-butyl dicarbonate 
 
CDDD, computational driven drug design 
CDK, cyclin dependent kinase 
Cnt, control 
Cpd, compound 
Crm1, chromosome region maintenance 1 
c-SrC, proto-oncogene tyr-protein kinase Src 
Ctr-1, copper transporter 1 
 
DCC, N,N-dicyclohexylcarbodiimide 
DCU, N,N-dicyclohexylurea 
DIBAL-H, diisobutylaluminium hydride 
DIPEA, N,N-diisopropylethylamine 
DLD-1, colorectal cancer cell line 
DMAP, 4-dimethylaminopyridine 
DMF, N,N-dimethylformamide 
DMSO-d6, dimethyl sulfoxide-d6 
DPPA, diphenylphosphoryl azide 
DTT, dithiolethione 
 
EDC.HCl = N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EGF, epidermal growth factor 
ElectDD, distance-dependent electrostatic energy according to Coulomb’s equation 
ESI, electrospray ionization 
Et2O, diethyl ether 
Et3N, triethylamine 
(EtO)2CO, ethyl carbonate 
EtOH, ethanol 
 
FBDD, fragment-based drug design 
FCS, fetal calf serum 
FDA, Food and Drug Administration  
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GSH, glutathione 
 
H460, non-small-cell lung carcinoma 
HBA, hydrogen bond acceptor 
HBD, hydrogen bond donor 
HCT-116, colorectal cancer cell line 
HeLa, cervical cancer cell line 
HOBt, hydroxybenzotriazole 
HSF, human skin fibroblast 
HTS, High-throughput screening 
 
IFN, interferon 
 
JAB, JAK-binding protein 
JAK, Janus kinase 
 
LiBHEt3, lithium triethylborohydride 
LLC, Lewis lung carcinoma 
 
MCF-7, breast cancer cell line 
MeOH, methanol 
MHC, major histocompatibility complex 
MLPInS, Molecular Lipophilic Potential Interaction Score 
MMAS, MAX-MIN Ant System 
MSTO-211H, mesothelioma 
MT, metallothionein 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTTS, methanethiosulfonate 
mw, microwave 
MW, molecular weight 
 
n-BuLi, n- butyllithium 
NaOAc, sodium acetate 
NBS, N-bromosuccinimide 
NCBI, National Center for Biotechnology Information 
NCI, National Cancer Institute 
NCS, N-chlorosuccinimide 
NER, nucleotide excision repair 
NES, nuclear export signals 
NF-кB, nuclear factor kappa-light-chain-enhancer of activated B cells 
NIH, National Institutes of Health 
NLS, nuclear lesions signals 
NMM, N-methylmorpholine 
NPC, nuclear pore complex 
NSCLC, non-small cell lung cancer  
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OCT, organic cation transporters 
 
Pd/C, palladium on carbon 
PDB, Protein Data Bank 
PDGF, platelet-derived growth factor 
Ph3P, triphenylphosphine 
PIAS, proteins that inhibit activated STAT proteins family 
PLANTS, Protein-Ligand ANT System 
Py, piridine 
 
RMSD, root-mean-square deviation 
rt, room temperature 
 
SAR, structure-activity relationship 
sFRP-1, secreted frizzled related protein-1 
SH2, Src homology 2 
SOCS, suppressors of cytokine signaling family 
SPR, surface plasmon resonance 
STAT, Signal Transducer and Activator of Transcription 
 
t-BuONO, tert-butyl nitrite 
t-BuOH, tert-butanol 
TBAB, tetra-N-butylammonium bromide 
TBTU, N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
TFA, trifluoroacetic acid 
THF, tetrahydrofuran 
TK, tyrosine kinase 
TLC, thin layer chromatography 
TMS, tetramethylsilane 
TMSCl, chlorotrimethylsilane 
 
uSTAT3, unphosphorylated STAT3 
 
VEGF-A: vascular endothelial growth factor 
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